Official Protocol Title:  
NCT number:  
Document Date:  A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of 
Pembrolizumab (MK-3475/SCH900475) in Combination with 
Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line 
Treatment of Subjects with Extensive Stage Small Cell Lung 
Cancer(KEYNOTE-604)
23-Apr-2019[STUDY_ID_REMOVED]
Product:   MK-3475 1
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialTHIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., 
WHITEHOUSE STATION, NJ, U.S.A.
SPONSOR:
Merck Sharp & Dohme Corp., a subsidiary  of Merck & Co., Inc. 
(hereafter referred to as the Sponsor or Merck)
One Merck Drive
P.O. Box 100
Whitehouse Station , New Jersey , 08889-0100, U.S.A.
Protocol -specific Sponsor Contact information can be found in the 
Investigator Trial File 
Binder (or equivalent) .
TITLE:
A Phase 3Randomized, Double- Blind, Placebo -controlled Trial of Pembrolizumab (MK -
3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for 
the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer 
(KEYNOTE -604)
IND NUMBER:   116833
EudraCT NUMBER:  2016-004309-15
Product:   MK-3475 2
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialTABLE OF CONTENTS
DOCUMENT HISTORY ..................................................................................................... 11
SUMMARY OF CHANGES ................................
................................................................ 13
1.0 TRIAL SUMMARY .................................................................................................. 15
2.0 TRIAL DESIGN........................................................................................................ 16
Trial Design ........................................................................................................... 16
Trial Diagram ........................................................................................................ 19
3.0 OBJECTIVE(S) & HYPOTHESIS(ES) .................................................................. 20
Primary Objective(s) & Hypothesis(es) .............................................................. 20
Secondary Objective(s) & Hypothesis(es) ........................................................... 20
Exploratory Objectives ......................................................................................... 21
4.0 BACKGROUND & RATIONALE .......................................................................... 21
Background ........................................................................................................... 21
Pharmaceutical and Therapeutic Background .................................................... 21
Information on Other Trial -related Therap y....................................................... 22
Etoposide/Platinum Therapy ........................................................................ 22
Prophy lactic Cranial Irradiatio n................................................................... 23
Rationale ................................................................................................................ 25
Rationale for the Trial and Selected Subject Population .................................... 25
Rationale for Dose Selection/Regi men/Modification ......................................... 27
Rationale for the Dose of Pembrolizumab ................................................... 27
Rationale for Use of Comparator/Placebo ................................................... 28
Rationale for Efficacy  Endpoints ........................................................................ 28
Primary  Efficacy  Endpoints ......................................................................... 28
Secondary  Efficacy  Endpoints ..................................................................... 29
Safety  Endpoints .......................................................................................... 29
Patient Reported Outcomes .......................................................................... 29
Immune -related RECI ST............................................................................. 30
Planned Exploratory  Biomarker Research ................................................... 30
Product:   MK-3475 3
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Future Biomedical Research ........................................................................ 32
Benefit/Risk ........................................................................................................... 32
5.0 METHODOLOGY ................................................................................................... 33
Entry Criteria ........................................................................................................ 33
Diagnosis/Condition for Entry  into the Trial ...................................................... 33
Subject I nclusion Criteria .................................................................................... 33
Subject Exclusion Criteria .................................................................................. 35
Trial Treatment(s) ................................................................................................ 38
Dose Selection/Modification .............................................................................. 38
Dose Selection (Preparation) ....................................................................... 38
Dose Modification ....................................................................................... 39
5.2.1.2.1 Pembrolizumab ..................................................................................... 40
5.2.1.2.2 Chemotherapeutic agents (etoposide/platinum) .................................... 48
Timing of Dose Administration .......................................................................... 51
Pembrolizumab (or Saline Placebo) ............................................................. 52
Chemotherap y.............................................................................................. 52
5.2.2.2.1 Carboplatin ............................................................................................ 52
5.2.2.2.2 Cisplatin ................................................................................................ 53
5.2.2.2.3 Etoposide .............................................................................................. 53
Trial Blinding...................................................................................................... 53
Randomization ...................................................................................................... 54
Stratification .......................................................................................................... 54
Concomitant Medications/Vaccinations (Allowed & Prohibited) .................... 54
Acceptable Concomitant Medications ................................................................ 54
Prohibited/Restricted Concomitant Medications ................................................ 55
Rescue Medications & Supportive Care ............................................................. 56
Supportive Care Guidelines ................................................................................ 56
Diet/Activity/Other Considerations ..................................................................... 57
Diet...................................................................................................................... 57
Contraception ...................................................................................................... 57
Use in Nursing Women ....................................................................................... 59
Subject Withdrawal/Discontinuation Criteria ................................................... 59
Product:   MK-3475 4
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Discontinuation of Treatment ............................................................................. 59
Withdrawal from the Trial .................................................................................. 61
Subject Replacement Strategy ............................................................................. 61
Beginning and End of the Trial ........................................................................... 61
Clinical Criteria for Early Trial Termination ................................................... 61
6.0 TRIAL FLOW CHART ........................................................................................... 62
Initial Treatment Phase ........................................................................................ 62
Second Course Treatment Phase ......................................................................... 68
7.0 TRIAL PROCEDURES ........................................................................................... 71
Trial Procedures ................................................................................................... 71
Administrative Procedures .................................................................................. 71
Informed Consent ......................................................................................... 71
7.1.1.1.1 General Informed Consent .................................................................... 71
7.1.1.1.2 Consent and Collection of Specimens for Future Biomedical 
Research ................................................................................................ 72
Inclusion/Exclusion Criteria ........................................................................ 72
Subject I dentification Ca rd.......................................................................... 72
Medical History ........................................................................................... 72
Prior and Concomitant Medications Review ............................................... 72
7.1.1.5.1 Prior Medications .................................................................................. 72
7.1.1.5.2 Concomitant Medications ..................................................................... 73
Assignment of Screening Number ............................................................... 73
Assignment of Treatment/Randomization Number ..................................... 73
Trial Compliance (Medication/Diet/Activity /Other) ................................... 73
Clinical Procedures/Assessments ........................................................................ 73
Adverse Event Monitoring ........................................................................... 73
Physical Examination ................................................................................... 74
7.1.2.2.1 Full Phy sical Examination .................................................................... 74
7.1.2.2.2 Directed Ph ysical Examination ............................................................. 74
Vital Signs.................................................................................................... 74
12-Lead Electrocardiogram ......................................................................... 74
Eastern Cooperative Oncology  Group Performance Status ......................... 74
Product:   MK-3475 5
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Prophy lactic Cranial Irradiation ................................................................... 75
Tumor I maging and Assessment of Disease ................................................ 75
7.1.2.7.1 Initial Tumor Imaging ........................................................................... 76
7.1.2.7.2 Tumor I maging During the Trial .......................................................... 76
7.1.2.7.3 End of Treatment and Follow -up of Tumor Imaging ........................... 77
7.1.2.7.4 Second Course (Retreatment) Phase Tumor Imaging ........................... 77
7.1.2.7.5 RECI ST 1.1 Assessment of Disease ..................................................... 78
7.1.2.7.6 irRECIST Assessment of Disease ......................................................... 78
Tumor Tissue Collection: PD -L1 Status ...................................................... 83
Laboratory  Procedures/Assessments .................................................................. 84
Clinical L aboratory  Evaluations .................................................................. 84
Pharmacokinetic/Pharmacody namic Evaluations ........................................ 86
Planned Genetic Anal ysis Sample C ollection.............................................. 87
Future Biomedical Research Samples ......................................................... 87
Other Procedures ................................................................................................ .87
Withdrawal/Discontinuation ........................................................................ 87
Subject Blinding/Unblinding ....................................................................... 88
Calibration of Critical Equipment ................................................................ 88
Visit Requirements .............................................................................................. 89
Screening...................................................................................................... 89
Treatment Period Visits ............................................................................... 89
Post-treatment Visits .................................................................................... 89
7.1.5.3.1 Safety  Follow -up Visit .......................................................................... 89
7.1.5.3.2 Progression -free Survival Follow -up Visits ......................................... 90
7.1.5.3.3 Survival Follow -up............................................................................... 90
Survival Status ............................................................................................. 90
Second Course Phase ................................................................................... 91
Continued Treatment Following Verified Progressive Disease ................... 92
Discontinued Subjects Con tinuing to be Monitored in the Trial ................. 92
Assessing and Recording Adverse Events .......................................................... 93
Definition of an Overdose for This Protocol and Reporting of Overdose to 
the Sponsor .......................................................................................................... 94
Product:   MK-3475 6
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Reporting of Pregnancy  and Lactation to the Sponsor ....................................... 94
Immediate Reporting of Adverse Events  to the Sponsor ................................... 95
Serious Adverse Events ............................................................................... 95
Events of Clinical I nterest ............................................................................ 96
Protocol -Specific Exceptions to Serious Adverse Event Reporting ............ 97
Evaluating Adverse Even ts................................................................................. 97
Sponsor Responsibility  for Reporting Adverse Events .................................... 100
TRIAL GOVERNANCE AND OVERSIGHT ................................................. 100
Data Monitoring Committee ............................................................................. 100
8.0 STATISTICAL ANALYSIS PLAN ...................................................................... 100
Statistical Analysis Plan Summary ................................................................... 101
Responsibility for Analyses/In -house Blinding ................................................ 102
Hypotheses/Estimation ....................................................................................... 103
Analysis Endpoints ............................................................................................. 103
Efficacy  Endpoints ............................................................................................ 103
Safety  Endpoints ............................................................................................... 104
Analysis Populations ........................................................................................... 104
Efficacy  Anal ysis Populations .......................................................................... 104
Safety Anal ysis Populations ............................................................................. 104
Statistical Methods .............................................................................................. 105
Statistical Methods for Efficacy  Anal yses........................................................ 105
Progression -free Survival ........................................................................... 105
Overall Survival ......................................................................................... 106
Objective Response Rate ........................................................................... 107
Duration of Response................................................................................. 107
Statistical Methods for Safety Anal yses........................................................... 108
Summaries of Baseline Characteristics and Demographics .............................. 110
Interim Analyses ................................................................................................ .110
Multiplicity .......................................................................................................... 110
Sample Size and Power Calculations ................................................................ 114
Subgroup Analyses and Effect of Baseline Factors ......................................... 114
Compliance (Medication Adherence) ................................................................ 115
Product:   MK-3475 7
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Extent of Exposure .............................................................................................. 115
9.0 LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES ............................................................................................................... 115
Investigational Product ...................................................................................... 115
Packaging and Labeling Information ............................................................... 116
Clinical Supplies Disclosure ............................................................................... 116
Storage and Handling Requirements ................................................................ 117
Discard/Destruction/Returns and Reconciliation ............................................ 117
Standard Policies ................................................................................................ .117
10.0 ADMINISTRATIVE AND REGULATORY DETAILS ..................................... 117
Confidentiality ..................................................................................................... 117
Confidentiality  of Data ..................................................................................... 117
Confidentiality  of Subject Records ................................................................... 118
Confidentiality  of Investigator Information ...................................................... 118
Confidentiality  of IRB/IEC I nformation ........................................................... 118
Compliance with Financial Disclosure Requirements ..................................... 119
Compliance with Law, Audit and Debarment ................................................. 119
Compliance with Trial Registration and Results P osting Requirements ......121
Quality Management System ............................................................................. 121
Data Managemen t............................................................................................... 122
Publications ......................................................................................................... 122
11.0 LIST OF REFERENCES ....................................................................................... 123
12.0 APPENDICES ......................................................................................................... 135
Merck Code of Conduct for Clinical Trials ...................................................... 135
Collection and Management of Specimens for Future Biomedical 
Research ............................................................................................................... 137
ECOG Performance Status ................................................................................ 141
Common Terminology Criteria for Adverse Events Version 4.0 ................... 142
Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 Criteria 
for Evaluating Response in Solid Tumors ........................................................ 143
List of Abbreviations .......................................................................................... 144
Product:   MK-3475 8
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential13.0 SIGNATURES ......................................................................................................... 148
Sponsor's Representative ................................................................................... 148
Investigator .......................................................................................................... 148
Product:   MK-3475 9
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialLIST OF TABLES
Table 1 Adequate Organ Function L ab Values ............................................................... 34
Table 2 Trial Treatments ................................................................................................. 38
Table 3 Dose Modifications for Study  Drugs ................................................................. 40
Table 4 Dose Modification and Toxicity  Management Guidelines for Immune -
Related AEs Associated With Pembrolizumab .................................................. 42
Table 5 Pembrolizumab Infusion Reaction Dose Modification and Treatment 
Guidelines .......................................................................................................... 46
Table 6 Recommended 
Chemotherap y Dose Modifications for Hematologic al 
Toxicity .............................................................................................................. 49
Table 7 Recommended 
Chemotherap y Dose Modifications for Non-hematologic 
Toxicity .............................................................................................................. 50
Table 8 Imaging and Treatment After First Radiologic Evidence of Progressive 
Disease ............................................................................................................... 82
Table 9 Clinica l Laboratory  Tests ................................................................................... 85
Table 10 Evaluating Adverse Events ................................................................................ 98
Table 11 Censoring Rules for Primary  and Sensitivity  Analyses of Progression
-free 
Survival ............................................................................................................ 106
Table 12
Censoring Rules for Duration of Response ..................................................... 107
Table 13 Efficacy  Anal ysis Methods for Primary  and Secondary  Efficacy  Endpoints ..108
Table 14 Analy sis Strategy
 for Safety  Parameters .......................................................... 109
Table 
15 Efficacy  Boundaries and Properties for Progression -free Survival Anal yses.112
Table 16 Efficacy  Boundaries and Properties for Overall Survival Anal yses................ 113
Table 17 Possible Alpha- levels and Approximate ORR Difference Required to 
Demonstrate Efficacy for ORR ........................................................................ 114
Table 18 Product Descriptions ........................................................................................ 116
Product:   MK-3475 10
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialLIST OF FIGURES
Figure 1 Trial Design Overview ....................................................................................... 19
Figure 2 Imaging and Treatment for Clinically  Stable Subjects After First 
Radiologic Evidence of PD Assessed b y the Site .............................................. 83
Figure 3 Multiplicity  Graph for Ty pe I Error Control .................................................... 111
Product:   MK-3475 11
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialDOCUMENT HISTORY
Document Date of Issue Overall Rationale
Original protocol 15 D EC-2016
Amendment 01 21-D EC- 2016 Corrected a typographical error in the numbering of the inclusion criteria so 
that the structure of the trial database and the electronic data capture forms can 
be created correctly .
Amendment 02 23-F EB- 2017 Corrected the wording of exclusion criterion #5, which stated the opposite of 
what was intended and to provide more detail and clarity  where needed.
Amendment 03 10-A PR- 2017 Removed the option to cross over from the etoposide/platinum/saline placebo 
arm to pembrolizumab treatment to improve the interpretation of the long -term 
benefit.
Amendment 04 02-JUN -2017 Removed the requirement for unblinding treatment assignment after 
documentation of progressive disease (PD) because the option to cross over to 
pembrolizumab was removed and, with it, the need to unblind.  
Amendment 05 01-S EP- 2017 Clarified exclusion criterion #4 regarding brain metastases to ensure that no 
subjects with brain metastases are enrolled in the study .
Amendment 06 30-N OV -2017 Updated the dose modification guidelines for pembrolizumab to include 
information regarding the treatment of myocarditis; revised the requirements 
for survival follow -up to allow for more frequent data collection; added a 
Day 8 visit during Cycles 1 through 4 to allow for more frequent safety  
monitoring.
Product:   MK-3475 12
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialDocument Date of Issue Overall Rationale
Amendment 07 03-O CT- 201 8  
 
 
 
; changed the alpha allocation 
between the primary  (overall survival [OS] and PFS) and key secondary  
(objective response rate [ORR]) hypothesis on the basis of accumulating  
external data on PFS and OS in immunotherapy -chemotherap y combinations 
in small cell lung cancer to allow more alpha to be allocated to the primary 
endpoints.
Amendment 08 07-DEC - 2018  
 
 
 
 the assumption for median PFS in the 
control arm was changed to 4.3 months based on external data published from 
other clinical trials; and the power and efficacy  bound calculations were 
updated to reflect the change in PFS median assumption and an alpha spending 
approach.
Amendment 09 23-APR -2019 Updated criteria for the final OS an alysis to be a minimum of 294 events, or 31 
months from study  start, whichever occurs later to ensure sufficient follow -up 
time for the final OS analysis. Added clarification to describe the alpha -
spending strategy  for PFS and OS in detail. Corrected a publishing error in 
Amendment 08.
CCI
CCI
Product:   MK-3475 13
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialSUMMARY OF CHANGES
PRIMARY REASON(S) FOR THIS AMENDMENT:
Section Number Section Title Description of Change(s) Rationale
8.7 Interim Anal yses The final analy sis timing was updated as 
follows: “The final OS analy sis isplanned 
when a minimum of294 deaths have been 
observed orapproximately  31 months after 
first subject enrolled, whichever occurs 
later.”By allowing the final OS analysisto occur 
after a minimum of
294 events have been 
observed or approximately  31 months after 
the first subject is enrolled, whichever 
occurs later, the trial ensure s adequate
follow -up time for the final OS anal ysis.
8.8 Multiplicity Added the following statements to describe 
the alpha -spending strategy  for PFS and 
OS in detail: “The alpha spending at each 
interim anal ysis is determined using a Lan-
DeMets O'Brien- Fleming spending 
function, and the information fraction 
(ratio of the actual number of events at the 
interim analysis relative to a targeted 294 
events at the final analy sis). The final 
analysis will use the remaining Type I 
error not spent at earlier analy ses, 
regardless of the number of events 
observed at the final analy sis. The p-value 
bounds at second interim and final analy sis 
will be calculated by considering the 
correlation between the test statistics as 
determined by the actual number of OS 
events at the previous and current 
analysis.”To clarify  that the alpha spending is event 
based ,and not subject edto change ,if the 
actual number of events at the final 
analysisexceeds the targeted number of 
events at final anal ysis.
Product:   MK-3475 14
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialADDITIONAL CHANGE (S)FOR THIS AMENDMENT:
Section Number Section Title Description of Change(s) Rationale
11.0 List of References Included all references cited in 
the text of the protocol.Due to a publishing error, the list of references in 
protocol Section 11.0 was truncated when Amendment 
08 was finalized. Therefore, it is being updated here.
Product:   MK-3475 15
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential1.0TRIAL SUMMARY
Abbreviated Title Phase 3trial of first line etoposide/platinum (EP) with or without 
pembrolizumab in ES-SCLC (KEYNOTE -604)
Sponsor Product Identifiers MK-3475
Pembrolizumab
Trial Phase III
Clinical Indication First-line treatment of extensive stage small cell lung cancer 
(ES-SCLC )in combination with standard of care (SOC) 
chemo therapy
Trial Type Interventional
Type of control Placebo
Route of administration Intravenous (IV)
Trial Blinding Double -blind
Treatment GroupsArm 1: Pembrolizumab +EP:  
Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1
Etoposide 10 0mg/m2IV Q3W on Days 1, 2, and 3
Platinum, investigator’s choice
Carboplatin titrated to an area under the plasma drug
concentration -time curve (AUC) of 5 IV Q3W on Day 1
OR
Cisplatin 75 mg/m2IV Q3W on Day 1
Arm 2: Placebo +EP:  
Placebo IV Q3W on Day 1
Etoposide 10 0mg/m2IV Q3W on Days 1, 2, and 3
Platinum, investigator’s choice
Carboplatin titrated to an AUC of 5 IV Q3W on Day 1
OR
Cisplatin 75 mg/m2IV Q3W on Day 1
Number of trial subjects Approx imately 430subjects will be enrolled.
Estimated duration of trial The Sponsor estimates that the trial will require approximately 
4.5years from the time the first subject signs the informed consent 
until the last subject’s last study -related phone call or visit.
Duration of Participation Each subject will participate in the trial from the time the subject 
signs the informed consent form through the fin al protocol -specified 
contact.
After a screening phase of up to 28 days, each subject will be 
randomized to receive trial treatment (pembrolizumab +EP or 
placebo +EP). The SOC treatment component (EP)will be given 
for the first 4cycles with pembrolizumab or placebo, after which 
partial and complete responders may receive prophylactic cranial 
irradiation at the discretion of the investigator. Treatment with 
pembrolizumab or placebo will continue until atotal of 35 cycles of 
treatment have been administered or until one of the treatment 
discontinuation criteria occurs: confirmed disease progression ,
unacceptable adverse event (s) (AEs), intercurrent illness,
Product:   MK-3475 16
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialinvestigator decision to withdraw  the subject, noncompliance ,or 
administrative reasons requiring cessation of treatment .
Subjects who experience documented progressive disease (PD)
verified by blinded independent central review will have the option 
to remain on study and continue receiving the originally assigned 
trial treatment for a total of 35cycles at the discretion ofthe 
investigator (Section 7.1.5.5 ).
Subjects who stop trial treatment after receiving 35 administrations 
of trial treatment for reasons other than PDor intolerability may be 
eligible for the Second Course Phase, up to 17 additional 
administrations of pembrolizumab (approximately 1 year) ,upon 
experiencing disease progression (Section 7.1.5.4). Subjects in the 
saline placebo arm are not eligible for the Second Course Phase.
After the end of treatment, each subject will be followed for the 
occurrence of AEs and spontaneously reported pregnancy 
(Section 7.2).
Subjects who discontinue for reasons other than PDwill have 
post-treatment follow -up for disease status until experiencing PD
confirmed by the site per immune -related Response Evaluation 
Criteria in Solid Tum ors (irRECIST) orper RECIST version 1.1
(modified to follow  a maximum of 10 target lesions and a maximum 
of 5 target lesions per organ) as assessed by BICR , i
nitiating a non-
study cancer treatment, withdraw ing consent, or becoming lost to 
follow -up.  All subjects will be follow ed by telephone for overall 
survival until death, withdrawal of consent, or the end of the study.
A list of abbreviations used in this document can be found in Section 12.6.
2.0TRIAL DESIGN
Trial Design
This is a worldwide, randomized, placebo -controlled, Phase 3, parallel group, multi -site, 
double -blind trial of pembrolizumab plus standard of care (SOC )chemotherap y (EP) in 
subjects with ES-SCLC who have not previously  received systemic therap yfor this 
malignancy .
Approximately  430subjects will be randomized (1:1) to either pembrolizumab +EP or 
placebo +EP. Randomization will be stratified by type of platinum therapy  (cisplatin or 
carboplatin), Eastern Cooperative Oncology  Group (ECOG) performance status score 
(0or1), and lactate dehy drogenase (LDH) measurement (≤or > upper limit of normal 
[ULN])at baseline .Positive tumor programmed cell death -ligand 1 (PD-L1) expression will 
not be required for enrollment; however, subjects’ tumors will be screened for PD-L1
expression. An overview of the trial design is depicted in Figure 1.
Prior to randomization, the investigator will determine whether the subject will receive 
cisplatin or carboplatin. Subjects are allowed to switch from cisplatin to carboplatin if the Randomization Ratio 1:1
Product:   MK-3475 17
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidentialsubject develops an adverse event (AE) ,becomes ineligible for further cisplatin therapy ,
and/orthe investigator considers switching to carboplatin to be in the best interest of the 
subject.
During theTreatment Phase, subjects will have a study  visitevery  3 weeks (Q3W )for 
assessments and trial treatment administration. In Cycles1 to 4, subjects will receive the 
SOC treatment component (EP)along with either pembrolizumab 200 mg or placebo.
Subjects in either treatment arm who achieve a partial response (PR) or complete response 
(CR) at the completion of Cy cle4may be offered prophy lactic cranial irradiation ( PCI)at the 
discretion of the investigator (Section 7.1.2.6). Treatment with PCI should begin within 2 to 
4weeks (no later than 6weeks) after the last trial treatment in Cycle4.Trial treatment may 
continue during PCI; however, if it is necessary  to suspend trial treatment, it must be 
restarted no later than 2weeks after completion of PCI. Subjects will continue to receive 
treatment with pembrolizumab or placebo Q3W for up to an additional 31cycles (up to 
35cyclestotal) or until occurrence of one or more treatment discontinuation criteria: disease 
progression as assessed by blinded independent central review (BICR) confirmed per 
Response Evaluation Criteria in Solid Tumors version 1.1 (RECI ST v1.1)(modified to 
follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ) , 
intolerable toxicity or unacceptable AEs, intercurrent illness that prevents further 
administration of treatment, investigator decision
to withdraw the subject, noncompliance 
with trial treatment or procedure requirements, or administrative reasons requiring cessation 
of treatment.
After randomization, subjects will be evaluated with radiographic imaging to assess response 
to treatment; treatment -based decisions should be made by the investigator based on 
immune -related RECIST (irRECI ST)(Section 4.2.3. 5).All imaging obtained on study  will 
be submitted forBI
CRusing RECI ST 1.1 for verification of progressive disease ( PD)and for 
determination of objective response rate (ORR) and progression -free survival (PFS). Adverse 
event monitoring will be ongoing throughout the trial and AEs will be graded forseverity 
according to the guidelines outlined in the National Cancer Institute (NCI) Common 
Terminology  Criteria for Adverse Events version 4.0(CTCAE 4.0) .
After verification of PD as assessed byBICR per RECI ST 1.1(modified to follow a 
maximum of 10 target lesions and a maximum of 5 target lesions per organ) , subjects will 
have the option to remain on study  and continue receiving the originally  assigned trial 
treatment for a total of 35cycles at the discretion of the investigator, provided they are 
deemed to be benefiting and are clinically  stable (Section 7.1.2.7.6). Alternatively , subjects 
may choose to receive treatment with an appropriate second -line (2L) therapy  as determined 
by the investigator.
At the discretion of the investigator and in consultation with the Sponsor , subjects assigned 
to the pembrolizumab arm who complete 35treatment
administrations may be eligible for 
retreatment with open -label pembrolizumab monotherap y at the time of radiographic disease 
progression (verified by BICR) , provided that no other systemic therapy  for SCLC has been 
administered .This retreatment is calle dthe Second Course Phase (Section 6.2 and 
Section 7.1.5.5). Subjects in the saline placebo arm are not eligible for the Second Course 
Phase. Treatment assignment 
will be unblinded for those subjects who meet all criteria for 
Product:   MK-3475 18
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidentialthe Second Course Phase. Response or progression during the Second Course Phase will not 
be included in the analy ses of the ORR or PFS endpoints in this trial.
After the end of treatment, each subject will be followed for a minimum of 30 days for AE
monitoring even if the subject started non-study antineoplastic treatment . Serious adverse 
events (SAEs )will be documented for up to 90 days following cessation of the Sponsor’s 
product, or 30 days following cessation of treatment if the subject initiates non-study  cancer 
treatment , whichever is earlier .
After this period, anySAEs considered to be related to the 
trial treatment must be reported .Subjects will have post-treatment follow -up for disease 
status, until initiating a non-study  cancer treatment, experiencing disease progressio n or
death, withdrawing consent, or becoming lost to follow -up. After documented disease 
progression or the start of non-study  cancer treatment ,subjects will have contact with study 
personnel by telephone until death, withdrawing consent, or becoming lostto follow -
up.The 
Sponsor may request survival status to be assessed at additional time points and entered into 
the database during the course of the trial. For example, survival status may be requested 
prior to, 
but not limited to, external Data Monitori ng Committee (DMC) review s,as well as 
atinterim and/or final analy ses.
This trial has dual primary  endpoints: 1) PFS as assessed by  BICR per RECIST 1.1 modified 
to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ and 2) 
overall survival (OS). Trial results will be considered positive if the hypothesis test for either 
one of these primary  endpoints is successful. Efficacy  also will be evaluated using ORR ( key 
secondary  endpoint )and duration of response (duration of respons e [DOR ]; secondary  
endpoint ) as assessed by BICR per RECI ST 1.1 
modified to follow a maximum of 10 target 
lesions and a maximum of 5 target lesions per organ (Details are provided in the Site I maging 
Manual ).
Safety  will be assessed using NCI CTCAE 4.0 andis a secondary  endpoint. Quality  of life 
assessments encompass both secondary  and exploratory  endpoints. Additional exploratory 
analyses will include: PFS using investigator -assessed irRECI ST;ORR using investigator -
assessed irRECI ST; DOR using investigator -assessed irRECI ST; PFS, OS,and ORR in 
PD-L1 subgroups ;and identification of additional biomarkers of response.
Two interim efficacy  analy ses and 1 final analy sisare planned in this study .This trial will 
use a group sequential design based on pre-specified criteria, using anindependent, external
DMC to monitor safety  and efficacy results. Details are described in Section 8.0.
Specific procedures to be performed during the trial, as well as their prescribed times and 
associated visit window s, are outlined in the Trial Flow Chart - Section 6.0. Details of each 
procedure are provided in Section 7
.0 –Trial Procedures.
Product:   MK-3475 19
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Trial Diagram
Abbreviations:  ECOG=Eastern Cooperative Oncology Group , EP=etoposide / platinum , LDH= lactate dehydrogenase , 
PD=progressive disease , PFS= progression -free survival , Q3W= every 3weeks , RECIST 1.1=Response Evaluation Criteria 
in Solid Tumors version 1.1 , SCLC= small cell lung cancer , ULN= upper limit of normal
See Study Flow Chart (Sec tion6.2) for details regarding S econd Course Phase
Figure 1Trial Design Overview

Product:   MK-3475 20
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential3.0OBJECTIVE(S) & HYPOT HESIS(ES)
To accomplish the objectives listed below, pembrolizumab +EPwill be compared with 
placebo +EP for thetreatment of subjects with 
newly  diagnosed ES-SCLC.
Primary Objective(s) & Hypothesis (es)
1)Objective:   To evaluate PFS as assessed by BICR per RECI ST 1.1 modified to 
follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ .
Hypothesis (H1):   Pembrolizumab +EPprolong sPFS per RECI ST 1.1 by BICR
compared with placebo +EP.
2)Objective:   To evaluate OS.
Hypothesis (H2):   Pembrolizumab +EPprolongs OScompared with placebo +EP.
The study  is considered to have met its objective if the pembrolizumab +EP arm is superior 
to placebo +EP in PFS or OS .
Secondary Objective(s) & Hyp othesis(es)
1)Objective :  To evaluate ORR as assessed by BICR per RECIST 1.1modified to 
follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ .
Hypothesis :  Pembrolizumab +EPimprove sORR per RECI ST 1.1 by BICR 
compared to placebo +EP.
2)Objective :  To evaluate DOR as assessed by BICR per RECIST 1.1 modified to 
follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ .
3)Objective:   To evaluate the safet y profile in each treatment arm using NCI CTCAE 
4.0.
4)Objective: To evaluate the following patient- reported outcomes ( PROs ):
Mean change from baseline at Week 18 in global health status/ quality of life 
using the European Organization for Research and Treatment of Cancer (EORTC )
Quality  of Life Questionnaire Core 30 (QLQ -C30)global health status/ quality  of 
lifescale . If the overall PRO completion or compliance rates at Week 18are less 
than 60% or 80%, respectivel y, then the primary  analysis time poin t will be 
moved to the next earliest time point in which the rates are at least 60% for 
completion and at least 80% for compliance .
Time to true deterioration in the composite endpoint of cough, chest pain,and 
dyspnea using the EORTC QLQ-C30 and Lung Canc er Module 13 ( QLQ -LC13 ).
Product:   MK-3475 21
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Exploratory Objectives
1)Objective: To evaluate changes in health- related quality oflife assessments from 
baseline using the EORTC QL Q-C30 and EORTC QLQ -LC13.
2)Objective: To characterize utilities using the European Quality of Life 
Five-dimension Five -level Scale Questionnaire (EQ -5D-5L).
3)Objective: To evaluate ORR, PFS, and DOR per irRECI ST as assessed by the 
investigator.
4)Objective: To evaluate ORR andPFS as assessed by BICR per RECI ST 1.1 modified 
to follow a maximum of 10 target lesions and a maximum of 5 target lesions per 
organ , and OS by PD-L1 expression (tumor proportion score [TPS]<1% versus ≥1%, 
combined positive score [CPS]<1 versus ≥1) .
5)Objective: To evaluate the relationship between deox yribonucleic acid (DNA)
mutational burden and ribonucleic acid (RNA )immune signatures analy ses and 
clinical outcome .
6)Objective: To identify  molecular (genomic, metabolic and/or proteomic) biomarkers 
that may be indicative of clinical response/resistance, safet y, pharmacody namic
activity , and/or the mechanism of action of pembrolizumab +EP.
4.0BACKGROUND & RATIONA LE
Background
Refer to the Investigator’s Brochure (IB)/ approved labeling for detailed background 
information on MK -3475 .
Pharmaceutical and Therapeutic Background
The importance of intact immune surveillance in controlling outgrowth of neoplastic 
transformation has been known for decades [1]. Accumulating evidence shows a correlation 
between tumor -infiltrating lymphocy tes(TILs) in cancer tissue and favorable prognosis in 
various malignancies [2] [3] [4] [5] [6][7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 
[19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . In 
particular, the presence of CD8+ T cells and the ratio of CD8+ effector T-cells to FoxP3+ 
regulatory  T-cells seems to correlate with improved prognosis and long -term survival in solid 
malignancies such as ovarian, colorectal, and pancreatic cancer, hepatoce llular carcinoma, 
malignant melanoma and renal cell carcinoma. Tumor -infiltrating lymphocy tes can be 
expanded ex vivo and re infused, inducing durable objective tumor responses in cancers such 
as melanoma [38] [39] .
The programmed cell death protein -1 (PD- 1) receptor -ligand interaction is a major pathway  
hijacked by tumors to suppress immune control. The normal function of PD-1, expressed on 
Product:   MK-3475 22
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialthe cell surface of activated T cells under healthy  conditions, is to down -modulate unwanted 
or excessive immune responses, including autoimmune reactions. The PD-1 receptor 
(encoded by the gene Pdcd1) is an immunoglobulin (Ig) superfamily  member related to 
CD28 and cytotoxic T-lymphocy te-associated protein 4 (CTLA -4) and has been shown to 
negativel y regulate antigen receptor signaling upon engagement of its ligands (PD-L1 and/or 
programmed cell death -ligand 2 [PD- L2]) [40] [41]. The mechanism by which PD-1 down 
modulates T -cell responses is similar to, but distinct from that of CTLA -4, as both molecules 
regulate an overlapping set of signaling proteins [34] [42]. The PD-1 receptor was shown to 
be expressed on activated lymphocy tes, including peripheral CD4+ and CD8+ T
-cells, B-
cells, regulatory  T cells, and natural killer cells [43] [44]. The ligands for PD-1 (PD- L1 and 
PD-L2) are constitutively  expressed or can be induced in a variet y of cell types, including 
non hematopoietic tissues as well as in various tumors [42] [45] [46] [47] . Both ligands are 
type I transmembrane receptors containing both IgV-and IgC-like domains in the 
extracellular region and contain short cytoplasmic regions with no known signaling motifs. 
Binding of either ligand to PD-1 inhibits T-cell activation trigge red through the T-cell 
receptor. Expression of PD-L1 occurs at low levels on various non hematopoietic tissues, 
most notably  on vascular endothelium, whereas expression of the PD L2 protein is only 
detectable on antigen -presenting cells found in lymphoid tissue or chronic inflammatory 
environments. Immune T-cell activation in lymphoid organs is thought to be controlled by 
PD-L2, whereas PD-L1 serves to dampen unwarranted T-cell function in peripheral tissues 
[45]. Although health y organs express little (if any) PD-L1, a variet y of cancers were shown 
to express abundant levels of this T-cell inhibitor. High expression of PD-L1 on tumor cells 
(and to a lesser extent, expression of PD -L2) has been found to correlate with poor prognosis 
and survival in various cancer types, including renal cell [48], pancreatic [49], hepatocellular 
[50], and ovarian [51]. Furthermore, PD-1 may also regulate tumor -specific T-cell expansion 
in subjects with melanoma [52]. The prognostic implications of PD-L1 expressio n in 
advanced tumors are being investigated further in ongoing epidemiologic studies.
Because the PD-1/PD -L1 pathway  plays a critical role in tumor immune evasion , it is an 
attractive target for therapeutic intervention .Pembrolizumab is a potent and highl y selective 
humanized monoclonal antibody  of the IgG4/kappa isoty pe designed to directly  block the 
interaction between PD-1 and its ligands, preventing attenuation of the immune system.
Pembrolizumab clinical trials are ongoing in a number of advanced cancer types, including
melanoma, non-small cell lung cancer (NSCL C), head and neck cancer, urothelial cancer, 
triple -negative breast cancer, gastric cancer ,and hematologic malignancies. For study  details ,
refer to the IB.
Information on Other Trial -related Therapy
Etoposide/Platinum Therapy
Standard first-line(1L) treatment for the vast majority  ofpatients with SCLC, regardless of 
stage, involves combination chemotherap y with etoposide plus cisplatin or carboplatin.
The etoposide/cisplatin regimen was tested in SCLC because this combination produced 
synergistic activity  in preclinical systems. In addition, both agents could be given at full 
doses because of less myelosuppression with cisplatin. The first report of demonstrated 
Product:   MK-3475 23
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialactivity  with the combination dates back to 1979 [53].Subsequent randomized trials 
compared etoposide/cisplatin to cyclophosphamide, vincristine, and an anthracy cline [54] 
[55] [56].Less myelosuppression occurred with etoposide/cisplatin, and, when given with 
radiation, patients experienced less esophagitis and interstitial pneumonitis. Retrospective 
analyses and meta -analy ses also support the superiority  of a cisplatin- or carbopla tin-
containing regimen for SCLC [57] [58] [59]. As a result, EPis now the standard 1L 
chemotherap y regimen for SCLC.Several randomized studies evaluating etoposide and 
cisplatin compared with other regimens have shown consistent results for this doublet with 
response rates of 45% to 60%, median time to progression of 5 months ,and median OS of 10 
months
[60] [61].  Notably, emerging data from recent global trials evaluating novel 
treatments in SCL C demonstrated a lower median PFS of approximately  4.3 to 4.4 months in 
the EPcontrol arm, yet median OS remains consistent at approximately  10.3 to 10.9 months
[62] [63] .
Carboplatin has been substituted for cisplatin in SCL C chemotherapy  regimens in an effort to 
decrease non-hematologic toxicities. Randomized trials comparing cisplatin and carboplatin 
suggest that these compounds may have similar efficacy .One such study  was conducted by 
the Hellenic Cooperative Oncology  Group, which randomized 147 patients with either 
limited or extensive disease to receive etoposide 100 mg/m2 on Days 1 to 3 and cisplatin 
100mg/m2 or carboplatin 300 mg/m2 on Day 1 of each cy cle [64]. Concurrent radiation was 
also administered to responding patients starting with the third cycle.Response and survival 
were similar in the 2 arms. Nausea, vomiting, nephrotoxicity , and neurotoxicity  were 
significantl y lower in the patients who received carboplatin, as was Grade 4 leukopenia.
Unfortunatel y, the sample size was inadequate to confirm equivalent efficacy .A subsequent
meta -analysis evaluated individual subject data from 4 randomized trials with a total of 663 
patients and found that median OS, median PFS,and response rates were similar in the 
cisplatin and carboplatin arms. While hematologic toxicities were higher in patients treated 
with carboplatin, non-hematologic toxicit ies were increased in patients treated with cisplatin 
[65].Based on these data, etoposide /carboplatin can be considered an appropriate 1L regimen
to treat SCL C, particularly in patients who cannot tolerate cisplatin.
Multiple randomized studies have evaluated whether continuation beyond 4to 6cycles of 
chemotherap y is necessary .Overall survival is not improved if patients receive additional 
cycles of the same regimen used for induction [66] [67], maintenance oral etoposide or 
sunitinib after an etoposide -containing 1Lregimen [68] [60] [69], or consolidation with 
different chemotherapeutic regimens after 4cycles of EP [70] [71].Treatment beyond 6
cycles of chemotherap y isnot recommended for ES-SCLC by the National Comprehensive 
Cancer Network [72], the European Society  of Medical Oncology  Guidelines [73], orthe 
American Society  of Clinical Oncology  [74]. Recent trials in this patient population have 
administe red 4cycles of therapy  [60] [61] [63] .
Prophylactic Cranial Irradiation
Brain metastases are common in SCL C. A pproximately  18% of patients have central nervous 
system involvement at diagnosis [75],and another 20% to 25% of patients develop brain 
metastasis during the course of their disease, thelikelihood increasing with lengthening 
Product:   MK-3475 24
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidentialsurvival [76] [77]. At postmortem examination, brain metastases are found in up to 65% of 
patients who had SCL C[78].
In a meta -analysis of almost 1,000 patients in 7 trials between 1977 and 1995, patients were 
evaluated with and without PCI after initially  obtaining a complete response [79]. 
Prophy lactic cranial irradiation doses ranged from 24 to 40 Gy in most patients. Three -year 
survival rates increased from 15% without PCIto almost 21% with PCI.Additional findings 
included a significantly  decreased probability  of brain metastases and increased likelihood of 
disease -free survival. Higher doses of radiation appeared to be more effective in preventing 
brain metastases, but had no impact on survival. A trend toward a decreased risk of brain 
metastases was observed when PCI  was administered earlier.
A survival benefit 
with PCI in patients with ES-SCLC who had a response to chemotherap y 
was demonstrated in anEORTC randomized trial (N=286) [80].Significantly , addition of 
PCI therap yimprove dthe rate of 1-year freedom from symptomatic brain metastases from 
14.6% to 40.4% and improved the1-year survival rate from 13.3% to 27.1%. Vario us 
fractionation schemes were used;the most common were 20Gy in 5fractions and 30 Gy in 
10fractions. Thetrial did not mandate pre-treatment brain imaging to rule out clinically 
occult brain metastases, which has raised the question of 
whether the observed survival 
benefit was due to treatment of patients who alread y had detectable brain metastases.
Regardless, the results of the EORTC trial established PCI as a standard consideration for all 
patients with ES-SCLCwho achiev ea response to initial thera py.Yet, the American Societ y 
of Clinical Oncology  Guidelines note that this may be subject to change upon final 
publication of a recentl y conducted study  in Japan .The study  randomized 163 patients with 
ES-SCLC who responded to 1L therap y to either PCI (25 Gy in 10 fractions) or observation 
andfailed to demonstrate a survival advantage for PCI [74].
More recentl y, standard -dose versus higher -dose PCI has been evaluated after complete 
response (CR) in patients with limited stage small cell lung cancer (LS-SCLC)in an 
Intergroup trial [81].Seven hundred twenty  patien ts were randomized to either 25Gy in 10 
fractions or 36 Gy delivered in 18 daily  fractions of 2Gy or 24 twice -daily  fractions of 1.5 
Gy.There was no significant difference in incidence of brain metastases between the 
standard -dose group and the high-dose group. The OS was significantl y worse in the higher -
dose group, further establishing 25 Gy  in 10 fractions as the standard dose of PCI  for patients
with L S-SCLC.
Prophy lactic cranial irradiation is associated with AEs such as fatigue, hair loss, and 
decreased quality  of life [73].Long-term survivors have neurologic and intellectual 
impairment ,as well as abnormalities on computed tomograph y (CT)imaging that may be 
related to PCI [82] [83],which for some , causes reluctance to propose this treatment.
Consequently , PCI guidelines recommend that patients who proceed with PCI have a good 
performance status and adequate neurocognitive functioning, and that a full discussion occurs 
between the patient and phy sician, especially  in extensive stage disease [73] [72] .
Product:   MK-3475 25
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Rationale
Rationale for the Trial and Selected Subject Population
Small cell lung cancer remains a worldwide public health problem ; it is a major cause of 
cancer mortalit yandisstrongl y associat ed with tobacco exposure [84] [85].While in the 
United States there has been a decline in prevalence of tobacco use resulting in a gradual 
decrease in SCLC incidence over the past decade s, SCLC still accounts for 14% of all lung 
cancers, with approximately  30,000 patients diagnosed annuall y [86] [87].Approximately
275,000 patients worldwide are diagnosed with SCLC annually [84] [85] .
Small cell lung cancer is an aggressive neuroendocrine malignancy  with a unique natural 
history  characterized by a short doubling time, high growth fraction, and early development 
of widespread metastases. Although a chemotherapy -and radiation -sensitive disease, SCLC 
typicall y recurs rapidly  after primary  treatment, with only 6% of patients surviving 5 years 
from diagnosis.
Treatment of SCLC is notable for the lack of major developments; nearl y4 decades after the 
introduction of an EPdoublet, therapeutic options have remained virtually  unchanged, with 
correspondingl y little improvement in survival rates.
Radiation therapy  is administered to patients with LS-SCLC, whose cancer is confined to th e 
chest in a single tolerable radiation field. Patients with L S-SCLC or ES-SCLC who achieve a 
response to 1Lplatinum -based therapy  generally are offered PCI, which has been shown to 
decrease the risk of intracranial recurrence and improve OS[79] [80]. Additional efforts at 
improving outcomes with 1Ltherapy  for SCLC patients have been unsuccessful. Examples 
include the use of irinotecan instead of etoposide (in Western countries), alternating multi -
drug combinations, addition of a third chemotherapeutic drug to etoposide and cisplatin, and 
prolonging the number of cy cles of etoposide and cisplatin or carboplatin [88].
First-line treatment for SCLC yields optimal tumor response rates as high as 60%to 80%, 
which unfortunately  translates to cure in only approximately  20% of patients with LS-SCLC 
[89].Essentially  all patients with ES-SCLC, and the majority  of patients with LS-SCLC, 
suffer relapse within months of completing initial therap y.The strongest predictor of 
outcome for patients with relapsed SCL C is the duration of remission. Patients with sensitive 
disease ,who maintain a response to initial treatment for 3 months or more ,have aresponse 
rate to additional chemotherap y of about 25% and a median survival of about 6months from 
the time of relapse. In contrast, those patients with refractory  disease who either have no 
response to initial therapy or progres s within 3months, rarely benefit from additional 
treatment, with response rates <10% and median survival of 4 months.
Topotecan is the only Food and Drug Administration (FDA )-approved agent for recurrent or 
progressive SCLC, based on the results of three Phase 3 trials [90] [91] [92].There are no 
accepted regimens for patients whose disease has progressed after 1Land 2Ltreatments for 
SCLC.This is in stark contrast to the progress that has been made in the treatment of 
NSCL C,thus underscoring the critical need for more effective therapies in SCL C.
Product:   MK-3475 26
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialWhen considering new approaches to 1L treatment of SCLC,the dramatic initial tumor 
response to an EPregimen seen inthe large majorit y of SCLC patients must be 
acknowledged; however, in nearl y all cases ,the tumors become resistant to this treatment.
Several lines of evidence support modulati on of immune response in SCLC as a treatment 
modality .The disease is associated with immunogenic effects, evidenced by the prolonged 
survival of patients with autoantibodies (ie, anti-Hu) and neurol ogic paraneoplastic 
syndromes [93].The expression of major histocompatibility  complex antigens is reduced in 
SCLC and this may play a role in this tumor’s ability  to escape immune surveillance [94] 
[95].Interestingl y, effector T-cells associated with cytolytic response s are significantl y 
higher in the peripheral blood of patients with LS-SCLC compared to those with ES-SCLC 
and in long term disease -free survivors relative tothose with recurrent disease [96].More
recentl y, the PD-1/PD-L1 pathway , a major target of anti-tumor immunotherap y, has been 
interrogated in SCLC utilizing immunohist ochemistry (IHC) and RNA -expression to 
evaluate the presence of PD -L1 in primary  and metastatic tumor tissue as well as in TILs [97] 
[98] [99] [100] [101] .In general, 50% to 80% of tumor specimens were PD-L1-positive (ie, 
>5% of cells in the specimen express
edPD-L1).In several of these reports, when other 
patient characteristics and treatment outcome swere considered, patients with PD -L1-positive 
tumors had a longer OS,and higher PD-L1 expression strongl y correlated with limited -stage 
disease [98] 
[99] [100] [101] .However, each of these studies utilized different types of 
specimens, as well as antibodies.
Mutational burden appears to be an important determinant of response to immune checkpoint 
inhibitors. In a recent study  analyzing tumor mutational burden in NSCLC patients treated 
with pembrolizumab, higher mutational burden was associated with improved objective 
response, durable clinical benefit ,and prolonged PFS [102] .The association between 
response to PD-1 inhibitors, mutation alburden, and tobacco exposure may have important 
implications for SCLC,as this disease is strongl y associated with smoking and has a 
markedl y elevated mutation burden, as highlighted previously.
KEYNOTE -028 i s a Phase 1b multi- cohort study  of pembrolizumab forthe treatment of 
PD-L1-positive, advanced solid tumors including SCLC.Of the 147 subjects with evaluable 
ES-SCLC biops yspecimens who were screened , 42 (29%) hadPD-L1-positive tumors and, 
of these , 24 previously treated subjects were eventuall y enrolled. Notably , 21 patients 
(87.5%) were in need of third- line or greater therap y.The patients were treated with 
pembrolizumab monotherap y for up to 2years. Median duration of follow -up was
9.8months (range : 0.5to 24.0). The ORR was 37.5% (95% confidence interval [CI] 18.8 to 
59.4) and included 1CR and 8PRs. Median DOR was 9.0months (range: 1.9to 19.9+).
Median PFS was 1.9 months (range: 1.7to 5.9) and at 6 and 12 months ,29.8% and 24.8% of 
subjects were alive and progression-free , respectively .Median OS was 9.7months (95% CI 
4.1 to not reached) ;66.0% and 35.7% of subjects were alive at 6 and 12months, 
respectivel y.Treatment -related AEs were reported for 66.0% of subjects, including 
2subjects with Grade s 3to 5 treatment -related AEs. No new safet y concerns were identified
[103] .These results demonstrate that pembrolizumab monotherapy  has meaningful anti-
tumor activity  in heavily  pre- treated subjects with PD-L1-positive SCLC.In contrast, studies 
of topotecan as 2Ltreatment of SCLC demonstrated response rates of approximately  18%, 
Product:   MK-3475 27
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialmedian survival of 6 months, and duration of response of 7.5 months [104] [105] [106] [107] .
Based on this information, incorporating pembrolizumab treatment inthe 1Lsetting in SCL C 
patients may  lead to further improvement in outcomes.
Recently , Langer and colleagues reported results from KEYNOTE -021 Cohort G, a Phase 2
randomized trial comparing pembrolizumab /pemetrexed/ carboplatin with
pemetrexed/carboplatin 
alone for the treatment of subjects with newly  diagnosed NSCL C
regardless of PD-L1 tumor expressio n [108] .The ORR was 55% in the 
pembrolizumab/pemetrexed/carboplatin arm compared with 29% in the pemetrexed/ 
carboplatin alone arm (p=0.0016), and response soccurred 1month earlier in the 
pembrolizumab/pemetrexed/carboplatin arm. The improvement in response was observed in 
subjects with tumors of all PD-L1 expression levels. Progression -free survival was improved 
for the pembrolizumab/pemetrexed/carboplatin arm compared with the pemetrexed/ 
carboplatin alone arm (13 months versus 8.9 months, respectively ; p=0.0102). These data 
indicate that pembrolizumab with chemotherap y has the potential to be an effective 1L
treatment for SCLC and potentially  may be a regimen that can chang e outcomes in this 
disease.
Based on the previousl y mentioned data and a critical need for new therapies in SCLC, we 
are undertaking this worldwide, randomized, placebo -controlled, Phase 3, parallel group, 
multi- site, double- blind trial of pembrolizumab plus SOC chemotherapy (EP) in subjects 
with ES -SCLC who have not previously  received sy stemic therap y.
Rationale for Dose Selection/Regimen /Modification
Rationale for the Dose of Pembrolizumab
The planned dose of pembrolizumab for this trial is 200 mg Q3W. Based on the totality  of 
data generated in the Keytruda®development program, 200 mg Q3W is the appropriate dose 
of pembrolizumab across all indications regardless of tumor type.As outlined below, this 
dose is justified by : 
oClinical data from 8 randomize d studies demonst rating flat dose-and exposure -
efficacy  relationships from 2 mg/kg Q3W to 10 mg/kg every 2 weeks (Q2W ),
oClinical data showing meaningful improvement in benefit -risk,
including 
improvement in OS at 200 mg Q3W across multiple indications, an d
oPharmacology  data showing full target saturation in both systemic circulation 
(inferred from PK data) and tumor (inferred from physiologicall y based PKanalysis
[PBPK] ) at 200 mg Q3W .
Among the 8 randomized dose-comparison studies, a total of 2262 subjec ts with melanoma 
or NSCL C were enrolled, covering different disease settings (treatment naïve, previously 
treated, PD-L1 enriched, and all-comers) and different treatment settings (monotherap y and 
in combination with chemotherapy ).Five studies compared 2 mg/kg Q3W and 10 mg/kg 
Q3W (KEYNOTE -001 B2, KEYNOTE -001 D, KEYNOTE -002, KEYNOTE -010, and 
Product:   MK-3475 28
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialKEYNOTE -021), and 3 studies compared 10 mg/kg Q3W and 10 mg/kg Q2W 
(KEYNOTE -001 B3, KEYNOTE -001 F2,and KEYNOTE -006). All of these studies 
demonstrated flat dose-and exposure -response relationships across the doses studied 
representing an approximate 5-to 7.5-fold difference in exposure. The 2 mg/kg (or 200 mg 
fixed -dose) Q3W provided similar responses to the highest doses studied. Subsequently , flat 
dose-exposure -response relationships were also observed in subjects with other tumor types,
including head and neck cancer, bladder cancer, gastric cancer, and classical Hodgkin 
Lym phoma, confirming 200 mg Q3W as the appropriate dose independent of the tumor ty pe.
These fi ndings are consistent with the mechanism of action of pembrolizumab, which acts by 
interaction with immune cells, and not via direct binding to cancer cells.
Additionally , pharmacology  data clearly  show target saturation at 200 mg Q3W. First, PK 
data inKEYNOTE -001 evaluating target -mediated drug disposition conclusively 
demonstrated saturation of PD-1 in systemic circulation at doses much lower than 200 mg 
Q3W. Second, a PBPK analy sis was conducted to predict tumor PD-1 saturation over a wide 
range oftumor penetration and PD-1 expression. This evaluation demonstrated that 
pembrolizumab 200 mg Q3W achieves full PD -1 saturation in both blood and tumor.
Finally , population PK analysis of pembrolizumab, which characterized the influence of 
body  weight andother subject covariates on exposure, has shown that fixed dosing provides 
similar control of PK variability as weight -based dosing, with considerable overlap in the 
distribution of exposures from the 200 mg Q3W fixed dose and 2 mg/kg Q3W dose.
Supported by these PK characteristics, and given that a fixed dose has advantages of reduced 
dosing complexity  and reduced potential of dosing errors, the 200 mg Q3W fixed dose was 
selected for evaluation across all pembroliz umab protocols.
Rationale for Use of Com parator/Placebo
The use of saline placebo in combination with standard chemotherapy  will ensure the 
objectivity  of investigator- assessed progression ,as well as any decisions to 
interrupt/discontinue therapy .
Rationale for Efficacy Endpoints
Primary Efficacy Endp oints
Primary: This trial has dual primary  endpoints of PFS and OS.
PFS is an acceptable measure of clinical benefit for a randomized Phase 3 trial that 
demonstrates superiorit y of a new antineoplastic therap y, especiall y if the magnitude of 
effect is large and the therap y has an acceptable risk-benefit profile. PFS, as assessed by 
BICR per RECIST 1.1(modified to follow a maximum of 10 target lesions and a maximum 
of 5 target lesions per organ ),will be used to determine the dates of progression as this 
methodology  is accepted by regulatory  authorities. Images read by BICR blinded to 
treatment assignment can minimize bias in the response assessments. In addition, final 
determination of radiologic PD will be based on the BICR assessment of progression , rather 
than local site investigator/radiology  assessment. Expedited assessment by the BICR in 
Product:   MK-3475 29
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialinstances of suspected radiologic progression identified at the site (verification of PD) will be 
communicated to the site study  team.
Notably , PFS has demonstr ated strong potential surrogacy  for OS in 1Ltreatment of 
ES-SCLC and may  be a good alternative endpoint to OS in this disease [109] .
Overall survival has been recognized as the gold standard for the demonstration of 
superiority  of a new antineoplastic therap y in randomized clinical studies.
Secondary Efficacy Endpoints
The key secondary  efficacy  endpoint of this study  isORR assessed by BICR using 
RECI ST1.1modified to follow a maximum of 10 target lesions and a maximum of 5 target 
lesions per organ .Additionally , DOR assessed by BICR according to RECI ST1.1modified 
to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ is a 
secondary  endpoint .
Safety Endpoints
The incidence of AE/SAEs (including fatal SAEs), immune -related AEs, laboratory  
abnormalities, and rates of dose interruption and discontinuation due to AEs are important 
endpoints for safety  and tolerability  evaluations.
Patient Reported Outcomes
The EORTC QLQ -C30 and EORTC QLQ -LC13 will be used to investigate :(1) quality  of 
life and (2) disease -related symptoms. These questionnaires are not purely  efficacy  or safet y 
endpoints because they are affected by both disease progression and treatment tolerability .
EQ-5D-5L is an exploratory  endpoint that will be used to calculate health utilities for health 
economic models.
EORTC QLQ-C30 was developed to assess the quality  of life of subjects with cancer. It has 
been translated into 81 languages , validated, and used in more than 3000 studies worldwide.
It contains 5 functioning scales (physical, role, cognitive, emotional, and social), 3 symptom 
scales (fatigue, nausea, and pain) and additional single symptom items. It is scored on a 
4-point scale (1=not at all, 2 =a little, 3= quite a bit, 4 =very much). The EORTC QLQ -
C30 instrument also contains 2 global scales that use 7-point scale scoring with anchors 
(1=very poor and 7 =excellent).
The EORTC QLQ -LC13, a supplemental lung cancer -specific module, comprise s multi -item 
and single -item measures of lung cancer -associated symptoms (ie, coughing, hemopt ysis, 
dyspnea, and pain) and side effects from chemotherap y and radiation (ie, hair loss, 
neuropath y, sore mouth, and dysphagia). It is scored on a 4-point scale (1=not at all, 2 =a 
little, 3 =quite a bit, 4 =very much) and has been translated into 64 languages and validated.
The EQ-5D-5Lis a standardized instrument for use as a measure of health outcome. The 
EQ-5D-5L will provide data for use in economic models and analy ses including developing 
Product:   MK-3475 30
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialhealth utilities or quality -adjusted life-years.The 5 health state dimensions addressed in this 
instrument are mobility , self-care, usual activities, pain/discomfort, and anxiety /depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe 
problems, and extreme problems .
Immune -related RECIST
Immune -related RECI ST is RECI ST 1.1 adapted to account for the unique tumor response 
seen with immunotherapeutics as described byNishino et al[110] .The assessment of 
unidimensional target lesions and response categories per irRECI ST are identical to 
RECI ST1.1. However, Merck has implemented an adaptation related to new lesions, 
non-target lesions,and tumor burden assessment in order to confirm radiographic 
progression.
Immunotherapeutic agents such as pembrolizumab may produce anti-tumor effects by 
potentiating endogenous cancer -specific immune responses. The response patterns seen with 
such an approach may extend beyond the typical time course of responses seen with 
cytotoxic agents, and can manifest a clinical response after an initial increase in tumor 
burden or even the appearance of new lesions. Thus, standard RECIST 1.1 may not provide 
anaccurate response assessment forimmunotherapeutic agents such as pembrolizumab.
Based on an analy sis of patients with melanoma enrolled in KEYNOTE -001 [111] , 7%of 
evaluable patients experienced delay ed or early tumor pseudo -progression. Of note, patients 
who had progressive disease by RECIST 1.1 but not by irRECIST ,had longer OS than 
patients with PDby both criteria. Additionally , the data suggest that RECI ST 1.1 may 
underestimate the benefit of pembrolizumab in approximately  15% of patients. These 
findings support the need to apply  a modification to RECI ST 1.1 that takes into account the 
unique patterns of atypical response toimmunotherap y and enable treatment beyond initial 
radiographic progres sion.
Local site investigators will use irRECI STto assess tumor response and progression and to 
make treatment decisions.
For further information on irRECI ST, see Section 7.1.2. 7.6.
Planned Exploratory Biomarker Research
Cancer immunotherapies represent an important and novel class of anti-tumor agents.
However, the mechanism of action of these exciting new therapies is not completel y 
understood and much remains to be learned regarding how best to leverage these new drugs 
in treating subjects .Thus, to aid future subjects , it is important to investigate the 
determinants of response or resistance to cancer immunotherapy  as well as determinants of 
AEs in the course of our clinical trials. These efforts will identify  novel 
predictive/pharmacod ynamic biomarkers and generate information that will better guide 
Product:   MK-3475 31
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidentialsingle -agent and combination therapy  with immuno -oncology  drugs. To identify  novel 
biomarkers, we will collect biospecimens (eg, blood components, tumor material) to support 
analyses of cellular components (eg, protein, DNA, RNA, metabolites) and other circulating 
molecules. Investigations may  include but are not limited to:
Germline (blood) genetic analyses (eg, single nucleotide polymorphism analy ses, whole 
exome sequencing, whole genome sequencing ):This research will evaluate whether genetic 
variation within a clinical trial population correlates with response to the treatment(s) under 
evaluation. If genetic variation is found to predict efficacy  or AEs, the data might inform 
optimal use of therapies in the patient population. Furthermore, it is important to evaluate 
germline DNA variation across the genome in order to interpret tumor -specific DNA 
mutations. Finally , microsatellite instability may be evaluated as this is an important 
biomarker for som e cancers (ie, colorectal cancer).
Genetic (DNA) analy ses from tumor : The application of new technologies, such as next 
generation sequencing, has provided scientists the opportunity  to identify  tumor -specific 
DNA changes (ie, mutations, methy lation status, microsatellite instability ). Key  molecular 
changes of interest to immun o-oncology  drug development include the mutational burden of 
tumors and the clonality  of T
-cells in the tumor microenvironment. Increased mutational 
burden (sometimes referred to as a‘hyper-mutated’ state) may generate neo-antigen 
presentation in the tumor microenvironment. In order to conduct this type of research, it is 
important to identify  tumor -specific mutations that occur across all genes in the tumor 
genome. Thus, genome -wide approaches may be used for this effort. Note that in order to 
understand tumor -specific mutations; it is necessary  to compare the tumor genome with the 
germline genome. Microsatellite instability may also be evaluated as this is an important 
biomarker for some cancers (ie, colorectal cancer).
Tumor and blood RNA analyses: Both genome -wide and targeted messenger RNA 
expression profiling and sequencing in tumor tissue and blood may be performed to define 
gene signatures that have a correlation to clinical response to treatment with pembrolizumab 
or other immunotherapies. Pembrolizumab induces a response in tumors that likely  reflects 
an inflamed/immune phenoty pe.Specific immune -related gene sets (such as those capturing 
interferon -gamma transcriptional pathwa ys) may be evaluated and new signatures may be 
identified. Individual genes related to the immune system may also be evaluated (eg, IL-10).
MicroRNA profiling may  also be pursued.
Proteomics and IHC using blood and tumor : Tumor and blood samples from this study  may 
undergo proteomic analy ses (eg, PD-L1 IHC). PD-L1 protein level in tumor sections, 
assessed by IHC, has been shown to correlate with response to pembrolizumab in subjects
with NSCL C, and anin vitro diagnostic device has been developed for use with 
pembrolizumab in NSCLC. Preliminary  data indicate that this association may  also be true in 
additional cancer types (ie, triple -negative breast cancer , head and neck cancer ,and gastric
cancer ).Since many tumor or blood -derived proteins may correlate with response to 
pembrolizumab, tumor tissue may be subjected to proteomic analy ses using a variet y of 
platforms including, but not limited to,immunoassays and liquid chromatograph y/mass 
Product:   MK-3475 32
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialspectrometry .This approach could identify  novel protein biomarkers toaid in patient 
selection for pembrolizumab therap y.
Other blood derived biomarkers : In addition to expression on the tumor tissue, PD-L1 and 
other tumor- derived proteins can be shed from tumor and released into the blood. Assay s 
such as enzyme-linked immunoassay smeasure these proteins in serum. The correlation of 
such expression with a response to pembrolizumab therap y may lead to identification of new 
approaches forusing predictive biomarkers in blood, representing a major advance from 
today’s reliance on assessing tumor biomarkers. This research would serve to develop such 
assay s for future clinical use .
Future Biomedical Research
The Sponsor will conduct Future Biomedical Research on specimens consented for future 
biomedical research during this clinical trial.  This research may include genetic anal yses 
(DNA), gene expression profiling (RNA), proteomics, metabolomics (serum, plasma) and/or 
the measurement of other analytes, depending on which specimens are consented for future 
biomedical research.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main trial) and will only be conducted on specimens from 
appropriatel y consented subjects. The objective of collecting /retaining specimens for Future 
Biomedical Research is to explore and identify  biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs /vaccines , and/or to ensure that 
subjects receive the correct dose of the correct drug/vaccine at the correct time.  The details 
of this Future Biomedical Research sub-trial are presented in Section 12.2 –Collection and 
Management of Specimens for Future Biomedical Research.
Benefit/Risk
It cannot be guaranteed that subjects in clinical trials will directly  benefit from treatment 
during participation ,as clinical trials are designed to provide information abou t the safety 
and effectiveness of an investigational medicine.
As described in Section 4.2.1, KEYNOTE -028 demonstrated that pembrolizumab 
monotherap y has meaningful anti-tumor activity  in heavil y pre-treated subjects with 
PD-L1-positive SCLC.Pembrolizumab in combination with chemotherapy  hassignificant 
clinical activity  as 1Ltherapy  in subjects with advanced NSCLC , regardless of PD-L1 
expression, as shown in KEYNOTE -021 Cohort G(Section 4.2.1) .Considering the high 
unmet medical need for new and tolerable treatment options in subjects with newl y 
diagnosed ES -SCLC, the anti -tumor activity and the favorable safet y profile of 
pembrolizumab in combination with chemotherap y regimens for other solid tumors , a 
combination of PD -1 blockade plus chemotherap y is a promising therapeutic strategy  and the 
benefit -risk assessment for subjects included in this trial is considered to be favorable.
Product:   MK-3475 33
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialAdditional details regarding specific benefits and risks for subje cts participating in this 
clinical trial may  be found in the accompan yingIB and informed c onsent documents.
5.0METHODOLOGY
Entry Criteria
Diagnosis/Condition for Entry into the Trial
Male and f emale subjects with ES-SCLCwill be enrolled in this trial.
Subje ct Inclusion Criteria
In order to be eligible for participation in this trial, the subject must:
1.Have a documented new diagnosis of SCLC by histology  or cytology  from brushing, 
washing ,or needle aspiration of a defined lesion .Subjects who do not have histology 
samples 
(defined as core or excisional biopsy , or resections) will need to undergo a 
new biopsy  to provide a tissue sample.
2.Have extensive stage disease defined as Stage IV (T any, N any, M 1a/b) by the 
American Joint Committee on Cancer, Seventh Edition .
3.Have at least 1 lesion that meets the criteria for being measurable, as defined by 
RECI ST 1.1, and is appropriate for selection as a target lesion, as determined by  local 
site investigator/radiology  review .Lesions that appear measurable ,but have 
undergone palliative irradiation, cannot be target lesions.
4.Have provided archival tumor tissue sample or newly  obtained core or excisional 
biopsy  of a tumor lesion not previously  irradiated. Formalin -fixed, paraffin -embedded 
tissue blocks are preferred to slides.
5.Have ECOG Performance Status of 0 or 1. See Section 12.3 for definitions.
6.Have a life expectancy  of at least 3 months.
7.Have adequate organ function as indicated bythe following laboratory  values
(Table 1).
Product:   MK-3475 34
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialTable 1 Adequate Organ Function L ab Values
System Laboratory Value
Hem atological
Absolute neutrophil count (ANC) ≥1,500 /mcL
Platelets ≥100,000 / mcL
Hem oglobin ≥8 g/da
Renal
Serum creatinine OR
calculated creatinine clearance (CrCl)b
(GFR can also be used in place of 
creatinine or CrCl)≤1.5 ×ULN OR
≥60 mL/min for subjects with creatinine levels >1.5 × ULN 
receiving cisplatin
≥50 mL/min for subjects with creatinine levels >1.5 × ULN 
receiving carboplatin
Hepatic
Serum total bilirubin ≤1.5 × ULN OR
Direct bilirubin ≤ULN for subjects w ith total bilirubin levels 
>1.5 × ULN
AST (SGOT) and ALT (SGPT) ≤2.5× ULN 
≤5× ULN for subjects with liver metastases
Coagulation
International Normalized Ratio (INR) or 
Prothrombin Time (PT)≤1.5 × ULN unless the subject is receiving anticoagulant 
therapy as long as PT or INR is within therapeutic range of 
intended use of anticoagulants
Abbreviations: ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); 
AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration 
rate; INR=International Normalized Ratio; ULN=upper limit o f normal.
aCriteri onmust be met without erythropoietin dependency and without packed red blood cell(pRBC) transfusion 
within last 2 weeks.
bCreatinine clearance (CrCl) should be calculated per institutional standard.
Note: This table includes eligibil ity-defining laboratory value requirements for treatment; laboratory value 
requirements should be adapted according to local regulations and guidelines for the administration of specific 
chemotherapies.
8.Be ≥18 y ears of age on day  of signing informed consent.
9.If female subject of childbearing potential ,have a negative urine or serum pregnanc y 
test within 72 hours prior to receiving the first dose of study  medication. If the urine 
test is positive or cannot be confirmed as negative, a serum pregnancy  test will be 
required.
10.If female and of childbearing potential ,be willing to use an adequate method of 
contraception as outlined in Section 5.7.2, starting with the first dose of study 
medication through 120 days after the last dose of pembrolizumab or sal ine placebo
orup to 180 days after last dose of chemotherapeutic agents , whichever is later .
Note: Abstinence is acceptable if this is the usual lifesty le and preferred contraception 
for the subject.
Product:   MK-3475 35
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential11.If male and of childbearing potential ,agree to use an adequate method of 
contraception as outlined in Section 5.7.2, starting with the first dose of study 
medication through 120 days after the last dose of pembrolizumab or saline placebo
orup to 180 day s after last dose of chemotherapeutic agents , whichever is later .
Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception 
for the subject.
12.Have voluntarily  agreed to participate by giving written informed consent/assent for 
thetrial. The subject may also provide consent/assent for Future Biomedical 
Research. However, the subject may participate in the main trial without participating 
in Future Biomedical Research.
Subject Exclusion Criteria
The subject must be excluded from participating in the trial if the subject:
1.Has received prior s ystemic therapy  for the treatment of SCL C.
Note: Palliative radiation therapy  is allowed until 7 day sprior to the first dose of trial
medication, provided that the radiated lesion is clinically  stable and the patient is not 
receiving steroids for at least 7daysprior to the first dose of study  medication. The 
radiated lesion must not be a thoracic lesion and must notbe included as a target 
lesion for RECIST 1.1 measurements.
2.Is currently  participating and receiving study  therapy  or has participated in a study  of 
an investigational agent and received study  therapy  or used an investigational device 
within 4 weeks of the first dose of treatment for another health- related problem .
Note: Subjects who have entered the follow -up phase of an investigational trial may 
participate as long as it has been at least 4 weeks since the last dose of the previous 
investigational agent.
3.Is expected to require any other form of antineoplastic therapyfor SCLC, including 
radiation therap y, while on study .
Note: Patients with PR or CRwill be offered PCI therapy  at the completion of the 
4cycles of chemotherapy  with or without pembrolizumab.
4.Has known central nervous system (ie, brain and/or spinal cord) metastases and/or 
carcinomatous meningitis. Subjects with brain metastases may  participate only ifthey
satisfy  all of the following :
Completed treatment (eg, whole brain radiation treatment [WBRT], stereotactic 
radiosurgery , or equivalent) at least 14 days prior to the first dose of trial 
treatment, 
Product:   MK-3475 36
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialHave no evidence of new orenlarging brain metastases confirmed by 
post-treatment repeat brain imaging (using the samemodality )performed at least 
3weeks after pre -treatment b rain imaging , and 
Are neurologicall y stable without the need for steroids for at least 7days before 
first dose of trial treatment as per local site assessment. 
5.Has had major surgery within 3 weeks prior to receiving the first dose of trial
treatment or has not recovered adequatel y from toxicity  and/or complications from an 
intervention prior to receiving the first dose of study treatment .
6.Has a history  of non-infectious pneumonitis that required steroids or has current 
pneumonitis
.
7.Has a kn own history  of interstitial lung disease.
8.Has a known additional malignancy  that is progressing or requires active treatment.
Exceptions include early stage cancers (carcinoma in situ or Stage 1) treated with 
curative intent, basal cell carcinoma of the sk in, squamous cell carcinoma of the skin, 
in situ cervical cancer, or in situ breast cancer that has undergone potentially  curative 
therap y.
9.Has active autoimmune disease that has required systemic treatment in the past 
2years (ie, with use of disease -modi fying agents, corticosteroids, or 
immunosuppressive drugs). Replacement therapy  (eg, thyroxine, insulin, or 
physiologic corticosteroid replacement therapy  for adrenal or pituitary  insufficiency ) 
is not considered a form of sy stemic treatment.
10.Has a known history  of
, oractive , neurologic paraneoplastic sy ndrome .
11.Has clinically  active diverticulitis, intra-abdominal abscess, gastrointestinal
obstruction, and/or abdominal carcinomatosis.
12.Has a history  ofa severe hypersensitivity  reaction to treatment with another 
monoclonal antibody .
13.Is taking chronic systemic steroids
(in dosesexceeding 10 mg daily of prednisone 
equivalent) within 7 day s prior to the first dose of trial treatment .
Note: Subjects with asthma or chronic obstructive pulmonary  disease that require 
intermittent use of bronchodilators, inhaled steroids, or local steroid injections would 
not be excluded from the study . 
14.Has a diagnosis of immunodeficiency  or is receiving any  form of immunosuppressive 
therap y within 7 days prior tothe firs t dose of trial treatment .
Product:   MK-3475 37
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential15.Has received a live vaccine within 30 days prior to the first dose of trial drug.
Examples of live vaccines include, but are not limited to, the following: measles, 
mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus 
Calmette –Guérin (BCG) , and typhoid vaccine. Seasonal influenza vaccines for 
injection are generally  killed virus vaccines and are allowed; however, intranasal 
influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allow ed.
16.Has received prior therapy with ananti-PD-
1, anti-PD-L1,or anti-PD-L2 agent or 
with an agent directed to another co-inhibitory  T-cell receptor (ie,CTLA -4, OX-40, 
CD137) or has previously participated in a Merck pembrolizumab (MK -3475) clinical 
trial.
17.Has severe hypersensitivity  (Grade ≥3) topembrolizumab and/or any of its 
excipients.
18.Has an active infection requiring systemic therapy .
19.Has a known history  of HIV infection. No HIV testing is required unless mandated by  
local health authorit y.
20.Has a known history  of hepatitis B (defined as hepatitis B surface antigen [HBsAg] 
reactive) or known active hepatitis C virus (defined as HCV RNA [qualitative] is 
detected) infection. 
Note: No testing for hepatitis B and hepatitis C is required unless man dated by local 
health authority .
21.Has a known history  of active TB (Bacillus Tuberculosis ).
22.Has a history or current evidence of any  condition, therapy , or laboratory  abnormality 
that might confound the results of the study , interfere with the subject’s participa tion 
for the full duration of the study , or is not in the best interest of the subject to 
participate, in the opinion of the treating investigator .
23.Has known psychiatric or substance abuse disorders that would interfere with 
cooperation with the requirements of the trial.
24.Has symptomatic ascites or pleural effusion. A subject who is clinically  stable 
following treatment for these conditions (including therapeutic thoraco- or 
paracentesis) is eligible.
25.Is pregnant or breastfeeding, or expecting to conceive or father children within the 
projected duration of the study starting with the screening visit through 120 days after 
the last dose of pembrolizumab or saline placebo or
up to 180 days after last dose of 
chemotherapeutic agents , whichever is later .
Product:   MK-3475 38
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Trial Treatment(s)
The t reatments to be used i n this trial are outlined below in Table 2.
Table 2 Trial Treatment s
Drug or
BiologicDose/
PotencyDose 
FrequencyRoute of 
AdministrationRegimen/
Treatment 
Period Use
Pembrolizumab 200 mg Q3W IVinfusion Day 1 of each 
cycle prior to 
chemotherapyExperimental
Saline Not 
applicableQ3W IV infusion Day 1 of each 
cycle prior to 
chemotherapyPlacebo 
comparator
Carboplatin AUC 5 Q3W IV infusion Day 1 of each 
cycle
Standard of 
careCisplatin 75 mg/m2Q3W IV infusion Day 1 of each 
cycle
Etoposide 100 mg/m2Q3W IV infusion Days 1, 2, 3 of 
each cycle
Trial treatment should begin on the day of randomization or as soon as possible, but no later 
than 3 day s after randomization .
All supplies indicated in Table 2above will be provided centrally  by the Sponsor or locally 
by the trial site, subsidiary or designee, depending on local country  operational or regulatory 
requirements.
For any commercially  available product that is provided by the trial site, subsidiary  or 
designee every  attempt will be made to source these supplies from a single lot/batch number. 
The trial site is responsible for recording the lot number, manufacturer, and expiry  date for 
any locally  purchased product as per local guidelines unless otherwise instructed by the 
Sponsor .
The investigator shall take responsibi lity for and shall take all steps to maintain appropriate 
records and ensure appropriate suppl y, storage, handling, distribution and usage of trial 
treatments in accordance with the protocol and an y applicable laws and regulations.
Dose Selection/Modification
Dose Selection (Preparation)
Pembrolizumab: The amount required to prepare the pembrolizumab infusion solution will 
be based on a fixed dose of 200 mg. Details on the preparation and administration are 
provided in the Pharmacy Manual .
Product:   MK-3475 39
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialStandard chemotherapeutic agents (etoposide and carboplatin or cisplatin) will be prepared 
and administered as per the local approved product label. Appropriate infusion times for each 
agent are noted in the respective subsections of Section 5.2.2.2 .
Therationale for selection of doses to be used in this trial is provided in Section 4.0.
Dose Modification
If a subject experiences a >10% weight change during Cycles1 to4, the doses of etoposide 
and cisplatin/carboplatin should be recalculated.
Dose modif ications due to AEs will depend on the investigator’s assessment of causality .If 
appropriate, the investigator may attribute each toxicity  event to etoposide, 
cisplatin/carboplatin, or pembrolizumab alone or to the combination and use a stepwise dose 
reduction according to Table 3through Table 7.Dose modifications must be based on the 
maximum toxicity  experienced during a cy cle.Toxicity  must resolve to Grade ≤1 or baseline 
prior to resuming the subsequent cycle, with the exception of alopecia, Grade 2 fatigue, 
endocrine -related AEs requiring treatment or hormone replacement, which may  be Grade ≤2, 
and creatinine clearance, for which the guidelines in Section 5.2.1.2.2 may  be followed .
If a dose reduction for toxicity  occurs with any agent, the dose may not be re-escalated. 
Subjects can have a maximum of 2 dose modifications (if applicable) to each of the 
component s of study  therap y throughout the course of the study  for toxicities. If a subject 
experiences several toxicities and there are conflicting recommendations, the most 
conservative dose adjustment recommended should be followed (ie, dose reduction 
appropriat e to the most severe toxicity ).Subjects who require a third dose modification to 
any particular component will have that agent discontinued. In the absence of theagent 
thought to be causing toxicity , treatment can continue with pembrolizumab or saline placebo 
and the remaining chemotherapeutic drug.
Reduction of 1 chemotherap y agent and not the other agent is appropriate if, in the opinion of 
the investigator , the toxicity  is clearl y related to one of the treatments. If, in the opinion of 
the investigat or, the toxicity  is related to the combination of both chemotherap y agents, both 
drugs should be reduced according to recommended dose modifications. If the toxicity  is 
related to the combination of 3agents, all 3 agents should be reduced (if applicable),
interrupted, or discontinued according to the recommended dose modifications.
Pembrolizumab dose reductions are not permitted. Pembrolizumab treatment may be 
delay ed/interrupted for a maximum of 12 weeks or discontinued due to toxicity.
Subjects may have chemotherapy  discontinued and continue on pembrolizumab or saline 
placebo alone. Similarly ,subjects may discontinue pembrolizumab or saline placebo and 
continue on chemotherapy  alone during the first 4cycles,if appropriate. Any requests for 
unblinding will be considered on an individual subject basis and only after consultation with 
the Sponsor .
Product:   MK-3475 40
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialDuring C ycles 1 through 4 of pembrolizumab +EPor placebo +EP:
If etoposide dosing is delay ed or interrupted , the platinum agent and pembrolizumab 
or saline placebo should also be delay ed/interrupted .If EP is delay ed or interrupted 
during C ycles 1 through 4, patients should be seen weekl y until toxicity  resolves.
If cisplatin/carboplatin dosing is delay ed or interrupted, etoposide and pembrolizumab or 
saline placebo should also be delay ed/interrupted. If EP is delay ed or interrupted during 
Cycles 1 through 4, patients should be seen weekly  until toxicity  resolves .
If pembrolizumab or saline placebo dosing is delay ed or interrupted, EPtherapy  can 
continue as scheduled. Pembrolizumab or saline placebo administration should be 
attempted at the next cy cle of therapy .
Each chemotherap y cycle may  not be delay ed by  more than 3 weeks (>21 consecutive 
days) despite supportive treatment. If only one of the agents is thought to be causing 
the specified toxicity leading to a 21-day delay of administration of the next cycle, 
that chemotherapeutic agent can be stopped and treatment can continue with 
pembrolizumab or saline placebo and the remaining chemotherapy drug.
Pembrolizumab/placebo dosing can continue with 1agent or as monotherapy .
The NCI CTCAE 4.0 must be used to grade the severit y of 
AEs. All dose modifications 
should be based on the AE requiring the greatest dose modification. Dose modifications are 
detailed in Table 3through Table 7.
Table 3 Dose Modifications for Study  Drugs
Etoposide Cisplatin CarboplatinPembrolizumab/
Placebo
Dose Level 0 
(starting dose)100mg/m2/day 75mg/m2AUC 5200mg
fixed dose
Dose Level -1 75mg/m2/day 56mg/m2AUC 4Dose reduction not 
permitted
Dose Level -2 50mg/m2/day 38mg/m2AUC 3Dose reduction not 
permitted
Dose Level -3 Discontinue Discontinue DiscontinueDose reduction not 
permitted
5.2.1.2.1 Pembrolizumab
Adverse events (both non-serious and serious) associated with pembrolizumab exposure may  
have an immunologic etiology .These immune -related AEs (irAEs) may occur shortl y after 
the first dose or several months after the last dose of treatment and may affect more than one 
body  system simultaneously .Therefore, early recognition and initiation of treatment is 
Product:   MK-3475 41
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidentialcritical to reduce complications. Based on existing clinical trial data, most irAEs were 
reversible and could be managed with interruptions of pembrolizumab, administration of 
corticosteroids, and/or other supporti ve care. For suspected irAEs, ensure adequate 
evaluation to confirm etiology  or exclude other causes. Additional procedures or tests such as 
bronchoscop y, endoscopy, or skin biops y ma y be included as part of the evaluation. Based on 
the severity  of the irA E, withhold or permanently  discontinue pembrolizumab and administer 
corticosteroids. Dose modification and toxicity  management guidelines for irAEs associated 
with pembrolizumab are provided inTable 4.
Product:   MK-3475 42
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialTable 4 Dose Modification and Toxicity  Management Guidelines for Immune -Related AEs Associated With Pembrolizumab
General instructions:
1.Corticosteroid taper should be initiated upon AE improving to Grade 1 or less and continue to taper over at least 4 w eeks.
2.For situations where pembrolizumab has been withheld, pembrolizumab can be resumed after AE has been reduced to Grade 1 or 0 and corticosteroid 
has been tapered. Pembrolizumab should be perm anently discontinued if AE does not resolve within 12 weeks of last dose or corticosteroids cannot 
be reduced to ≤10 mg prednisone or equivalent per day within 12 weeks. 
3.For severe and life-threatening irAEs, IV corticosteroid should be initiated first followed by oral steroid. Other immunosuppressive treatment should 
be initiated if irAEs cannot be controlled by co rticosteroids.
Immune -related 
AEsToxicity grade or 
conditions 
(CTCAEv4.0)Action taken to 
pembrolizumabirAE management with 
corticosteroid and/or other 
therapies Monitor and follow -up
Pneumonitis Grade 2 Withhold Administer corticosteroids 
(initial dose of 1-2 mg/kg 
prednisone or equivalent) 
followed by taperMonitor subjects for signs and symptoms of 
pneumonitis
Evaluate subjects with suspected 
pneumonitis with radiographic imaging and 
initiate corticosteroid treatment
Add prophylactic antibiotics for 
opportunistic infectionsGrade 3 or 4, or 
recurrent Grade 2Perm anently 
discontinue
Diarrhea / colitis Grade 2 or 3 Withhold Administer corticosteroids 
(initial dose of 1-2 mg/kg 
prednisone or equivalent) 
followed by taperMonitor subjects for signs and symptoms of 
enterocolitis (ie,diarrhea, abdominal pain, 
blood or mucus in stool with or without 
fever) and of bowel perforation (ie,
peritoneal signs and ileus).
Subjects with Grade ≥2 diarrhea suspecting 
colitis should consider GI consultation and 
performing endoscopy to rule out colitis. 
Subjects with diarrhea/colitis should be 
advised to drink liberal quantities of clear 
fluids. If sufficient oral fluid intake is not 
feasible, fluid and electrolytes should be 
substituted via IV i nfusion.Grade 4 Perm anently 
discontinue
AST / ALT 
elevation or 
Increased 
BilirubinGrade 2 Withhold Administer corticosteroids 
(initial dose of 0.5-1mg/kg 
prednisone or equivalent) 
followed by taperMonitor with liver function tests (consider 
weekly or more frequently until liver 
enzyme value return sto baseline or is stable
Product:   MK-3475 43
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialImmune -related 
AEsToxicity grade or 
conditions 
(CTCAEv4.0)Action taken to 
pembrolizumabirAE management with 
corticosteroid and/or other 
therapies Monitor and follow -up
Grade 3 or 4 Perm anently 
discontinueAdminister corticosteroids 
(initial dose of 1-2 mg/kg 
prednisone or equivalent) 
followed by taper
Type 1 diabetes 
mellitus (T1DM) 
or 
HyperglycemiaNew onset T1DM or 
Grade 3 or 4 
hyperglycemia 
associated with evidence 
of -cell failureWithhold Initiate insulin replacement 
therapy for subjects with 
T1DM 
Administer anti-
hyperglycemic in subjects 
with hyperglycemia Monitor subjects for hyperglycemia or other 
signs and symptoms of diabetes.
Hypophysitis Grade 2 Withhold Administer corticosteroids 
and initiate horm onal 
replacements as clinically 
indicated.Monitor for signs and symptoms of 
hypophysitis (including hypopituitarism and 
adrenal insufficiency)
Grade 3 or 4 Withhold or 
permanently 
discontinue1
Hyperthyroidism Grade 2 Continue Treat with non-selective beta-
blockers (eg,propranolol) or 
thioamides as appropriate Monitor for signs and symptoms of thyroid 
disorders. 
Grade 3 or 4 Withhold or 
Perm anently 
discontinue1
Hypothyroidism Grade 2 -4 Continue Initiate thyroid replacement 
horm ones (eg,levothyroxine 
or liothyronine) per standard 
of careMonitor for signs and symptoms of thyroid 
disorders. 
Nephritis and
renal dysfunctionGrade 2 Withhold Administer corticosteroids 
(prednisone 1-2 mg/kg or 
equivalent) followed by taper.Monitor changes of renal function
Grade 3 or 4 Perm anently 
discontinue
Myocarditis Grade 1 or 2 Withhold Based on severity of AE 
administer corticosteroids Ensure adequate evaluation to confirm 
etiology and/or exclude other causes
Grade 3 or 4 Perm anently 
discontinue
Product:   MK-3475 44
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialImmune -related 
AEsToxicity grade or 
conditions 
(CTCAEv4.0)Action taken to 
pembrolizumabirAE management with 
corticosteroid and/or other 
therapies Monitor and follow -up
All Other 
immune -related 
AEsIntolerable/ Persistent 
Grade 2Withhold Based on severity of AE 
administer corticosteroids Ensure adequate evaluation to confirm 
etiology or exclude other causes
Grade 3 Withhold or 
discontinue 
based on the type 
of event. Events 
that require 
discontinuation 
include and not 
limited to: 
Guillain -Barre 
Syndrome, 
encephalitis
Grade 4 or recurrent 
Grade 3 Perm anently 
discontinue
Abbreviations:  AE=adverse event, ALT=alanine transaminase, AST=aspartate transaminase, CTCAEv4.0=Common Terminology Criteria for Adverse Eve nts version 4.0,
irAE=immune -related adverse event, IV=intravenous, T1DM=Type 1 diabetes mellitus
1. Withholding or permanently discontinuing pembrolizumab is at the discretion of the investigator or treating physician.
2. For subjects with Grade 3 or 4 imm une-related endocrin opathy where withholding of pembrolizumab is required, pembrolizumab may be resumed when AE resolves 
to Grade ≤2 and is controlled with hormonal replacement therapy or achieved metabolic control (in case of T1DM).
Product:   MK-3475 45
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialDose modification and toxicity management of infusion -reactions related to 
pembrolizumab
Pembrolizumab may cause severe or life-threatening infusion- reactions including severe 
hypersensitivity  or anaphy laxis. Signs and symptoms usually  develop during or shortly  after 
drug infusion and generally  resolve completel y within 24 hours of completion of infusion. 
Dose modification and toxicity management guidelines forpembrolizumab associated 
infusion reaction sare provided in Table 5.
Product:   MK-3475 46
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialTable 5 Pembrolizumab I nfusion Reaction Dose M odification and Treatment Guidelines
NCI CTCAE Grade Treatm ent Prem edication at Subsequent Dosing
Grade 1
Mild reaction; infusion 
interruption not indicated; 
intervention not indicatedIncrease monitoring of vital signs as medically indicated until the subject 
is deemed medically stable in the opinion of the investigator.None
Grade 2
Requires therapy or infusion 
interruption but responds 
prom ptly to symptomatic 
treatment (eg, antihistamines, 
NSAIDs, narcotics, IV fluids); 
prophylactic medications 
indicated for ≤24 hStop Infusion.
Additional appropriate medical therapy may incl ude but is not limited to:
IV fluids
Antihistamines
NSAIDs
Acetaminophen
Narcotics
Increase monitoring of vital signs as medically indicated until the subject 
is deemed medically stable in the opinion of the investigator.
If symptoms resolve within 1 hour of stopping drug infusion, the infusion 
may be restarted at 50% o f the original infusion rate (e g,from 100 mL/h
to 50 mL/h ).Otherwise dosing will be held until symptoms resolve and 
the subject should be premedicated for the next scheduled dose.
Subjects who develop Grade 2 toxicity despite adequate 
premedication should be permanently discontinued from further 
study drug treatm entSubject may be premedicated 1.5 h 
(±30 minutes) prior to infusion of 
pembrolizumab with:
Diphenhydramine 50 mg po (or 
equivalent dose of antihistamine).
Acetaminophen 500 -1000 m g po (or 
equivalent dose of analgesic).
Product:   MK-3475 47
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialNCI CTCAE Grade Treatm ent Prem edication at Subsequent Dosing
Grades 3 or 4
Grade 3:
Prolonged (ie, not rapidly 
responsive to symptomatic 
medication and/or brief 
interruption of infusion); 
recurrence of symptoms 
follow ing initial improvement; 
hospitalization indicated for 
other clinical sequelae (e.g., 
renal impairment, pulmonary 
infiltrates)
Grade 4:
Life-threatening; pressor or 
ventilatory support indicatedStop Infusion.
Additional appropriate medical therapy may inc lude but is not limited to:
Epinephrine**
IV fluids
Antihistamines
NSAIDs
Acetaminophen
Narcotics
Oxygen
Pressors
Corticosteroids
Increase monitoring of vital signs as medically indicated until the subject 
is deemed medically stable in the opinion of the investigator.
Hospitalization may be indicated.
**In cases of anaphylaxis, epinephrine should be used immediately.
Subject is per manently discontinued from further study drug 
treatm ent.No subsequent dosing
Abbreviations:  CTCAE=Common Terminology Criteri a for Adverse Events, IV=intravenous, NCI=National Cancer Institute, NSAID=nonsteroidal anti-inflammatory 
drug
Appropriate resuscitation equipment should be available at the bedside and a physician readily available during the period of drug administration .
For further information, please refer to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE) at http://ctep.cance r.gov
Product:   MK-3475 48
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialOther allowed dose interruption sfor pembrolizumab 
Pembrolizumab may be interrupted for situations other than treatment -related AEs such as 
medical/surgical events or logistical reasons not related to study  therap y. Subjects should be
placed back on study  therap y within 3 weeks of the scheduled interruption, unless otherwise 
discussed with the Sponsor. The reason for interruption should be documented in the patient's 
study  record.
5.2.1.2.2 Chemotherapeutic agents ( etoposide/platinum)
Study  drug-related toxicities must be resolved to baseline or Grade ≤1 (with the exception of 
alopecia ,Grade 2 fatigue , and endocrine -related AEs requiring treatment or hormone 
replacement, which may be Grade ≤2, and creatinine clearance, for which the guidelines 
provided below may be followed ) prior to administering the next dose. Subjects must not 
receive the next cy cle of chemotherap y if any of the following apply:
Absolute neutrophil count (ANC) <1,500/mm3
Platelet count <100,000/mm3
Hemoglobin level <8 g/dL
Total bilirubin level >1.5 ×ULN
Aspartate aminotransferase ( AST )and alanine aminotransferase (ALT) levels 
≥2.5 ×ULN, or ≥5 ×ULN if liver metastases are present
Recommended dose modifications for key chemotherap y toxicities (etoposide and 
cisplatin/carbopl atin) are outlined in Table 6and Table 7.These serve as a guide and do not 
replace investigator judgment and 
applicable local label recommendations, if more stringent.
A subject isallowed to switch from cisplatin to carboplatin if the subject develops
unexpected toxicities with the use of cisplatin (including hearing loss) , becomes ineligible for 
further cisplatin therap y
,and/orthe investigator considers switching to carboplatin to be in 
the best interest of the subject.
A maximum of 2 dose reductions per chemotherap y agent are permitted; if additional 
reductions are required, that particular agent must be discont inued. Once the dose has been 
decreased, it should remain reduced for all subsequent administrations or be further reduced ,
if necessary .There will be no dose escalations in this study .Each chemotherap y cycle may 
not be delay ed by more than 3 weeks (>21 consecutive days) despite supportive treatment. If 
unacceptable toxicities related to etoposide, cisplatin ,or carboplatin occur, and only one of 
the agents is thought to be causing a specified toxicity  leading to a 21-day delay of 
administration of the next cycle, as determined by investigator judgment, the agent will be 
discontinued but the other drugs may  be continued.
Product:   MK-3475 49
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialTable 6 Recommended Chemotherap y Dose Modifications for Hematological Toxicity
Drug Related ToxicityaEtoposide Cisplatin Carboplatin
Dose Level (DL) from Table 3
Neutrophils (ANC) <500/mm3without fever DL -1 DL -1 DL -1
Febrile neutropenia (fever ≥38.5C and ANC 
<1,000/mm3) DL -1 DL -1 DL -1
Platelets <50,000/mm3 without significant bleeding  
or requiring blood transfusion DL -1 DL -1 DL -1
Platelets <50,000/mm3with Grade ≥2 hemorrhage or 
requiring blood transfusion DL -2 DL -2 DL -2
Grade 4 hemoglobin DL -1 DL -1 DL -1
Abbreviations:  ANC=absolute neutrophil count, DL=dose level
Note: If toxicity can clearly be attributed to one of the drugs, the investigator may choose to only reduce the 
dose of one of the chem otherapy agents .Investigators may decide to use supportive measures/treatment 
and/or secondary prophylaxis as per institutional standards (e g,filgrastim, pegfilgrastim, transfusions) 
instead of dose reductions for the next cycle, if considered in the best interest of the subject.
aShould the hematologic toxicity recur, the dose of the agent could be reduced further. However, not more 
than 2 dose reductions per chemotherapy agent are permitted.
Product:   MK-3475 50
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialTable 7 Recommended Chemotherap y Dose Modifications for Non- hematologic Toxicity
Drug Related ToxicityaCTCAE Grade Etoposide Cisplatin Carboplatin
Dose Level (DL) from Table 3
Nausea/vomiting Grade ≥3bDL 0 DL -1 DL -1
Mucositis Grade ≥3bDL -1 DL -1 DL -1
Diarrhea Grade ≥3bDL -1 DL -1 DL -1
Peripheral neuropathyGrade 2 No modification DL -1cNo modification
Grade 3 No modification DiscontinuedDL -1
Grade 4 No modification Discontinue DL -1
Total bilirubinGrade 2 DL-2 No modification No modification
Grade 3 Discontinue No modification No modification
Grade 4 Discontinue No modification No modification
AST or ALT ElevationGrade 3 DL -1 DL -1 DL -1
Grade 4 Discontinue Discontinue Discontinue
Other Non-
hematologic Toxicity 
(except fatigue and 
transient arthralgia and 
myalgia)Grade ≥3 DL -1 DL -1 DL -1
Note: If considered in the best interest of the subject, and consistent with local practice, investigators may 
decide to use supportive measures/treatment, and/or secondary prophylaxis instead of dose reductions for the 
next cycle. Also, if toxicity can clearly be attributed to one of the drugs, the investigator may choose to only 
reduce the dose of one of the chemotherapy agents .
aShould the toxicity recur, the dose of the agent could be reduced further. How ever, not more than 2dose 
reductions per chemotherapy agent are permitted.
bThe first occurrence of Grade ≥3 nausea/vomiting, mucositis, and diarrhea should be managed 
symptomatically with optim al medical therapy, and improve to Grade ≤1 prior to proceeding with additional 
therapy.Should these events recur despite aggressive management, a dose modification can be employed 
once the AEimproves to Grade 
≤1.
cIf Grade 2 neurotoxicity recurs after DL-1, drug will be given at DL-2or switch can be made to the 
appropriate dose of carboplatin at the discretion of the investigator in consultation with the Sponsor. If 
Grade 2 neurotoxicity persists after 2 dose level reductions and 21-day hold, switch can be made to the 
appropriate dose of carboplatin at the discretion of the investig ator in consultation with the Sponsor.
dIf Grade 3 neurotoxicity occurs, cisplatin will be discontinued and,
upon improvement, a switch can be 
made to the appropriate dose of carboplatin at the discretion of the investigator in consultation with the 
Spons or.
Creatinine clearance:
Creatinine clearance (CrCl) will be based on either the Cockcroft -Gault formula 
(Section 5.2.2.2.1) or another acceptable standard formula.
Product:   MK-3475 51
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialFor patients receiving cisplatin, the scheduled dose of cisplatin may only be administered if 
the calculated CrCl is≥50 m L/min:
If CrCl falls to <50 mL/min, delay  the start of that cycle for ≤21 days.In the interim, 
monitor renal function weekl y and consider intravenous (IV)hydration. When CrCl
improves to ≥50m
L/min, decrease cisplatin to dose level ( DL) -1 ( Table 3).
Alternativel y, if in the investigator’s judgment it is in the best interest of the patient, 
cisplatin can be switch edto carboplatin if the calculated CrCl is appropriate , andin 
consultation with the Sponsor .
At the second occurrence of CrCl <50 mL/min, decrease cisplatin to DL-2 upon 
improvement of CrCl to ≥50mL/min.Alternatively , if in the investigator’s judgment 
it is in the best interest of the patient, cisplatin can be switched to carboplatin if the 
calculated CrCl is appropriate, and in consultation with the Sponsor.
At the third 
occurrence of CrCl <50 mL/min, cisplatin should be discontinued. If in 
the investigator’s judgment it is in the best interest of the patient, cisplatin can be 
switched to carboplatin if the calculated CrCl is appropriate, at the discretion of the 
investigator andin consultation with the Sponsor.
For patients receiving carboplatin, the scheduled dose of carboplatin may only be 
administered if the calculated CrCl is≥40 m L/min:
If CrCl falls to <40 mL/min, delay  the start of that cycle for ≤21 days.In the interim, 
monitor renal function weekl y and consider IV hydration. When CrCl improves to 
≥40 mL /min, decrease c arboplatin to DL -1 (Table 3).
At the second occurrence ofCrCl <40 mL/min, decrease carboplatin to DL-2 upon 
improvement of CrCl to ≥40 mL /min.
At the third oc currence of CrCl <40 mL /min, carboplatin should be disconti nued.
Timing of Dose Administration
All trial treatments will be administered on an outpatient basis.
Trial treatment should be administered beginning on Day  1 of each cy cle after all procedures
and assessments have been completed (time points listed in Section 6).Day 1 of each cycle
should occur as scheduled (or in a window of±3 days foradministrative reasons onl y).
Etoposide must be administered on 3consecutive days without interruption (Day s1, 2, 
and3) in Cy cles1 to4.
For subjects who experien ce disease progression, investigators may elect to continue trial 
treatment until confirmation of disease progression or may elect to interrupt treatment by 
deferring the decision to continue/discontinue treatment in the trial until confirmation of 
disease progression per modified RECI ST 1.1 at least 28 days from the date of imaging 
Product:   MK-3475 52
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialdemonstrating disease progression. Subjects for whom disease progression is not confirmed 
on subsequent imaging may  resume treatment. Please see Section 5.8 for other exceptions.
Pembrolizumab (or Saline Placebo)
Pembrolizumab or saline placebo will be administered first in the sequence of medications.
Upon completion of the pembrolizumab or saline placebo infusion, premedication for the 
chemotherap y should be administered as per local SOC , followed by  chemotherapy .
Pembrolizumab or saline placebo will be administered as a 30-minute IV infusion Q3W on 
Day 1 of each cy cle.Sites should make every  effort to target infusion timing to be as close to 
30minutes as possible. However, given the variability  of infusion pumps from site to site, a 
window of −5 minutes to+10 minutes is permitted (ie, infusion time is 25 to 40 minutes).
The Pharmacy  Manual contains specific instructions for pembrolizumab dose calculation, 
reconstitution, infusion fluid preparation, and administration.
Chemotherapy
Chemotherap y should be administered as described in the following subsections . Subjects are 
allowed to switch from cisplatin to carboplatin, if the subject becomes ineligible for further 
cisplatin therap y according to local guidelines and the investigator considers switching to 
carboplatin to be in the best interest of the subject.
5.2.2.2.1 Carboplatin
Carboplatin at a dose calculated to achieve an area under the plasma drug concentration time 
curve (AUC) of 5 will be administered as an IV infusion over approximately 60minutes 
Q3W on Day 1 for 4 cycles .Carboplatin dose should not exceed 750mg. AUC should be 
calcu lated using the Calvert formula:
Total dose (mg) = (target AUC) (CrCl + 25)
Theestimated CrCl in the Calvert formula should not exceed 125 mL/min
Maximum carboplatin dose (mg) = target AUC 5  (125 + 25)
= 5 150
= 750 mg
Creatinine clearance must be calculated using either the Cock croft-Gault formula or another 
acceptable standard formula for estimating CrCl in mL /min based on serum creatinine:
Men: [(140 -age (y)) weight (kg)]/[72  serum creatinine (mg/dL)]
Women: [(140 -age ( y)) weight (kg)]  0.85/[72  serum creatinine (m g/dL)] 
Note: Due to differences in serum creatinine units, sites may useeither the standard 
Cockc roft-Gault formula or another acceptable standard formula used at their institution.
Product:   MK-3475 53
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialDose may  be rounded to the nearest 50 mg at the discretion of the investigator, and according 
to institutional standards.
Unless there is a change in weight >10%, the same doseof carboplatin can be used 
throughout the 4 cycles (provided there are no additional toxicities).
Additional premedications should be administered as per standard practice.
5.2.2.2.2 Cisplatin
Cisplatin 75 mg/m2will be administered as an IV infusion Q3W on Day 1 for 4 cycles. An 
infusion time of 60 minutes is recommended, but cisplatin may be administered over 30to 
180minutes to accommodate local SOCs .
Body surface area (BSA) will be obtained using
the Dubois and Dubois or Mosteller formula. The BSA calculated on Cycle1, Day 1
 of 
therap y can be used throughout the 4cycles, unless there is a change in weight >10%.
Cisplatin will be given for up to 4 cycles.Additional premedications should be administered 
as per standard practice.
5.2.2.2.3 Etoposide
Etoposide 100 mg/m2will be administered as an IV infusion Q3W on Days1, 2, and 3 of 
Cycles 1 to 4.Days 1, 2, and 3 must be consecutive days without interruption. Aninfusion 
time of 30to 60minutes is recommended, but etoposide may be administered over 30to 
120minutes to accommodate local standards of care. Body surface area will be obtained 
using the Dubois andDubois or Mosteller formula. The BSA calculated on C ycle 1, 
Day 1 of 
therap y can be used throughout the 4cycles, unless there is a change in weight >10%.
Additional premedications should be administered as per standard practice.
Trial Blinding 
This is a double -blinded trial with respect to pembrolizumab and placebo treatment. The 
subject, the investigator, and Sponsor personnel or delegate(s) who are involved in the 
treatment administration or clinical evaluation of the subjects will beunaware of the 
treatment assignments. The chemotherap y agents will be open -label. Pembrolizumab will be 
supplied to the sites in an open label manner. The study  site’s unblinded pharmacist will 
obtain each subject’s study  identification number and study  drug assignment from the 
interactive voice response sy stem/integrated web response system (IVRS/IWRS )and prepare 
the solutions for infusion. The unblinded pharmacist will provide the investigative staff with 
ready-to-use blinded pembrolizumab orsaline placebo infusion solutions, packaged 
identically  in order to maintain the blinding, for administration at scheduled infusion visits.
In addition to emergency unblinding for severe or life-threatening AEs with potential 
immunologic etiology , non-emergency unblinding to pembrolizumab versus placebo 
administration may occur on an individual subject basis and only after consultation with the 
Sponsor at the time of (1) centrall y verified disease progression and subject has discontinued 
all study  treatments or,(2)when the subject has discontinued all study  treatments and a new 
anti-cancer treatment is going to be started . Non- emergency unblinding ,only after 
Product:   MK-3475 54
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialconsultation and approval from the Sponsor ,is implemented through interactive response 
technology  (IRT)by following the instructions in the I RT site user manual.
Additionally , imaging data will be centrally  reviewed by radiologists who are blinded to 
subject treatment assignment, and the allocation schedule will be blinded in the database, 
preventing agg regate analy sis.
See Section 7.1.4.2, Blinding/Unblinding, for a description of the method of unblinding a 
subject during the trial, should such action be warranted.
Randomization
Treatment randomization will occur centrall y using aninteractive voice response system / 
integrated web response sy stem (IVRS/I WRS). There are 2treatment arms.  Subjects will be 
assigned randoml y in a 1:1 ratio to pembrolizumab +EPor placebo +EP.Prior to 
randomization, the investigator’s choice of platinum agent (cisplatin or carboplatin) will be 
documented in the IVRS/IWRS sy stem.
Stratification
Treatment r andomization will be stratified according to the following factors:
Type of platinum therap y (carboplatin or cisplatin) 
Baseline ECOG performance status (0 or 1)
Baseline LDH ( ≤or >ULN)
Concomitant Medications /Vaccinations (Allowed & Prohibited)
Medications or vaccinations specifically  prohibited in the exclusion criteria are not allowed 
during the ongoing trial.  If there is a clinical indication for any medication or vaccination 
specificall y prohibited during the trial, discontinuation from trial therapy  or vaccination may 
be required.  The investigator should discuss any questions regarding this with the Sponsor 
Clinical Director.  The final decision on any supportive therap y or vaccination rests with the 
investigator and/or the subject's primary  physician.  However, the decision to continue the 
subject on trial therapy or vaccination schedule requires the mutual agreement of the 
investigator, the Sponsor and the subject.
Acceptable Concomitant Medications
All treatments that the investigator considers necessary  for a subject’s welfare may be 
administered at the discretion of the investigator in keeping with the community  standards of 
medical care. All concomitant medication swill be recorded on theelectronic case report 
form ( eCRF)including all prescription, over-the-counter (OTC), herbal supplements, and IV 
medications and fluids. If changes occur during the trial period, documentation of drug 
dosage, f requency , route, and date will also be included on the eCRF.
Product:   MK-3475 55
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialPalliative and supportive care is permitted during the course of the trial for underl ying 
medical conditions and management of symptoms. Surgery  or radiotherapy  for tumor control 
is not permitted during the study ; however, radiotherap y or procedures for symptom 
management are allowed.
All concomitant medications received within 28days before 
the first dose of trial treatment 
and up to 30 days after the last dose of trial treatment should be recor ded. Concomitant 
medications administered more than 30 days after the last dose of trial treatment should be 
recorded for SAEs and events of clinical interest ( ECIs)as defined in Section 7.2.
Colony- Stimulating Factors
The use of colon y-stimulating factors (CSFs) is highl y recommended as primary  prophy laxis 
to reduce the risk of febrile neutropenia in this patient population, especially as many 
subjects have multiple co-morbidities and advanced disease. The American Society of 
Clinical Oncology  guidelines for use of CSFs should be followed for this trial [112] .
Antiemetic therapy
Antiemetic therap y should follow the Multinational Association of Supportive Care in 
Cancer guideli nes [113] . 
Prohibited /Restricted Concomitant Medications
Subjects are prohibited from receiving the following therapies during Screening, Initial 
Treatment Phase , and Second Cour se Phase of this trial:
Antineoplastic sy stemic chemotherap yor biological therap y
Immunotherapy  not specified in this protocol
Investigational agents other than pembrolizumab
Surgery  for tumor control
Radiation therap y
Note: Subjects are allowed to receive palliative radiothera py for painful bone lesions. 
Targeted external beam irradiation should not be used in the primary  lung field where 
assessment for tumor is indicated.
Note: PCI is permitted in subjects achieving CR or PR after C ycle 4.
Live vaccines within 30 days prior to the first dose of trial treatment and while 
participating in the trial (eg,measles, mumps, rubella, varicella/zoster, yellow fever, 
rabies, BCG, and typhoid vaccine );seasonal influenza vaccines for injection are 
generall y killed virus vaccines and are allowed; however, intranasal influenza 
vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed
Product:   MK-3475 56
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialSystemic glucocorticoids for an y purpose other than :
oTomodulate symptoms ofan AEthat is suspected to have an immunologic 
etiology
oAs required during and after PCI (subjects requiring chronic glucocorticoid 
use following PCI should be discontinued from study  therapy )
oAs needed for the prevention of emesis (as outlined in Section 5.5.1)
oFor topical use or ocular use
oPremedication for IV contrast allergies
oFor inhalation in the management of asthma or chronic obstructive pulmonary 
disease
Subjects who, in the assessment ofthe investigator, require the use of any of the 
aforementioned treatments for clinical management should be removed from the trial.
Subjects may receive other medications that the investigator deems to be medically 
necessary .
Other medications that are prohibited in this trial are discussed in Section 5.1.3
.
There are no prohibited therapies during the Post -Treatment Follow -up Phase.
Rescue Medications & Supportive Care
No rescue or supportive medications are specified to be used in this trial.
Supportive Care Guidelines
Subjects should receive appropriate supportive care measures as deemed necessary  by the 
treating investigator. Suggested supportive care measures for the management of AEswith 
potential immunologic etiology  are outlined along with the dose modification guidelines in 
Section 5.2.1.2.1 , [Table 4].Where appropriate, these guidelines include the use of oral or IV 
treatment with corticosteroids, as well as additional anti- inflammatory  agents if symptoms do 
not improve with administration of corticosteroids. Note that several courses of steroid 
tapering may be necessary  as symptoms may worsen when the steroid dose is decreased. For 
each disorder, attempts should be made to rule out other causes such as metastatic disease or 
bacterial or viral infection, which might require additional supportive care. The treatment 
guidelines are intended to be applied when the investigator determines the events to be 
related to pembrolizumab.
Note: If after evalu ation of the event, it is determined not to be related to pembrolizumab, 
the investigator does not need to follow thetreatment guidance. It may be necessary  to 
perform conditional procedures such as bronchoscopy , endoscopy , or skin photograph y as 
part of evaluation of the event.
Product:   MK-3475 57
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialInstructions regarding supportive care needed with the chemotherapeutic agents administered 
in this study  can be found in the local product label for each agent. Infusion reactions and 
injection site reactions will be managed by the investigator according to local product 
label ing.
Diet/Activity/Other Considerations
Diet
Subjects should maintain a normal diet unless modifications are required to manage an AE 
such as diarrhea, nausea, or vomiting.
Contraception
Pembrolizumab may have adverse effects on a fetus in utero. Furthermore, it is not known if 
pembrolizumab has transient adverse effects on the composition of sperm.
For this trial, male subjects will be considered to be of non-reproductive potential if they 
have azoospermia (whether due to having had a vasectom y or due to an underly ing medical 
condition). 
Chemotherap y can cause fetal harm if administered to pregnant women. Therefore, 
non-pregnant, non-breastfeeding women may be enrolled if they are considered of 
non-reprodu ctive potential .
Female subjects will be considered of non-reproductive potential if they meet one of the 
following criteria:
She is postmenopausal, defined as at least 12 months with no menses without an 
alternative medical cause. In women <45years of age who are not using hormonal 
contraception or hormonal replacement therapy , a high follicle -stimulating hormone 
(FSH) level in the postmenopausal range may be used to confirm a post-menopausal 
state. In the absence of 12 months of amenorrhea, a single FSH measurement is 
insufficient.
She had a hysterectomy and/or bilateral oophorectomy , bilateral salpingectomy ,or 
bilateral tubal ligation/occlusion at least 6 weeks prior to screening.
She has a congenital or an acquired condition that prevents childbearing.
Product:   MK-3475 58
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialFemale and male subjects of reproductive potential must agree to avoid becoming pregnant 
or impregnating a partner, respectivel y, while receiving trial drug and for 120 days after the 
last dose of pembrolizumab and for180 days after the last dose of chemotherap y by 
comply ing with oneof the following:
Practice abstinence from heterosexual activity .
Abstinence (relative to heterosexual activity ) can be used as the sole method of 
contraception if it is consistently  employ ed as the subject’s preferred and usual 
lifesty le and if considered acceptable by local regulatory  agencies and Ethics Review 
Committees (ERCs)/I nstitu tional Review Boards (IRBs). Periodic abstinence 
(eg,calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are 
not ac ceptable methods of contraception.
Use (or have their partner use) acceptable contraception during heterosexual activity .
Acceptable methods of contraception are‡:
Single method ( oneof the following is acceptable):
oIntrauterine device (IUD)
oVasectom y of a female subject’s male partner
oContraceptive rod implanted into the skin
Combination method (requires use of 2 of the following):
oDiaphragm with spermicide (cannot be used in conjunction with cervical 
cap/spermicide)
oCervical cap with spermicide (nulliparous women only )
oContraceptive sponge (nulliparous women only )
oMale condom or female condom (cannot be used together)
oHormonal contraceptive: oral contraceptive pill (estrogen/progestin pill or 
progestin -only pill), contraceptive skin patch, vagina l contraceptive ring, or 
subcutaneous contraceptive injection
‡If a contraceptive method listed above is restricted by local regulations/guidelines, then it 
does not qualify  as an acceptable method of contraception for subjects participating at sites in 
this country /region.
Subjects should be informed that taking the trial medication may involve unknown risks to 
the fetus (unborn baby) if pregnancy  were to occur during the trial. In order to participate in 
Product:   MK-3475 59
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialthe trial, subjects of childbearing potential must adhere to the contraception requirement 
(described above) from the day  of trial medication initiation (or 14 day s prior to the initiation 
of trial medication for oral contraception) throughout the trial period up to 120days after the 
last dose of pembroli zumab and up to 180 days after last dose of chemotherapeutic agents .If 
there is any  question that a subject of childbearing potential will not reliably  compl y with the 
requirements for contraception, that subject should not be entered into the trial.
If afemale subject inadvertently  becomes pregnant while on treatment in this study , the 
subject will immediately  be removed from the study .The site will contact the subject at least 
monthly  and document the subject’s status until the pregnancy  has been compl eted or 
terminated. The outcome of the pregnancy  will be reported to the Sponsor without delay  and 
within 24 hours if the outcome is a
nSAE (eg, death, abortion, congenital anomaly , or other 
disabling or life-threatening complication to the mother or newbo rn).The study  investigator 
will make every effort to obtain permission to follow the outcome of the pregnancy  and 
report the condition of the fetus or newborn to the Sponsor. If a male subject impregnates his 
female partner ,the study  personnel at the site must be informed immediately  and the 
pregnancy  reported to the Sponsor and followed as described above and in Section 7.2.
Use in Nursing Women
It is unknown whether pembrolizumab is excreted in human milk. As many  drugs are 
excreted in human milk, and because of the potential for serious adverse reactions in the 
nursing infant, subjects who are breast -feeding are not eligible for enrollment.
Subject Withdrawal/Discontinuation Criteria
Discontinuation of Treatment
Discontinuation of trial treatment does not represent withdrawal from the trial.
As certain data on clinical events beyond treatment discontinuation may be/areimportant to 
the study , they must be collected through the subject’s last scheduled follow -up, even if the 
subject has discontinued trial treatment.  Therefore, all subjects who discontinue trial 
treatment prior to completion of the treatment period will still continue to participate in the 
trial as specified in Section 6.0 and Section 7.1.5. 7.
Subjects may discontinue treatment at any time for any reason or be dropped from trial 
treatment at the discretion of the investigator should any untoward effect occur.  In addition, 
a subject may be discontinued from trial treatment by the investigator or the Sponsor if 
treatment is inappropriate, the trial plan is violated, or for administrative and/or other safet y 
reasons.  Specific details regarding procedures to be performed at treatment discontinuation
are provided in Section 7.1.4 –Other Procedures.
Product:   MK-3475 60
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialA subject must be discontinued from trial treatment but continue to be monitored in the trial 
for an y of the following reasons:
oThe subject or subject’s legally acceptable representative requests to discontinue trial 
treatment .
oConfirmed radiographic disease progression ,as outlined in Section 7.1.5 (exception if 
the Sponsor approves treatment continuation)
Note: Subjects with new asymptomatic brain metastasis may be eligible tocontinue 
study treatment at the discretion of the investigator after consultation with the 
Sponsor . Section 7.1.2.7.6 provides details regarding eligibility  requirements and 
subsequent radiographic assessments.
oUnacceptable AEs , as described in Section 7.2
oAny progression or recurrence of any malignancy , or any occurrence of another 
malignancy  that requires active treatment
oIntercurrent illness other than another malignancy  as noted above that prevents 
further administration of treatment
oRecurrent Grade 2 pneumonitis
oRecurrent Grade 3 diarrhea
oA confirmed positive serum pregnancy  test
oNoncompliance w ith trial treatment or procedure requirements
oInvestigator’s decision to withdraw the subject
oCompletion of 35 cy cles of trial treatments (approximately  2 years)
Note: The number of treatments is calculated starting with the first dose. Subjects who stop 
trial treatment after receiving 35 doses of pembrolizumab or saline placebo may be eligible 
for the Second Course Phase (retreatment )if they progress after stopping trial treatment ,
provided they meet the requirements detailed in Section 7.1.5.5. Only  subjects who were 
assigned to the pembrolizumab arm may be retreated in the Second Course Phase for up to an 
additional 17 cycles (approximately  1year).
For subjects who are discontinued from trial treatment but continue to be monitored in the 
trial, all visits and procedures, as outlined in the trial flowchart, should be completed.
Discontinuation from trial treatment is “permanent.” Once a subject is discontinued, he/she 
shall not be allowed to restart treatment.
Product:   MK-3475 61
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Withdrawal from the Trial
A subject must be withdrawn from the trial if the subject or subject ’s legally  acceptable 
representative withdraws consent from the trial.
If a subject withdraws from the trial, they will no longer receive trial treatment or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the trial 
including the procedures to be performed should a subject repeatedl y fail to return for 
scheduled visits and/or if the study  site is unable to contact the subject, as well as specific 
details regarding withdrawal from Future Biomedical Research are outlined in Section 7.1.4 
–Other Procedures.
Subject Replacement Strategy
A subject who is discontinue d from trial treatm ent or withdraws from the trial will not be 
replaced.
Beginning and End of the Trial
The overall trial begins when the first subject signs the informed consent form.  The overall 
trial ends when the last subject completes the last study-related phone -call or visit, withdraws 
from the trial or is lost to follow -up (i.e. the subject is unable to be contacted by the 
investigator).
Clinical Criteria for Early Trial Termination
Early trial termination will be the result of the criteria specified below:
The trial will be stopped early if the risk/benefit ratio to the trial population as awhole is 
unacceptable.
Statistical criteria for stopping the trial are provided in Section 8.0.
Further recruitment in the trial or at 1 or more particular trial sites may be stopped due to 
insufficient compliance with the protocol, Good Clinical Practice (GCP ),or other applicable 
regulatory  requirements; procedure -related problems ;or excessive number of 
discontinuat ions for administrative reaso ns.
Product:   MK-3475 62
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
Confidential6.0TRIAL FLOW CHART
Initial Treatment Phase
Screening 
PhaseTreat ment Phase (3-Week Cycles)End of 
Treat mentFollow -up
Treat ment CycleScreening 
(Visit 1)1 1 1 2 2 2 3 3 3 4 4 4 5-35 Discon1Safety 
Follow -
up2PFS 
Follow -
up 
Visits3Survival
Follow -
up4
Day (in Cycle) 1 2&3 8 1 2&3 8 1 2&3 8 1 2&3 8 1 NA NA NA NA
Scheduling Window 
(Days):5 -28 to -1 + 3 ± 1 ± 3 ± 1 ± 3 ± 1 ± 3 ± 1 ± 3At Time of 
Discon
± 330 Days 
From 
Last 
Dose
+7 Every 6 
or 9 
Weeks 
(±7 
days) 
per 
imaging 
scheduleEvery 8 
Weeks
±7 days
Administrative Procedures
Informed Consent X
Informed Consent for 
Future Biomedical 
Research (optional)X
Inclusion/Exclusion 
CriteriaX
Subject Identification 
CardX
Demographics and 
Medical HistoryX
Prior and Concomitant 
Medications6 X X X X X X X X X X X X X X
SCLC Disease Details X
Obtain allocation number 
using IVRSX
Clinical Procedures/Assessments
Review Adverse Events X X X X X X X X X X X X X X X7X7X7
Product:   MK-3475 63
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialScreening 
PhaseTreat ment Phase (3-Week Cycles)End of 
Treat mentFollow -up
Treat ment CycleScreening 
(Visit 1)1 1 1 2 2 2 3 3 3 4 4 4 5-35 Discon1Safety 
Follow -
up2PFS 
Follow -
up 
Visits3Survival
Follow -
up4
Day (in Cycle) 1 2&3 8 1 2&3 8 1 2&3 8 1 2&3 8 1 NA NA NA NA
Scheduling Window 
(Days):5 -28 to -1 + 3 ± 1 ± 3 ± 1 ± 3 ± 1 ± 3 ± 1 ± 3At Time of 
Discon
± 330 Days 
From 
Last 
Dose
+7 Every 6 
or 9 
Weeks 
(±7 
days) 
per 
imaging 
scheduleEvery 8 
Weeks
± 7 days
Full Physical Examination X X
Directed Physical 
ExaminationX X X X X X X X X
Vital Signs X X X X X X X X X X X X X X X X
Height and Weight8X X X X X X X X
12-Lead ECG X
ECOG Performance Status X9X X X X X X X X X X X
Prophylactic Cranial 
Irradiation10 X
Laboratory Procedures/Assessments: Analysis Performed by Local Laboratory
Pregnancy Test – Urine or 
Serum β -HCG11 X
PT/INR12X
CBC with Differential12X X X X X X X X X X X X
Comprehensive Chemistry 
Panel12 X X X X X X X X X X X X
Urinalysis12,13X X X
Thyroid Function 
Tests12,14 X X X X X
Hepatitis Serologies12X
Product:   MK-3475 64
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialScreening 
PhaseTreat ment Phase (3-Week Cycles)End of 
Treat mentFollow -up
Treat ment CycleScreening 
(Visit 1)1 1 1 2 2 2 3 3 3 4 4 4 5-35 Discon1Safety 
Follow -
up2PFS 
Follow -
up 
Visits3Survival
Follow -
up4
Day (in Cycle) 1 2&3 8 1 2&3 8 1 2&3 8 1 2&3 8 1 NA NA NA NA
Scheduling Window 
(Days):5 -28 to -1 + 3 ± 1 ± 3 ± 1 ± 3 ± 1 ± 3 ± 1 ± 3At Time of 
Discon
± 330 Days 
From 
Last 
Dose
+7 Every 6 
or 9 
Weeks 
(±7 
days) 
per 
imaging 
scheduleEvery 8 
Weeks
± 7 days
Analysis Performed by Central Laboratory
Blood for Genetic 
Analysis15 X XC5D1 
onlyX
Blood for RNA Analyses X XC5D1 
onlyX
Blood for Plasma 
Biomarker AnalysesX XC5D1 
onlyX
Blood for Serum 
Biomarker AnalysesX XC5D1 
onlyX
Tumor Tissue Collection
Archival or Newly 
Obtained Tissue 
CollectionX
Efficacy Measurements
CT/MRI Imaging of 
Chest, Abdomen, and 
Pelvis16X X17X17X18X17
MRI of Brain19X X17,20X17,21X18X
Bone Scan22X
Survival Status4
Subsequent Anti-cancer 
TherapiesX X X X
Product:   MK-3475 65
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialScreening 
PhaseTreat ment Phase (3-Week Cycles)End of 
Treat mentFollow -up
Treat ment CycleScreening 
(Visit 1)1 1 1 2 2 2 3 3 3 4 4 4 5-35 Discon1Safety 
Follow -
up2PFS 
Follow -
up 
Visits3Survival
Follow -
up4
Day (in Cycle) 1 2&3 8 1 2&3 8 1 2&3 8 1 2&3 8 1 NA NA NA NA
Scheduling Window 
(Days):5 -28 to -1 + 3 ± 1 ± 3 ± 1 ± 3 ± 1 ± 3 ± 1 ± 3At Time of 
Discon
± 330 Days 
From 
Last 
Dose
+7 Every 6 
or 9 
Weeks 
(±7 
days) 
per 
imaging 
scheduleEvery 8 
Weeks
± 7 days
Study Drug Administration23
Pembrolizumab or Saline 
Placebo24 X X X X X
Carboplatin or Cisplatin25X X X X
Etoposide26X X X X X X X X
Patient Reported Outcomes27
EQ-5D-5L X X X X X X X
EORTC QLQ -C30 X X X X X X X
EORTC QLQ -LC13 X X X X X X X
1. The Discontinuation Visit should occur at the time study drug is discontinued for any reason. If the Discontinuation Visit occurs 30 days from the last dose of study 
treatment (ie, at the time of the mandatory Safety Follow up Visit ), procedures required at both visits only need to be performed once .
2. The mandatory Safety Follow -up Visit for all subjects should be conducted approximately 30 days after the last dose of trial treatment or before the initiation of new 
antineoplastic treatment, whichever comes first. Subjects with an AE of Grade >1 will be further followed until the resolution of the AE to Grade 0 -1 or until beginning of 
a new antineoplastic therapy, whichever occurs first. If the Discontinuation Visit occurs approximately 30 (±3) days from last dose trial treatment the same procedures do 
not need to be repeated for the Safety Follow-up Visit.
3. Subjects who discontinue from the treatment phase prior to disease progression will continue to be followed in PFS follow -up until they experience disease progression or 
start a new antineoplastic therapy. Subjects with an AE of Grade >1 will be further followed until the resolution of the AE to Grade 0-1 or until beginning of a new 
antineoplastic therapy, whichever occurs first.
4. Once the subject stops the imaging assessments (eg,for PD or starting a new antineoplastic therapy), the subject moves into the Survival Follow -up Phase and should be 
contacted by telephone approximately every 8 weeks to assess for survival status. Post-study antineoplastic treatments and the subject’s response to them will also be 
collected .Updated survival status may be requested by the Sponsor at any time during the course of the study. Upon Sponsor notification, all participants who do not/will 
not have a scheduled study visit or study contact during the Sponsor defined time period will be contacted for their survival status (excluding participants that have a death 
event previously recorded).
Product:   MK-3475 66
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
Confidential5. In general, the window for Day 1 of each cycle is ±3 days unless otherwise noted. Days 1, 2, and 3 must be consecutive without interruption for Cycles 1 to4;therefore ,
there is no visit window for Days 2 and 3 during the first 4 cycles .If treatment cycles are adjusted ,all procedures except imaging will be completed according to the cycle 
number and not weeks on treatment; imaging will not be adjusted for delays in treatment cycles and will be performed per calendar schedule.
6. All concomitant medications received within 28days before the first dose of trial treatment through the Safety Follow -up Visit (30 days after the last dose of trial 
treatment) should be recorded. Serious AEs that occur within 90 days after the end of treatment or before initiation of a non-study anticancer treatment must be 
documented and reported to the Sponsor immediately; after the Safety Follow -up Visit, all medications taken during the 14 days prior to an SAE and all medications taken 
to treat the SAE must be recorded as defined in Section 7.2. All non -study antineoplastic treatments should be documented.
7. See Section 7.2.3.1 for details on reporting timef rame for SAEs .
8. Height will be measured only at Visit 1. Only if there is a change in weight of >10%, should the dose of chemotherapy administered during Cycles 1 to 4 change.
9. ECOG for screening should be performed within 10 days prior to the first dose of trial treatment.
10. Subjects in either arm who achieve CRor PRafter Cycle 4 may be offered PCI at the discretion of the treating investigator. See Section 7.1.2.6 for details.
11. For women of reproductive potential, a urine pregnancy test should be performed within 72 hours prior to first dose of trial treatment. A serum test can be considered if 
urine is not appropriate. Monthly pregnancy testing should be conducted as per local regulations where applicable.
12. Laboratory tests for screening are to be performed within 10 days prior to the first dose of trial treatment , with the exception of hepatitis serologies which may be 
performed within 28 days of the first dose of trial treatment . Testing for Hepa titis B and Hepatitis Cshould be performed as mandated by the local health authority .
Starting with Cycle1, laboratory safety tests must be conducted within 72hours prior to the first dose of trial treatment in each cycle , with the exception of the thyroid 
function tests and LDH, which may be co nducted up to 10 days prior to first dose of trial treatment . Laboratory results must be known prior to dosing.
13. Urinalysis isto be repeated every 6 cycles beginning at Cycle 6.
14. Thyroid tests areto be repeated every 2 cycles beginning atCycle 2.
15. This sample should be drawn for planned analysis of the association between genetic variants in DNA and drug response. If there is either a documented law or regulation 
prohibiting collection, or if the IRB/IEC does not approve the collection of the sample for these purposes, then this sample will not be collected at that site. If the sample is 
collected, leftover extracted DNA will be stored for Future Biomedical Research if the subject signs the Future Biomedical Research consent. If the planned genetic 
analys is is not approved, but Future Biomedical Research is approved and consent is given, this sample will be collected for the purpose of Future Biomedical Research .
16. CT with contrast (preferred) of the chest, abdomen and pelvis is required for all subjects; non-contrast CT of the chest andMRI of the abdomen and pelvis may be used 
for subjects in whom iodinated contrast is contraindicated .
17. Tumor imaging to be performed every 6 weeks (42 [± 7] days) for the first 48 weeks of treatment from the date of randomization , then every 9 weeks (63[± 7] days) 
subsequently until documented disease progression, or the start of new anti -cancer treatment. Refer toSection 7.1.2.7 for additional details .Imaging is to follow calendar 
days regardless of any delays in dosing. For patients treated beyond progression of disease as verified by BICR, the timing of imaging should continue from the date of 
randomization (every 6 weeks (42 [± 7] days) for the first 48 weeks, then every 9 weeks (63 [± 7] days) or at shorter int ervals, as deemed necessary by the investigator) .
18. If previous tumor imaging was obtained within 4 weeks prior to the date of discontinuation, then tumor imaging at treatment discontinuation is not mandatory.
19. MRI (strongly preferred) or CT with contrast of the brain at baseline for all subjects .For subjects without brain metastases at diagnosis, brain imaging is required prior to 
initiating PCI and as clinically indicated. For subjects with brain metastases at diagnosis tha t have undergone treatment, repeat brain imaging is to be performed at all post -
baseline imaging assessments.
20. MRI ( strongly preferred) or CT with contrast of the brain for subjects with met astases at diagnosis that have undergone treatment, repeat brain i maging is to be performed 
at all post -baseline imaging assessments. 
21. MRI ( strongly preferred) or CT with contrast of the brain for all subjects prior to initiating PCI .
22. Nuclear Medicine bone scan for all subjects , at baseline, to assess for bone lesions. Bone scan is to be repeated in patients with bone lesions at baseline who achieve a 
radiographic CR (to confirm osseous response) and as clinically indicated.
23. Study drug administration should begin on the day of randomization, but no later than 3 days after randomization.
24. Pembrolizumab 200mg (or saline placebo) will be administered as a 30-minute IV infusion every 3 weeks ( Q3W ) for up to 35cycles. During Cycles1 to4 
pembrolizumab (or saline placebo) will be administered prior to administration of chemotherapy.
25. Carboplatin dosed to a target AUC of 5 and cisplatin 75 mg/m2will be administered as an IV infusion over approximately 60 minutes Q3W and over 30 to 180minutes 
Q3W, respectively, on Day 1. Dose should be recalculated if there is a >10% weig ht change.
Product:   MK-3475 67
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
Confidential26. Etoposide 100 mg/m2will be administered as an IV infusion over 30to 60 minutes (up to 120 minutes to accommodate local standards of care) Q3W on Day s1, 2, and 3.
Days 1, 2, and 3 must be consecutive days without interruption. Dose should be recalculated if there is a >10% weight change.
27. PROs are completed every cycle for Cycles 1 to 9while the subject is receiving study treatment, then every other cycle up to Cycle 17 (ie, Cycles 11, 13, 15, and 17).
PROs will also be obtained at the Treatme nt Discontinuation visit and 30-day Safety Follow - up visit. If the Treatment Discontinuation visit occurs 30 days from the last 
dose of study treatment, at the time of the mandatory Safety Follow -up visit, PROs do not need to be repeated. PROs are to be administered by trained site personnel and 
completed electronically by subjects prior to all other study procedures and receiving results of any tests (including diseas e status). The PROs should be administered in 
the following order: EQ -5D-5L, EORTC QLQ -C30, EORTC QLQ -LC13 .
Product:   MK-3475 68
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
Confidential
Second Course Treatment Phase
Second course retreatment subjects may receive up to 17cycles (approximately 1 year) of pembrolizumab therapy .For subjects to be 
eligible for the Second Course Treatment Phase, it is necessary  to fulfil l conditions outlined in Section 7.1.5.5 and verify  progression 
of disease b y BICR.
Treat ment Phase End of Treatment Phase Follow -up Phase
Treat ment Cycle / Scheduled 
Time112-17Discontinuation Visit2Safety Follow up 
Visit3PFS Follow -up4Survival Follow -up5
Day in cycle 1 NA NA NA NA
Scheduling Window (Days):6± 3 ± 3At Study Drug 
Discontinuation
(± 3
)30 Days From  
Last Dose 
(+ 7)Every 6 or 9weeks 
per imaging schedule
(± 7)Every 8 Weeks ± 7
Administrative Procedures
Eligibility Criteria X
Prior and Concomitant 
Medications X X X X X7X7
Clinical Procedures / Assessments
Review Adverse Events X X X X8X8X8
Full Physical Examination X
Directed Physical Examination X X X
Vital Signs and Weight X X X X
ECOG Performance Status X X X X
Laboratory Procedures / Assessments: analysis performed by local laboratory
CBC with Differential9X X X X
PT/INR9X
Comprehensive Chemistry Panel9X X X X
Urinalysis9,10X X X X
Thyroid Function Tests9,11X X X X
Pregnancy Test –Serum or 
Urine12X
Product:   MK-3475 69
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialTreat ment Phase End of Treatment Phase Follow -up Phase
Treat ment Cycle / Scheduled 
Time112-17Discontinuation Visit2Safety Follow up 
Visit3PFS Follow -up4Survival Follow -up5
Day in cycle 1 NA NA NA NA
Scheduling Window (Days):6± 3 ± 3At Study Drug 
Discontinuation
(± 3)30 Days From  
Last Dose 
(+ 7)Every 6 or 9weeks 
per imaging schedule
(± 7)Every 8 Weeks ± 7
Efficacy Measurements
CT/MRI Imaging of Chest, 
Abdomen, and Pelvis13,14 X X X X X
MRI of Brain14,15X X X X X
Bone Scan14,16X
Subsequent Antineoplastic 
Therapy StatusX X X X
Survival Status5
Study Drug Administration
Pembrolizumab17X X
1. Procedures and assessments completed at the time of withdrawal from the main study may be used, as appropriate, for the start of the Second Course Phase of the study.
Otherwise, assessments and procedures are to be performed on Day 1 and prior to the first dose of trial treatment for each cycle, unless specified.
2. The Discontinuation Visit should occur at the time study drug is discontinued for any reason. If the Discontinuation Visit occurs 30 da ys from the last dose of study  
treatment (ie, at the time of the mandatory Safety Follow -up Visit), procedures required at both visits only need to be performed once.
3. The mandatory Safety Follow -up Visit for all subjects should be conducted approximately 30 days after the last dose of trial treatment or before the initiation of new 
antineoplastic treatment, whichever comes first. Subjects with an AE of Grade >1 will be further followed until the resolution of the AE to Grade 0-1 or until beginning of a 
new antineoplastic therapy, whichever occurs first. If the Discontinuation Visit occurs approximately 30 (± 3) days from last dose trial treatment the same procedures do not 
need to be repeated for the Safety Follow -up Visit.
4. Subjects who discontinue from the treatment phase prior to disease progression will continue to be followed in PFS follow -up until they experience disease progression or 
start a new antineoplastic therapy. Subjects with an AE of Grade >1 will be further followed until the resolution of theAE to Grade 0-1 or until beginning of a new 
antineoplastic therapy, whichever occurs first.
5. Once the subject stops the imaging assessments for this protocol (eg, for PD or starting a new antineoplastic therapy), the subject moves into the Survival Follow -up and 
should be contacted by telephone every 8 weeks to assess for survival status. Post-study treatments and the subject’s response to them will also be collected .Updated 
survival status may be requested by the Sponsor at any time during the course of the study. Upon Sponsor notification, all participants who do not/will not have a scheduled 
study visit or study contact during the Sponsor defined time period will be contacted for their survival status (excluding participants that have a death event previously 
recorded).
6. In general, the window for each visit is ±3 days unless otherwise noted. If treatment cycles are adjusted all procedures except imaging will be completed according to the 
Cycle number and not weeks on treatment ;imaging will not be adjust ed for delays in treatment cycles and will be performed per calendar schedule. The visit windows for 
follow -up are indicated in days.
Product:   MK-3475 70
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
Confidential7. After the Safety Follow -up Visit, record all medications taken during the 14 days prior to an SAE and all medications taken to treat an SAE as defined in Section 7.2.All 
non-study antineoplastic treatments should be documented.
8. See Section 7.2.3.1 for details on reporting timeframe for SAEs.
9. Laboratory tests for determining eligibility for retreatment are to be performed within 10 days prior to the first dose of pembrolizumab .Starting with Cycle 1 Day 1, 
laboratory safety tests must be conducted within 72hours prior to first dose of trial treatment in each cycle , with the exception of the thyroid function tests and LDH which 
may be conducted up to 10 days prior to first dose of trial treatment. Laboratory results , with the exception of thyroid function tests and LDH, must be known prior to 
dosing.
10. Urinalysis is to be perform edevery 6 cycles.
11. Thyroid tests are to be repe ated every 2 cycles beginning at Cycle 2.
12. For women of reproductive potential, a urine pregnancy test should be performed within 72 hours prior to first dose of trial treatment. A serum test can be considered if urine
is not appropriate. Monthly pregnancy testing should be conducted as per local regulations where applicable.
13. CT with contrast (preferred) of the chest, abdomen and pelvis is required for all subjects; non-contrast CT of the chest andMRI of the abdomen and pelvis may be used for 
subjects in whom iodinated contrast is contraindicated.
14. Tumor imaging to be performed within 28 days prior to restar ting treatment with pembrolizumab. Tumor response assessment is required every 6 weeks (42 [± 7] days) for 
the first 26 weeks of the Second Course Phas e, then every 9 weeks (63 [±7] days) until the subject starts a non-study cancer therapy. Refer to site imaging manual for 
additional details. Additional imaging at Discontinuation Visit and Safety Follow -up Visit is not required provided that previous imaging assessments have been performed 
per schedule. Additional imaging after study drug discontinuation is not required for subjects who start a non-study cancer therapy. Refer to Section 7.1.2.7 for additional 
details.
15. MRI (strongly preferred) or CT with contrast of the brain at baseline for all subjects. For subjects without brain metastases at diagnosis, brain imaging is required as 
clinically indicated. For subjects with brain metastases at diagnosis that have undergone treatment, repeat brain imaging is to be performed at all post-baseline imaging 
assessments.
16. Nuclear medicine bone scan for all subjects, at baseline, to assess for bone lesions. Bone scan is to be repeated in subjects with bone lesions at baseline who achieve a 
radiographic CR (to confi rm osseous response) and as clinically indicated.
17. Pembrolizumab can be administered for up to 17 cycles.
Product:   MK-3475 71
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential7.0 TRIAL PROCEDURES
Trial Procedures
The Trial Flow Chart -Section 6.0summarizes the trial procedures to be performed at each 
visit.  Individual trial procedures are described in detail below.  It may be necessary  to 
perform these procedures at unscheduled time points if deemed clinically necessary  by the 
investigator.
Furthermore, additional evaluations/testing may  be deemed necessary  by the investigator and 
or the Sponsor for reasons related to subject safety . In some cases, such evaluation/testing 
may be potentially  sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations 
may require that additional informed consent be obtained from the subject.  In these cases, 
such evaluations/testing will be performed in accordance with those regulations.
Administrative Procedures
Informed Consent
The investigator or qualified designee must obtain documented consent from each potential 
subject or each subject’s legally  acceptable representative prior to participating in a clinical 
trial or Future Biomedical Research .If there arechanges to the subject’s status during the 
trial ( e.g.,health or age of majority  requirements ), the investigator or qualified designee must 
ensure the ap propriate consent is in place. 
7.1.1.1.1 General Informed Consent
Consent must be documented by the subject’s dated signature or by the subject’s legally 
acceptable representative’s dated signature on a consent form along with the dated signature 
of the person conducting the consent discussion. 
A copy  of the signed and dated consent form should be given to the subject before 
participation in the trial.
The initial informed consent form, any subsequent revised written informed consent form 
and any written information provided to the subject must receive the IRB/ERC’s 
approval/favorable opinion in advance of use.  The subject or his/her legally  accepta ble 
representative should be informed in a timel y manner if new information becomes available 
that may be relevant to the subject’s willingness to continue participation in the trial.  The 
communication of this information will be provided and documented via a revised consent 
form or addendum to the original consent form that captures the subject’s dated signature or 
by the subject’s legall y acceptable representative’s dated signature.
Specifics about a trial and the trial population will be added to the consent form template at 
the protocol level.  
Product:   MK-3475 72
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialThe informed consent will adhere to IRB/IEC requirements, applicable laws and regulations 
and Sponsor requirements.
7.1.1.1.2 Consent and Collection of Specimens for Future Biomedical Research
The investigator or qualifie d designee will explain the Future Biomedical Research consent 
to the subject, answer all of his/her questions, and obtain written informed consent before 
performing an y procedure related to the Future Biomedical Research sub -trial.  A copy  of the 
informed consent will be given to the subject.
Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by  the investigator or qualified designee 
to ensure that the subject qualifies for the trial.
Subject Identification Card
All subjects will be given a Subject Identification Card identify ing them as participants in a 
research trial. The card will contain trial site contact information (including direct telephone 
numbers) to be utilized in the event of an emergency . The investigator or qualified designee 
will provide the subject with a Subject Identification Card immediately  after the subject 
provides written informed consent. At the time of treatment allocation/randomization, site 
personnel will add the treatment/randomization number to t he Subject Identification Card.
The subject identification card also contains contact information for the emergency  
unblinding call center so that a health care provider can obtain information about trial 
medication/vaccination in emergency  situations wher e the investigator is not available.
Medical History
A medical history  will be obtained by the investigator or qualified designee. The medical 
history  will collect all active conditions and any condition diagnosed within the prior 
10years that the investi gator considers to be clinically  significant. Details regarding the 
disease for which the subject has enrolled in this trial will be recorded separately  and not 
listed as medical history .
Prior and Concomitant Medications Review
7.1.1.5.1 Prior Medications
The inves tigator or qualified designee will review prior medication use, including any 
protocol -specified washout requirement, and record prior medication taken by the subject 
within 28 days before starting the trial treatment .Any treatment provided for the diseas e for 
which the subject has enrolled in this trial will be recorded separatel y and not listed as a prior 
medication.
Product:   MK-3475 73
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential7.1.1.5.2 Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by the subject 
during the trial through the Safety  Follow -up visit. In addition, new medications started 
during the Second Course Phase through the respective Safet y Follow -up visit should be 
recorded .All medications related to reportable SAEs and ECIs should be recorded as defined 
in Section 7.2.
Assignment of Screening Number
All consented subjects will be given a unique screening number that will be used to identify 
the subject for all procedures that occur prior to randomization or treatment allocation.  Each 
subject will be assigne d only  one screening num ber.  Screening numbers must not be re -used 
for different subjects.
Any subject who is screened multiple times will retain the original screening number 
assigned at the initial screening visit.
Specific details on the Screening Visit requirements (screening/rescreening) are provided in 
Section 7.1.5.1.
Assignment of Treatment/ Randomization Number
All eligible subjects will be randoml y allocated and will receive a treatment/ randomization 
number.  The treatment/ randomization number identifies the subject for all procedures 
occurring after randomization.  Once a treatment/randomization number is assigned to a 
subject, it can never be re -assigned to another subject.
A single subject cannot be assigned more than 1 treatment/ randomizatio n number.
Trial Compliance (Medication/Diet/Activity/Other)
Interruptions from the protocol specified treatment plan for greater than 12 weeks between 
pembrolizumab doses for non-drug-related or administrative reasons require consultation 
between the investigator and the Sponsor and written documentation of the collaborative 
decision on subject management.
Administration of trial medication(s) will be witnessed by the investigator and/or trial staff.
The total volume o f pembrolizumab infused will be compared to the total volume prepared to 
determine compliance with each dose administered. Start and stop times of drug 
administration should be recorded in the source documents.
Clinical Procedures/Assessments
Adverse Even t Monitoring
The investigator or qualified designee will assess each subject to evaluate for potential new 
or worsening AEsas specified in the Trial Flow Chart (Section 6.0) and more frequentl y if 
Product:   MK-3475 74
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialclinically  indicated. Adverse experiences will be graded and recorded throughout the study 
and during the follow -up period according to NCI CTCAE 4.0 (see Section 12.4).Toxicities 
will be characterized in terms including seriousness, causality , toxicity  grading, and action 
taken with regard to trial treatment.
Please refer to Section 7.2 for detailed information regarding the assessment and recording of 
AEs.
Physical Examination
7.1.2.2.1 Full Physical Examination
The investigator or qualified designee will perform a full physical exam ination during the 
screening period before the Initial Treatment Phase, and on Cycle1, Day 1 of theSecond 
Course Treatment Phase.Clinically  significant abnormal findings should be recorded as 
medical history .The time points for full phy sical exam ination are described in theTrial Flow 
Chart (Section 6).After the first dose of trial treatment new clinically  significant abnormal 
findings should be recorded as AEs.
7.1.2.2.2 Directed Physical Examination
For cycles/visits that do not require a full physical exam ination per the Trial Flow Chart
(Section6), the investigator or qualified designee will perform a directed physical 
exam ination as clinically indicated prior to trial treatment administration and at other times 
according to the Trial Flow Chart (Section 6).New clinically  significant abnorm al findings 
should be recorded as A Es.
Vital Signs
Vital signs include temperature, pulse, respiratory  rate, weight ,and blood pressure. The 
investigator or qualified designee will take vital signs at screening, prior to the administration 
of each dose of trial treatment ,during the follow -up phase , and at other visits as specified in 
the Trial Flow Chart (Section 6 .0).Height will be measured at Visit 1 only .
12-Lead Electrocardiogram
A standard 12-lead electrocardiogram will be performed using local stand ard procedures 
once at screening. Clinically  significant abnormal findings should be recorded as medical 
history .
Eastern Cooperative Oncology Group Performance Status
The investigator or qualified designee will assess ECOG status (see Section 12.3) at 
screening, prior to each cycle of trial treatment and during the Follow -up period as specified 
in the Trial Flow Chart (Section 6).
Product:   MK-3475 75
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Prophylactic Cranial Irradiation
Subjects in either arm who achieve CRor PRafter Cycle 4 may be offered PCI at the 
discret ion of the treating investigator. Imaging of the brain must occur after the completion 
of 4cycles of trial treatment, just prior to PCI .
Subjects selected to receive PCI may receive up to 25 Gy in 10fractions (or the biologic
equivalent), as tolerated bythe subject. If given, PCI must begin within 6 weeks (preferabl y 
within 2 to 4 weeks) after the last dose of stud y medication in Cy cle 4. Study  medication may  
continue during PCI;however, if it is necessary  to suspend study  treatment, dosing must be 
restarted no later than 2weeks after completion of PCI.Steroids can be administered, as 
required, during and after PCI .
Tumor Imaging and Assessment of Disease
The process for image collection and transmission to BICR can be found in the Site Imaging 
Manual .The same imaging technique regarding modality  and use of contrast should be used
consistently  throughout the trial. Imaging schedule should follow calendar days and should 
not be adjusted for cy cle delay s.
Screening (baseline) imaging:
CT with IV and oral contrast (preferred) of the chest, abdomen and pelvis for all 
subjects , or non-contrast CT of the chest andmagnetic resonance imaging (MRI )of 
the abdomen and pelvis with IV gadolinium for subjects in whom iodinated contrast 
is contraindicated
MRI  (strongl y preferred) or CT with contras t (when MRI  is medically 
contraindicated) of the brain for all subjects
Nuclear medicine bone scan for bone lesions
Post baseline imaging:
CT or MRI of the chest, abdomen and pelvis , consistent with the method used at 
baseline
Imaging of the brain, consistent with the method used at baseline :
oAt all post -baseline visits for subjects with baseline brain metastases 
oFor subjects who will undergo PCI , should be performed prior to PCI
oIf clinicall y indicated
Product:   MK-3475 76
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialNuclear medicine b one scan for bone lesions:
oIf clinicall y indicated
oIn subject s with bone lesions at baseline who achieve a radiographic CR to 
confirm osseous response
Local site investigator/radiology  assessment based on RECI ST 1.1(modified to follow a 
maximum of 10 target lesions and a maximum of 5 target lesions per organ) will be used to 
determine subject eligibility .All scheduled images for all study  subjects from the sites will 
be submitted to the BICR .In addition, all other imaging (including allmodalities) obtained at 
an unscheduled time point to determine disease progression, as well as supplemental imaging 
obtained for other reasons thatcaptures radiologic progression, should be submitted to the 
BICR .
The BICR will review images for the verification of progression following the first
radiologic evidence of PDbased on local investigator assessment .Expedited verification of 
radiologic PD by the BICR will be communicated to the study  site and Sponsor (See 
Section 7.1.2.7.2). Details can be found in the Site I maging Manual.
7.1.2.7.1 Initial Tumor Imaging
Initial tumor imaging at screening must be performed within 28 days prior to the date of 
randomization. The site investigator/local radiology  reviewer must review screening images 
to confirm the subject has measurable disease per RECI ST 1.1 (modified to follow a 
maximum of 10 target lesions and a maximum of 5 target lesions per organ ).The screening 
images must be submitted to the BICR for retrospective review.
Tumor imaging via CTperformed as part of routine clinical management (prior to informed 
consent form signature) isacceptable for use as screening tumor imaging if they are of 
diagnostic quality ,areperformed within 28 days prior to the date of randomization
,and can 
be asses sed b y BICR .
7.1.2.7.2 Tumor Imaging During the Trial
Thefirst on-trial imaging assessment should be performed at 6 weeks (42 ± 7 days) from the 
date of randomization. Subsequent tumor imaging should be performed every  6  w eeks 
(42±7 day s) for the first 48 weeks of treatment, then every  9 weeks (63 [± 7] days), or more 
frequentl y if clinicall y indicated. Timing of tumor imaging
should follow calendar days and 
should not be adjusted for delay s in cycle starts. (Note: the date imaging is performed is the 
date of the imaging, not the date the images arereviewed.) Imaging should continue to be 
performed until disease progression verified by BICR (unless site PI elects to continue 
treatment and follow irRECI ST), the start of a non -study anti-cancer treatment, withdrawal of 
consent, or death, whichever occurs first. Supplemental imaging must be submitted to the 
central imaging vendor if it shows evidence of progression or if it is used to support a 
determination of PR or CR.
Product:   MK-3475 77
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialPer RECI ST 1.1(modifi ed to follow a maximum of 10 target lesions and a maximum of 
5target lesions per organ) , PR and CRshould be confirmed by a repeat tumor imaging 
assessment not less than 4 weeks from the date the response was first documented. The tumor 
imaging for confir mation of response may  be performed at the next scheduled tumor imaging
(ie, 6 or 9weeks later), whichever is clinically  indicated. Subjects will then return to regular 
scheduled imaging every 6 or 9 weeks , starting with the next scheduled imaging time point.
Subjects who obtain confirmat ory imaging do not need to undergo the next scheduled tumor 
imaging if it is <4weeks later; tumor imaging may resume at the subsequent scheduled 
imaging time point.
Per irRECI ST (see Section 7.1.2.7.6), disease progress ion should be confirmed by the site at 
least 4 weeks after BICR verification of site-assessed first radiologic evidence of PD in 
clinically  stable subjects. Subjects who have unconfirmed disease progression may continue 
on treatment at the discretion of the site investigator until progression is confirmed (by the 
site)provided they have met the condit ions detailed in Section 
7.1.2.7.6. Subjects who have
confirmatory  imaging do not need to undergo the next scheduled tumor imaging if it is 
<4weeks later; tu mor imaging may  resume at the subsequent scheduled imaging time point if 
clinically  stable. Subjects who have confirmed disease progression as assessed by the site 
will discontinue 
trialtreatment , except in some cases as detailed in Section 7.1.2. 7.6.
7.1.2.7.3 End of Treatment and Follow -up of Tumor Imaging
For subjects who discontinue trial treatment, tumor imaging should be performed at the time 
of treatment discontinuation. If prev
ious tumor imaging was obtained within 4 weeks prior to 
the date of discontinuation, then tumor imaging at treatment discontinuation is not required .
For subjects who discontinue trial treatment due to documented disease progression, this is 
the final required tumor imaging.
In subjects who discontinue trial treatment without documented disease progression, every 
effort should be made to continue monitoring disease status by  tumor imaging using the same 
imaging schedule and modality  used while on treatment (every  6 weeks [427days]for the 
first 48 weeks after randomization, then every  9 weeks [637days])to monitor disease 
status until the start of non-study anticancer treatment, disease progression, death, or the end 
of the trial, whichever occurs first.
7.1.2.7.4 Second Course (Retreatment) Phase Tumor Imaging
Tumor imaging must be performed within 28 days prior to restarting treatment with 
pembrolizumab in the Second Course Phase . Disease progression must be verified by BICR 
using RECI ST 1.1(modified to follow a maximum of 10 target lesions and a maximum of 
5 target lesions per organ).
The first on study  imaging assessment of the Second Course Phase should be performed at 
6weeks (42 [± 7] days) after the first dose of trial treatment in that phase .Subsequent tumor 
imaging should be performed every  
6weeks (42 [± 7] days) for the first 26weeks of that 
phase, then every  9weeks (63 [±7]days), or more frequently  if clinicall y indicated.
Product:   MK-3475 78
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialPer irRECI ST (Section 7.1.2.7.6), if tumor imaging shows initia l PD, tumor assessment 
should be repeated ≥4 weeks later in order to confirm PD .Investigators and subjects have the 
option to continue treatment while awaiting 
radiologic confirmation of progression. Subjects 
who have confirmat oryimaging are not required to complete the next scheduled tumor 
imaging if it is <4 weeks later and may  wait until the following scheduled imaging time point 
if clinically  stable.
Imaging should continue to be performed until disease progression, the start of a non-study
anticancer treatment, withdrawal of consent, death, or notification by  the Sponsor, whichever 
occurs first. Disease progression may be confirmed 
≥4weeks after the first tumor imagin g 
indicating PD in clinically  stable subjects.
In subjects who discontinue trial treatment, tumor imaging should be performed at the time 
of treatment discontinuation. If previous tumor imaging was obtained within 4 weeks prior to 
the date of discontinuation, then tumor imaging at treatment discontinuation isnot required .
In subjects who discontinue trial treatment due to documented disease progression, this is the 
final required tumor imaging.
In subjects who discontinue trial treatment without documented disease progression, every 
effort should be made to continue 
monitoring disease status by radiologic imaging every 
6weeks (42[±7] days) for the first 26 weeks after the first dose of trial treatment in that 
phase, then every  9weeks (63 [± 7] days) until either the start of a non-study anticancer 
treatment, disease progression, death, or the end of the trial, whichever occurs first.
7.1.2.7.5 RECIST 1.1 Assessment of Disease
RECI ST 1.1(see Section 12.5) will be applied by the BICR as the primary  measure for 
assessment of tumor response, date of disease progression, and as a basis for all protocol 
guidelines related to disease status (eg, discontinuation of study  therap y).Although RECIST 
1.1 references amaximum of 5 target lesions in total and 2 per organ, Merck allows a 
maximum of 10 target lesions in total and 5 per organ , if clinically  relevant, to enable a 
broader sampling of tumor burden .Initial tumor imaging showing site -assessed PD should be 
subm itted to the BICR immediately .The site will be notified of the result ofBICR tumor 
imaging assessment using RECI ST 1.1 , ie, verification of progression .Figure 2illustrates the 
imaging flow involving verification of PD for clinically stable subjects.
7.1.2.7.6 irRECIST Assessment of Disease
To account for the unique tumor response seen with immunotherapeutic drugs, irRECI ST is 
RECI ST 1.1 adapted as described be low. The site investigator/local radiology review will use 
irRECI ST to assess tumor response and progression, and to make treatment decisions. This 
data will be collected in the clinical database. Treatment efficacy  based on irRECI ST will be 
evaluated retr ospectively as an exploratory  endpoint.
When feasible, subjects should not be discontinued until progression is confirmed by the 
local site investigator/radiology  assessment. This allowance to continue treatment despite 
initial radiologic PD takes 
into account the observation that some subjects can have a 
Product:   MK-3475 79
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidentialtransient tumor flare during the first few months after the start of immunotherap y, and then 
experience subsequent disease response. Subjects that are deemed clinically  unstable are not 
required to have repeat tumor imaging for confirmation of PD.Tumor flare includes any of 
the following scenarios:
Worsening of existing target lesion(s)
Worsening of existing non- target lesion(s)
Development of new lesion(s)
In subjects who have shown initial evidence of radiologic disease progression as assessed by 
BICR per RECI ST 1.1(modified to follow a maximum of 10 target lesions and a maximum 
of 5 target lesions per organ ), it is at the discretion of the principal investigator whether to 
continue a subject on study  treatment until repeat imaging is obtained (using irRECI ST for 
subject management, see Table 8and Figure 2).This clinical judgment decision by the site 
investigator should be based on the subject’s overall clinical condition, including 
performance status, clinical symptoms, and laboratory  data. Subjects may receive study  
treatment and tumor assessment should be repeated ≥4 weeks later in order to confirm PD by  
irRECI ST per site assessment. Clinical stability is defined as the following:
Neurologicall y stable without the need for steroids (for subjects with brain 
metastasis)
;
Absence of symptoms and signs indicating clinically  significant progression of 
disease, including worsening of laboratory  values ;
No decl ine in ECOG performance status;
Absence of rapid progression of disease ; and
Absence of progressive tumor at critical anatomical sites (eg, cord compression) 
requiring urgent alternative medical intervention (including immediate need for 
surgery  or WBRT inthe case of new brain metastases) .
Any subject deemed clinically unstable should be discontinued from trial treatment at BI CR 
verification of site-assessed first radiologic evidence of PD and is not required to have repeat 
imaging for PD confirmation.
In determining whether or not the tumor burden has increased or decreased per irRECI ST, 
the local site investigator should consider all target and non-target lesions as well as any 
incremental new lesion(s).
Product:   MK-3475 80
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialDisease progression will be considered to be “not confirmed” at repeat imaging if ALL  of the 
following occur (as assessed by  irRECIST):
Target lesion sum of diameters is <20% or <5 mm absolute increase compared to 
nadir
Non-target disease resulting in initial PD is stable or qualitatively  improved
New le sion resulting in initial PD is stable or qualitatively  improved
No incremental new lesion(s) since last evaluation
No incremental new non -target lesion progression since last evaluation
If repeat imaging does not confirm PD per irRECI ST as assessed by thelocal site 
investigator and the subject continues to be clinically  stable, treatment may continue and 
follow the regular imaging schedule.
Disease progression will be considered to be “confirmed” at repeat imaging if ANY of the 
following occur (as assesse d by irRECIST):
Target lesion sum of diameters reaches or remains ≥20% and ≥5 mm absolute 
increase compared to nadir
Non-target disease shows unequivocal progression, or the non -target disease resulting 
in initial PD is qualitatively  worse
New lesions appe ar for the first time, or the new lesions resulting in initial PD are 
increased in size or number
If repeat imaging confirms PD due to any of the scenarios listed above, subjects will be 
discontinued from study  therapy .
Note:If a subject has confirmed radiographic progression (ie, 2 scans at least 4 weeks apart 
demonstrating PD) per irRECI ST, but the subject is achieving a clinically  meaningful 
benefit, and there is no further increase in the tumor burden at the confirmatory  tumor 
imaging, an exception to continue treatment may be considered following consultation with 
the Sponsor (see Section 7.1.5.6 for details). In this case, if treatment is continued, tumor 
imaging should continue to be performed following the intervals as outlined in the Trial
Flowc hart(Section 6.0) and be submitted to the BICR.
Product:   MK-3475 81
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialIf a subject develops a new brain metastasis during treatment, the following steps will be 
taken :
Subjects with sy mptomatic brain metastases will be removed from study  treatment.
Subjects with asymptomatic brain metastases (no need for steroids, no symptoms and 
signs indicating clinical lysignificant progression of disease, no decline in ECOG 
performance status) can continue on study  treatment under the following conditions:
oIf no immediate WBRT, both systemic lesions and brain lesions can be followed 
by irRECIST .
oIf immediate WBRT is chosen, the brain lesions will be non-evaluable for 
irRECI ST.
oBrain MRI will be required at each subsequent image assessment.
Additional details about irRECI ST are refere nced in the Merck Imaging Tip Sheet for 
RECI ST 1.1 and irRECIST.
Product:   MK-3475 82
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialTable 8 Imaging and Treatment After First Radiologic Evidence of Progressive Disease
Clinically Stable Clinically Unstable
Imaging Treatment Imaging Treatment
First radiologic 
evidence of PD by 
RECIST 1.1
(modified to follow a 
maximum of 10 target 
lesions and a 
maximum of 5 target 
lesions per organ),
which has been 
verified by the BICRRepeat imaging at 4weeks 
at site to confirm PDMay continue study
treatment at the local site 
investigator ’s discretion 
while awaiting confirmatory 
tumor imaging by site by 
irRECIST.Repeat imaging at 4weeks 
to confirm PD per physician 
discretion only (Imaging 
should be reviewed by 
radiology as soon as 
possible.)Discontinue treatment
Repeat tumor 
imaging confirms PD
irRECIST at the local 
siteNo additional imaging 
requiredDiscontinue treatment 
(exception is possible upon 
consultation with Sponsor )No additional imaging 
requiredN/A
Repeat tumor 
imaging shows SD, 
PR or CR by 
irRECIST at the local 
siteContinue regularly 
scheduled imaging 
assessmentsContinue study treatment at 
the local site investigator ’s
discretionContinue regularly 
scheduled imaging 
assessments May restart study treatment 
if condition has improved 
and/or clinically stable per 
investigator ’sdiscretion. 
Next tumor imag ingshould 
occur according to the 
regular imaging schedule
outlined in the protocol
Abbreviations:  BICR=blinded independent central review; CR=complete response; irRECIST=immune- related Response Evaluation Criteria in Solid Tumors; 
N/A=not applicable; PD=progressive disease; PR=partial response; SD=stable disease
Product:   MK-3475 83
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialAbbreviations:  BICR=blinded independent central review, irRECIST =immune -related Response Evaluation 
Criteria in Solid Tum ors, PD=progressive disease, PI=principal investigator, RECIST=Response Evaluation 
Criteria in Solid Tumors
*If subject is clinically stable, may continue study treatment at the local site investigator ’s discretion while 
awaiting verification of PD per RECIST 1.1 by BICR and/or confirmatory tumor imaging by site by irRECIST.
Figure 2 Imaging and Treatment for Clinically  Stable Subjects After First Radiologic 
Evidence of PD Assessed by  the Si te
Tumor Tissue Collection: PD -L1 Status
Participation in this trial will be dependent upon supply ing tumor tissue for PD-L1 testing 
from locations not radiated prior to biopsy .Subjects whose submitted tissue is not evaluable 
for PD- L1 status can still be eligible to participate in the study .

Product:   MK-3475 84
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialAll subjects should submit either a newly  obtained core or excisional biopsy  or archival 
tissue (fine needle aspiration [FNA ], endobronchial ultrasound [EBUS] ,guided 
transbronchial needle aspiration [TBNA] , cell pellets, cytology ,and blood smears arenot 
adequate for both archival and new tissue samples) to a central laboratory  for 
characterization of PD -L1 status prior to treatment allocation.
Note: Submission of formalin -fixed paraffin embedded tumor tissue sample blocks are 
preferred; if submitting unstained slides, the slides should be freshly  cut and submitted to the 
testing laboratory  within 14 days from the site slide section date, otherwise a new specimen 
will be requested.
If the sample is determined to be non-evaluable prior to testing by the central laboratory , a 
new sample should be submitted if available. This may include additional cut slides that are 
outside of the 14- day window noted above.
Individual subject PD -L1 status will not be disclosed to inves tigative sites and study  subjects.
Analy ses by  PD-L1 biomarker status will be limited and documented.
If the subject signs the Future Biomedical Research consent, any leftover samples that would 
be ordinaril y discarded at the end of the main study  will be retained for Future Biomedical 
Research.
Laboratory Procedures/Assessments
Details regarding specific laboratory  procedures/assessments to be performed in this trial are 
provided below. The total amount of blood/tissue to be drawn/collected over the course of 
the trial (from pre-trial to post-trial visits), including approximate blood/tissue volumes 
drawn/collected by visit and by sample type per subject can be found in the Laboratory
Manual.Refer to the Trial Flow Chart (Section 6 .0) for the timing of laboratory assessments .
Clinical Laboratory Evaluations
Clinical l aboratory  tests are specified in Table 9.
Product:   MK-3475 85
Protocol/Amendment No.: 604-09
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialTable 9 Clinical Laboratory Tests
Hematology Hematocrit, hemoglobin, platelet count , WBC (total and 
differential), RBC, absolute ly mphocy te count, absolute 
neutrophil count
Chemistry Albumin, alkaline phosphatase, alanine aminotransferase, 
aspartate aminotransferase, bicarbonate (onl y required if done as 
part of standard of care by local laboratory ), calcium, chloride, 
creatinine, glucose, phosphorus, potassium, sodium, total 
bilirubin, direct bilirubin (if total bilirubin >ULN) , total protein, 
blood urea nitrogen or urea (one or the other should be colle cted 
per institutional standard; both of these laboratory  tests arenot 
required ), LDHa
Thyroid Function TestsaTotal T3 or free T3 (T3 is preferred; if not available ,free T3 may  
be tested) , FT4, and TSH
Coagulation Parameters PT/INR
Hepatitis SerologiesbHbsAg, HCV RNA (qualitative), Anti- HCV
Pregnancy  test If the urine test is not negative, then a serum test must be 
performed.
Urinaly sis Blood , glucose, protein, specific gravity
Microscopic exam should be performed if abnormal results are 
noted
Abbreviations:  FT4=free thyroxine; H bsAg=hepatitis B surface antigen; HCV=hepatitis C virus; LDH=Lactate 
dehydrogenase; PT=prothrombin time; RBC=red blood cells; T3=triiodothyronine; TSH=thyroid -stimulating 
horm one; ULN=upper limit of normal; WBC=white blood cells.
a If the local laboratory is unable to perform these tests, the site should submit the sample to the central 
laboratory for testing. Details are provided in the Laboratory Manual.
bHepatitis C antibody testing is allowed in countries where HCV RNA is not part of standard of care.  Testing 
for Hepatitis B and Hepatitis C should be perfor med as mandated by the local health authority.  
For both the Initial Treatment Phase and the Second Course Phase:
Screening laboratory  tests should be performed within 10 days prior to the first dose 
of trial treatment , with the exception of the hepatitis serologies which may be 
performed within 28 days of the first dose of trial treatment in the Initial Treatment 
Phase only. Testing for hepatitis B and hepatitis C should be performed as mandated 
by the local health authority .
Clinical laboratory tests must be conducted within 72hours prior to first dose of trial 
treatment in each cycle, with the exception of laboratory  tests performed by the 
central lab, which may be conducted 
up to 10 days prior to first dose of trial 
Product:   MK-3475 86
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialtreatment. Laboratory  testresults must be reviewed by the investigator or qualified 
designee and found to be acceptable prior to administration of first trial treatment.
For laboratory  tests performed by the central laboratory , any results not available 
prior to dosing must be reviewed by the investigator or qualified designee within 
48hours of receipt and found to be acceptable prior to subsequent administration of 
trial treatment.
During the Initial Treatment Phase ,laboratory  tests will also be performed at the
Day 8 Visit of each cycle.Results must be reviewed by the investigator or qualified 
designee within 48 hours of receipt.
Unresolved abnormal laboratory  test result s that are drug-related AEs should be 
follow ed until resolution.
Laboratory  tests do not need to be repeated after the end of treatment if lab oratory  test result s 
are within the normal range.
Pharmacokinetic/Pharmacodynamic Evaluations
Pembrolizumab
The accumulation of robust PK and anti-drug antibo dies (ADA) data has allowed for the 
adequate characterization of the clinical pharmacology  of pembrolizumab across indications. 
Therefore, upon approval of Amendment 07,each site is to stop the collection of PK and 
ADA samples for all subjects. Blood samp les for PK and ADA collected prior to 
Amendment 07may be stored. Anal ysis will be performed onl y if required.
Exploratory drug -drug interaction analysis
The accumulation of robust PK data has allowed for adequate characterization ofthe 
potential for drug-drug interactions between pembrolizumab and chemotherap y.Therefore, 
upon approval of protocol amendment 06,each site is to stop the collection of PK samples 
for etoposide only.Blood samples for etoposide PK collected prior to protocol 
amendment 06 may  be stored. Anal ysis will be performed onl y if required.
Patient -reported Outcomes
For PROs, the EQ-5D-5L, EORTC QLQ -C30,and EORTC QLQ -LC13 questionnaires will 
be administered by trained study  site personnel and completed electronically  by the subjects
themselves.
It is strongly  recommended that electronic PROs are administered prior to drug 
administration, AE evaluation ,and disease status notification. The electronic PROs are 
completed in the following order: EQ-5D-5Lfirst, then EORTC QLQ -C30, and lastly,the 
EORTC QLQ -LC13 at the time points specified in the Trial Flow Charts and briefl y 
summarized below.
Product:   MK-3475 87
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialThe EQ-5D-5L, EORTC QLQ-C30, and EORTC QLQ-LC13 are completed every  cycle for 
Cycles1 to9, then every other cycle up to Cycle 17 (ie, Cycles 11, 13, 15, and 17)while the 
subject is receiving study treatment .Patient -reported 
outcomes will also be obtained at the
treatment discontinuation visit and 30 -day Safety Follow -up visit.
Planned Genetic Analysis Sample Collection
Sample collection, storage and shipment instructions for Planned Genetic Anal ysis samples 
will be provided in the Laboratory Manual .
Future Biomedical Research Sample s
The following specimens are to be obtained as part of Future Biomedical Research:
DNA for future research
Leftover RNA
Leftover plasma and serum from biomarker anal yses
Leftover tumor
Other Procedures
Withdrawal/Discontinuation
Subjects who discontinue treatment prior to completion of the treatment regimen should be 
encouraged to continue to be followed for all remaining stud y visits.
When a subject discontinues/withdraws from participation in the trial, all applicable activities 
scheduled for the final trial visit should be performed at the time of discontinuation.  Any 
adverse events which are present at the time of discontinuation/withdrawal should be 
followed in accordance with the safety  requirements outlined in Section 7.2 -Assessing and 
Recording Adverse E vents.
Withdrawal From Future Biomedical Research
Subjects may withdraw their consent for Future Biomedical Research .  Subjects may 
withdraw consent at any time by contacting the principal investigator for the main trial.  If 
medical records for the main trial are still available, the investigator will contact the Sponsor 
using the designated mailbox (clinical.specimen.management@merck.com).  Subsequently , 
the subject's consent for Future Biomedical Research will be withdrawn .  A letter will be sent 
from the Sponsor to the investigator confirming the withdrawal . It is the responsibility  of the 
investigator to inform the subject of completion of withdrawal .  Any analyses in progress at 
the time of request for withdrawal or alread y performed prior to the reque st being received 
by the Sponsor will continue to be used as part of the overall research trial data and results.  
No new analy ses would be generated after the request is received.
Product:   MK-3475 88
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialIn the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by regulatory  authorities to retain the main trial records) or 
the specimens have been completely  anony mized, there will no longer be a link between the 
subject’s personal information and their specime ns.  In this situation, the request for 
specimen withdrawal cannot be processed.
Subject Blinding/Unblinding
When the investigator or delegate needs to identify  the drug used by  a subject and the dosage 
administered in case of emergency  e.g., the occurrenc e of serious adverse events , he/she will 
contact the emergency  unblinding call center by  telephone and make a request for emergency  
unblinding.  As requested by the investigator or delegate the emergency  unblinding call 
center will provide the information to him/her promptly  and report unblinding to the Sponsor .  
Prior to contacting the emergency  unblinding call center to request unblinding of a subject’s 
treatment assignment, the investigator or delegate must enter the toxicity  grade of the adverse 
events observed, the relation to study  drug, the reason thereof, etc., in the medical chart etc.
Subjects whose treatment assignment has been unblinded by the investigator/delegate and/or 
non-study  treating phy sician must be discontinued from study  drug, but shou ld continue to be 
monitored in the trial.
Treatment identification information is to be unmasked ONLY if necessary  for the welfare of 
the subject.  Every  effort should be made not to unblind the subject unless necessary . 
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason and person performing the unblinding ) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible. Once an emergency  unblinding or a 
non-emergency  unblinding has taken place, the principal investigator, site personnel, and 
Sponsor personnel may be unblinded so that the appropriate follow -up medical care can be 
provided to the subject.
Calibration of Critical Equipment
The investigator or qualified designee hasthe responsibility  to ensure that any critical device
or instrument used for a clinical evaluation/test during a clinical trial that provides important 
information about inclusion/exclusion criteria and/or safet y or efficacy  parameters shall be 
suitably  calibrated and maintained to ensure that the data obtained is reliable and/or 
reproducible.  Documentation of equipment calibration must be retained as source 
documentation at the trial site.
Critical Equipment for this trial includes:
None
Product:   MK-3475 89
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Visit Requiremen ts
Visit requirements are outlined in Section 6.0-Trial Flow Chart. Specific procedure -related 
details are provided above in Section 7.1 - Trial Procedures.
Screening
Within 28 days prior to randomization, potential subjects will be evaluated to determine that 
they fulfill the entry  requirements as set forth in Section 5.1.Visit requirement sare outlined 
in the Trial Flow Chart (Section 6 .0).Screening procedures may  be repeated.
Written consent must be obtained prior to performing any protocol -specific procedure.
Results of a test performed prior to the subject signing consent as part of routine clinical 
management are acceptable in lieu of a screening test if performed within the specified time 
frame. Screening procedures are to be completed within 28 day s prior to the first dose of trial 
treatment except for the following:
Laboratory  tests are to be performed within 10 days prior to the first dose of trial 
treatment with the exception ofhepatitis serologies testing ,which may be done up to 
28 days prior to the first dose of trial treatment. Testing for hepatitis B and hepatitis C 
should be performed as mandated b y the local health authority.
For women of reproductive potential, a urine pregnancy  test will be performed within 
72 hours prior to first dose of trial treatment. If urine pregnancy  results cannot be 
confirmed as negative, a serum pregnancy  test performed by the local study  site 
laboratory  will be required.
Tumor imaging must be performed within 28 days prior to randomization.
Subjects may be rescreened once after initially  failing to meet the inclusion/exclusion 
criteria. Results from assessments performed during the initial screening period are 
acceptable in lieu of repeating a screening test if performed within the specified time frame
and the results meet the inclusion/exclusion criteria.
Treatment Period Visit s
Visit requirements are outlined in Section 6. 0.Specific procedure -related details are provided 
above in Section 7.1.
Post-treatment Visits
7.1.5.3.1 Safety Follow -up Visit
The mandatory Safet y Follow -up Visit should be conducted approximately  30 days after the 
last dose of trial treatment or before the initiation of a new antineoplastic treatment, 
whichever comes first. All AEs that occur prior to the Safety  Follow -up Visit should be 
recorded. Subjects with an AE of Grade >1 will be further followed until the resolution of the 
Product:   MK-3475 90
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialAE to Grade ≤1 or until beginning of a new antineoplastic therap y, whichever occurs first.
Serious AEs that occur within 90days of the end of treatment or before initiation of a non-
study anticancer treatment should also be followed and recorded ; additionally , all 
medications taken during the 14days prior to an SAE and all medications taken to treat the 
SAE must be recorded .
Subjects who are eligible for retreatment with pembrolizumab may have up to2 Safety 
Follow -up visits, the first after the Initial Treatment Phase and the second after the Second 
Course Phase .
7.1.5.3.2 Progression-
free Survival Follow -up Visits
Subjects who discontinue trial treatment for a reason other than disease progression will 
move into the PFS Follow -up Phase and should be assessed as follows to monitor disease 
status by  imaging depending on the trial phase:
Initial Treatment Phase :tumor imaging every  6 w eeks (42 [± 7] days) for the first 
48weeks after randomization , then every  9  w eeks (63 [± 7] days) per the imaging 
schedule .
Second Course Phase: tumor imaging every  6 weeks (42 [±7] days) for the first 
26weeks from the date of the first dose of trial medication in this phase, then every 
9weeks (63 [± 7] day s) per the imaging schedule.
The Sponsor may request survival status to be assessed at additional time points during the 
course of the study  (not to exceed approximately every  8  w eeks). Every  effort should be 
made to collect information regarding disease status until the start of new anti-cancer 
therap y, disease progression, death, end of trial. Information regarding post-trial anticancer 
treatment will be collected if new treatment is initiated.
Follow -up visit re quirements are outlined in the Trial Flow Chart (Section 6.0 ).
7.1.5.3.3 Survival Follow -up
Once a subject experiences PD or starts a non-study anti-cancer therapy , the subject will 
move into the Survival Follow -up Phase and should be contacted by  telephone approxim ately  
every  8weeks to assess for survival status until death, withdrawal of consent, orthe end of 
the study , whichever occurs first. Post-study  treatments and the subject’s response to them 
will also be collected.
Survival Status
To ensure current and complete survival data is available at the time of database locks, 
updated survival status may be requested during the course of the study  by the Sponsor. For 
example, updated survival status may be requested prior to. But not limited to,an external 
DMC review, interim and/or final analy ses.Upon Sponsor notification, all participants who 
do not/will not have a scheduled study  visit or study  contact during the Sponsor defined time 
Product:   MK-3475 91
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialperiod will be contacted for their survival status (excluding participants that have previousl y 
recorded a death event in the collection tool).
Second Course Phase
Subjects who have stable disease (SD), PR, or CR after receiving 35 pembrolizumab 
treatment smay be eligible for retreatment with up to an additional 17 cycles (approxi mately  
1 year) of pembrolizumab treatment. This retreatment is termed the Second Course Phase of 
this trial and will only be available upon consultation with the Sponsor if the trial remains 
open and if the subject meets the following conditions:
Had SD, PR, or CR and stopped treatment after completion of 35 administrations 
(approximately  2 years) of pembrolizumab in the Initial Treatment Phase .
(Consultation with the Sponsor will be needed in those cases where pembrolizumab 
was stopped for reasons other than disease progression or intolerability  before 
35cycles.)
AND
Experienced a BICR -verified radiographic disease progression by modified 
RECI ST1.1 after stopping initial treatment, and
oNo new anticancer treatment was administered after the last dose of trial 
treatment, and
oThe subject meets all of the safety  parameters listed in the inclusion criteria 
and none of the safet y parameters listed in the exclusion criteria, and
oThe trial is ongoing.
Treatment assignment will be unblinded only for those subjects who meet all criteria for the 
Second Course Phase. Subjects in the saline placebo arm are not eligible for the Second 
Course Phase.
Procedures and assessments for the Second Course Phase will be initiate donce radiographic 
disease progression by modified RECI ST 1.1 has been determined by the investigator and 
verified by BICR, and the subject has met the criteria listed above. All procedures and 
assessments completed at the time of withdrawal from the Initial Treatment Phase may be 
used,as appropriate ,for the start of the Second Course Phase of the study . Procedures and 
assessments must be completed within 28 days after radiographic progression by modified 
RECI ST1.1.
An objective response or disease progression that occurs during the Second Cours e Phase for 
a subject will not be counted as an event for the primary  anal ysis of an y endpoint in this trial.
Product:   MK-3475 92
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialVisit requirem ents are outlined in the Trial Flow Chart ( Section 6.2).Survival assessments 
and their respective entries into the database may be required more frequently  around the 
time of the projected analyses (eg, DMC reviews, interim anal yses).
Specific procedure -related details are provided above in Section 7.1
.
Continued Treatment Following Verified Progressive Disease
Subjects who are deemed by the investigator to be benefiting clinicall y despite documented 
PD assessed by BICR using RECIST 1.1 (modified to follow a maximum of 10 target lesions 
and a maximum of 5 target lesions per organ) , may remain on study  and continu e receiving 
the originall y assigned trial treatment for a total of 35 cycles.Continued post- PD treatment is 
optional and will be determined at the discretion of the investigator (in consultation with the 
Sponsor ).
Subjects who meet the following criteria will be eligible for continued post -PD treatment :
Documentation of PD will be defined as BICR assessment .
AEs (except alopecia and peripheral neuropathy ) due to therap y must have improved 
to NCI CTCAE 4.0 Grade ≤1.
If a subject is unstable as a result of anew or progressing brain metastasis(es), the 
subject will not be eligible for continued treatment .
ECOG Performance Status of0or 1.
Subject must not have received an y non-study systemic anti -cancer therapies.
Subject has adequate organ function as indicated by the laboratory  assessments listed 
in Section 5.1.2.
Visit requirements are outlined in the Trial Flow Chart ( Section 6.1).Survival assessments 
and their respective entries into the database may be required more frequently  around the 
time of the projected analy ses (eg, DMC reviews, interim analy ses). Specific procedure -
related details are provided above in Section 7.1.
Discontinued Subjects Continuing to be Monitored in the Trial
Subjects who discontinue from the treatment phase prior to disease progression will continue 
to be followed in PFS follow -up until they experience disease progression or start a new 
antineoplastic therapy .Subjects with an AE of Grade >1 will be further followed until the 
resolution of theAE to Grade ≤1 or until beginning of a new antineoplastic therap y, 
whichever occurs first .
Date of disease recurrence or metastatic progression, start and stop dates of subsequent 
anti-cancer treatments, and reasons for treatments should be recorded in the appropriate 
Product:   MK-3475 93
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialeCRF. Survival assessments and their respective entries into the database may be required 
more frequently  around the time of the projected analyses (eg, DMC reviews, interim 
analyses).For subjects who die during the follow -up period, the date and cause of death 
should be recorded in the appropriate eCRF.
Assessing and Recording Adverse Events      
An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily 
have to have a causal relationship with this treatment. An adverse event can therefore be any 
unfavourable and unintended sign (including an abnormal laboratory  finding, for example), 
symptom, or disease temporally  associate d with the use of a medicinal product or protocol -
specified procedure, whether or not considered related to the medicinal product or protocol -
specified procedure.  Any worsening (i.e., any clinically  significant adverse change in 
frequency  and/or intensity ) of a preexisting condition that is temporally  associated with the 
use of the Sponsor’s product, is also an adverse event.
Changes resulting from normal growth and development that do not vary significantl y in 
frequency  or severit y from expected levels are not to be considered adverse events.  
Examples of this may include, but are not limited to, teething, typical crying in infants and 
children and onset of menses or menopause occurring at a ph ysiologically  appropriate time.
Sponsor's product includes any pharmaceutical product, biological product, device, 
diagnostic agent or protocol -specified procedure, whether investigational (including placebo 
or active comparator medication) or marketed, manufactured by, licensed by, provided by or 
distributed by  the S ponsor for human use.
Adverse events may occur during clinical trials, or as prescribed in clinical practice, from 
overdose (whether accidental or intentional), from abuse and from withdrawal.
Progression of the cancer under study  is not considered an adve rse event.
All adverse events that occur after the consent form is signed but before treatment 
allocation/ randomization must be reported by the investigator if they cause the subject to be 
excluded from the trial, or are the result of a protocol -specified intervention, including but 
not limited to washout or discontinuation of usual therap y, diet, placebo treatment or a 
procedure. From the time of treatment allocation/ randomization through 30days following 
cessation of treatment, all adverse events must bereported by the investigator. Such events 
will be recorded at each examination on the Adverse Event case report forms/worksheets.  
The reporting timeframe for adverse events meeting any serious criteria is described in 
Section 7.2.3.1. The investigator will make every attempt to follow all subjects with non-
serious adverse events for outcome.
Electronic reporting procedures can be found in the Electronic Data Capture (EDC )data 
entry  guidelines. Paper reporting procedures can be found in the Investigator Trial File 
Binder (or equivalent).
Product:   MK-3475 94
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Definition of an Overdose for This Protocol and Reporting of Overdose to the 
Sponsor
For purposes of this trial, an overdose will be defined as any dose exceeding the prescribed 
dose for pembrolizumab by ≥1000 mg (5 times the dose) .For subjects treated with 
pembrolizumab an overdose will be defined as any dose exceeding 5X the 
protocol -prescribed dose. No specific information is available on the treatment of overdose 
of pembrolizumab . In the event of overdose, pembrolizuma bshould be discontinued and the 
subject should be observed closel y for signs of toxicity .  Appropriate supportive treatment 
should be provided if clinically  indicated.
If an adverse event(s) is associated with (“results from”) the overdose of Sponsor's product, 
the adverse event(s) is reported as a serious adverse event, even if no other seriousness 
criteria are met.
If a dose of Sponsor's product meeting the protocol definition of overdose is taken without 
any associated clinical symptoms or abnormal laboratory  results, the overdose is reported as 
a non-serious Event of Clinical Interest (ECI), using the terminology  “accidental or 
intentional overdose without adverse effect.”
All reports of overdose with and without an adverse event must be reported by the 
investigator within 24 hours to the Sponsor either by electronic media or paper. Electronic 
reporting procedures can be found in the EDC data entry  guidelines. Paper reporting 
procedures can be found in the I nvestigator Trial File Binder (or equival ent).
Reporting of Pregnancy and Lactation to the Sponsor
Although pregnancy  and lactation are not considered AEs, it is the responsibility  of 
investigators or their designees to report any pregnancy  or lactation in a subject 
(spontaneousl y reported to the m) that occurs during the trial .
Pregnancies and lactations that occur after the consent form is signed but before treatment 
allocation/ randomization must be reported by the investigator if they cause the subject to be 
excluded from the trial or are the re sult of a protocol -specified intervention, including but not 
limited to washout or discontinuation of usual therap y, diet, placebo treatment or a 
procedure. Pregnancies and lactations that occur from the time of treatment 
allocation/ randomization through 120days following cessation of Sponsor’s product ,or 
180days after last dose of chemotherapeutic agents, or 30days following cessation of trial 
treatment ifthe subject initiates new anticancer therap y, whichever is earlier, must be 
reported by the inves tigator. All reported pregnancies must be followed to the 
completion/termination of the pregnancy . Pregnancy  outcomes of spontaneous abortion, 
missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, 
miscarriage and stillb irth must be reported as serious events (Important Medical Events). If 
the pregnancy  continues to term, the outcome (health of infant) must also be reported.
Product:   MK-3475 95
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialSuch events must be reported within 24 hours to the Sponsor either by electronic media or 
paper. Electronic reporting procedures can be found in the EDC data entry guidelines. Paper 
reporting procedures can be found in the Investigator Trial File Binder (or equivalent).
Immediate Reporting of Adverse Events to the Sponsor
Serious Adverse Events
AnSAE is any  AEoccurring at any  dose or during an y use of Sponsor’ s product that:
Results in death;
Is life -threatening;
Results in persistent or significant disability /incapacity ;
Results in or prolongs an existing inpatient hospitalization;
Is a congenital anomal y/birth defect;
Is another important medical event.
*Note: In addition to the above criteria, AEs meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the Sponsor in the same 
timeframe as SAEs to meet certain local requirements. Therefore, these events are 
considered serious b y the Sponsor for collection purposes.
Is a new cancer (that is not a condition of the study);
Is associated with an overdose.
Refer to Table 10for additional details regarding each of the above criteria.
For the time period beginning when the consent form is signed until treatment 
allocation/ randomization, an y SAE , or follow up to a nSAE , including death due to any  cause
other than progression of the cancer under study (seeSection 7.2.3.3 for additional details) , 
that occurs to any subject must be reported within 24hours to the Sponsor if it causes the 
subject to be excluded from the trial, or is the result of a protocol -specified intervention, 
including but not limited to washout or discontinuation of usual therapy , diet, placebo 
treatment or a procedure.
For the time period beginning at treatment allocation/ randomization through 90 days 
following cessation of trial treatment, or 30 days following cessation of trial treatment if the 
subject initiates new anticancer therap y, whichever is earlier, any SAE , or follow up to a 
SAE , including death due to any cause other than progre ssion of the cancer under study  (see
Section 7.2.3.3 for additional details) , whether or not related to the Sponsor ’s product, must 
be reported within 24 hours to the Sponsor either by electronic media or paper. Electronic 
Product:   MK-3475 96
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialreporting procedures can be found in the EDC data entry  guidelines. Paper reporting 
procedures can be found in the I nvestigator Trial File Binder (or equivalent).
Additionally , any SAE , considered by an investigator who is a qualified physician to be 
related to the Sponsor ’s product that is brought to the attention of the investigator at any  time 
following consent through the end of the specified safet y follow -up period specified in the 
paragraph above, or at any  time outside of the time period specified in the previous paragraph 
also must be reported immediately  to the Sponsor.  
All subjects with SAEs must be followed up for outcome.
Events of Clinical Interest
Selected non-serious and serious adverse events are also known as Events of Clinical I nterest 
(ECI) and must be reported to the S ponsor.
For the time period beginning when the consent form is signed until treatment 
allocation/ randomization, any  ECI, or follow up to an ECI , that occurs to any  subject must be 
reported within 24 hours to the Sponsor if it causes the subject to be exclu ded from the trial, 
or is the result of a protocol -specified intervention, including but not limited to washout or 
discontinuation of usual therap y, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/ randomization through 30days 
following cessation of treatment, any ECI, or follow up to an ECI, whether or not related to 
the Sponsor’s product, must be reported within 24 hours to the Sponsor, either by electronic 
media or paper.  Electronic reporting procedures can be found in the EDC data entry 
guidelines.  Paper reporting procedures can be found in the Investigator Trial File Binder (or 
equivalent).
Events of clinical interest for this trial include:
an overdose of Sponsor's product, as defined in Section 7.2.1 -Definition of an 
Overdose for This Protocol and Reporting of Overdose to the Sponsor, that is not 
associated with clinical symptoms or abnormal laboratory results. 
an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit 
of normal and an elevated total bilirubin lab value that is greater than or equal to 2X 
the upper limit of normal and, at the same time, an alkaline phosphatase lab value that 
is less than 2X the upper limit of normal, as determined by way of protocol- specified 
laboratory  testing or un scheduled laboratory  testing.*
*Note:  These criteria are based upon available regulatory  guidance documents. The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that may  require 
an additional evaluation for an underl ying etiology. The trial site guidance for assessment 
and follow up of these criteria can be found in the Investigator Trial File Binder (or 
equivalent).
Product:   MK-3475 97
Protocol/Amendment No.: 604-09
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Protocol -Specific Exceptions to Serious Adverse Event Reporting
Efficacy  endpoints as outlined in this section will not be reported to the Sponsor as described 
in Section 7.2.3.
Specificall y, the suspected/actual events covered in this exception include any event that is 
disease progression of the cancer under stud y.
The Sponsor will monitor unblinded aggregated efficacy  endpoint events and safet y data to 
ensure the safety  of the subjects in the trial. Any suspected endpoint which upon review is 
not progression of the cancer under study  will be forwarded to global safety  as a SAE within 
24 hours of determination that the event is not progression of the cancer under study.
Evaluating Adverse Events
An investigator who is a qualified physician will evaluate all adverse events according to the 
NCI Common Terminology  for Adverse Events (CTCAE), version 4. Any adverse event 
which changes CTCAE grade over the course of a given episode will have each chang e of 
grade recorded on the adverse event case report forms/worksheets.
All adverse events regardless of CTCAE grade must also be evaluated for seriousness.
For studies in which multiple agents are administered as part of a combination regimen, the 
investig ator may attribute each adverse event causality  to the combination regimen or to a 
single agent of the combination.  In general, causality  attribution should be assigned to the 
combination regimen (i.e., to all agents in the regimen). However, causality  attribution may 
be assigned to a single agent if in the investigator’s opinion, there is sufficient data to support 
full attribution of the adverse event to the single agent.
Product:   MK-3475 98
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialTable 10 Evaluating Adverse Events
An investigator who is a qualified physician, will evaluate all adverse events as to:
V4.0 CTCAE 
GradingGrade 1 Mild; asymptomatic or mid symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age -appropriate instrumental ADL.
Grade 3 Severe or medically significant but not immediate ly life-threatening; hospitalization or prolongation or hospitalization indicated; 
disabling; limiting self -care ADL.
Grade 4 Life threatening consequences; urgent intervention indicated.
Grade 5 Death related to AE
Seriousness A serious adverse event is any adverse event occurring at any dose or during any use of Sponsor’s product that:
†Results in death ; or
†Is life threatening; orplaces the subject, in the view of the investigator, at immediate risk of death from the event as it occurred (Note: This does not include an 
adverse event that, had it occurred in a more severe form, might have caused death.); or
†Results in a persiste nt or significant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or
†Results in or prolongs an existing inpatient hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay, even if the 
hospitalization is a precautionary measure for continued observation. (Note: Hospitalization for an elective procedure to treat a pre-existing condition that has not 
worsened is not a serious adverse event.  A pre-existing condition is a clinical condition that is diagnosed prior to the use of a Merck product and is documented in 
the patient’s medical history.); or
†Is a congenital anomaly/birth defect (in offspring of subject taking the product regardless of time to diagnosis);or
Is anew cancer (that is not a condition of the study) (although not serious per ICH definition, is reportable to the Sponsor within 24 hours to meet certain local 
requirements); or
Is an overdose (whether accidental or intentional).  Any adverse event associated with an overdose is considered a serious adverse event for collection purposes . An 
overdose that is not associated with an adverse event is considered a non -serious event of clinical inter est and must be reported within 24 hours.
Other important medical events that may not result in death, not be life threatening, or not require hospitalization may be considered a serious adverse eve nt when, 
based upon appropriate medical judgment, the event may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes 
listed previously (designated above by a †).
Duration Record the start and stop dates of the adverse event. If less than 1 day, indicate the app ropriate length of time and units
Action taken Did the adverse event cause the Sponsor’s product to be discontinued?
Relationship to 
Sponsor’s 
ProductDid the Sponsor’s product cause the adverse event? The determination of the likelihood that the Sponsor’s product caused the adverse event will be provided by an 
investigator who is a qualified physician. The investigator’s signed/dated initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medic ally qualified assessment of causality was done. This initialed document must be retained for the required regulatory time frame. The 
criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationsh ip between the test drug and the adverse event 
based upon the available information.
The following components are to be used to assess the relationship between the Sponsor’s product and the AE ; the greater the correlation with the components 
and their resp ective elements (in number and/or intensity), the more likely the Sponsor’s product caused the adverse event (AE):
Exposure Is there evidence that the subject was actually exposed to the Sponsor’s product such as: reliable history, acceptable compli ance assessment (pill 
count, diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?
Time Course Did the AE follow in a reasonable temporal sequence from administration of the Sponsor’s product? 
Is the time of onset of the AE compatible with a drug -induced effect (applies to trials with investigational medicinal product)?
Likely Cause Is the AE not reasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host or enviro nmental factors
Product:   MK-3475 99
Protocol/Amendment No.: 604-09
MK-3475 -604-09Final Protocol 23-Apr-2019
ConfidentialRelationship The following components are to be used to assess the relationship between the test drug and the AE: (continued)
to Sponsor's 
Product
(continued) Dechallenge Was the Sponsor’s product discontinued or dose/exposure/frequency reduced?
If yes, did the AE resolve or improve?
If yes, this is a positive dechallenge. If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent disability; (2) the AE resolved/improve d despite continuation of 
the Sponsor’s product; or (3) the trial is a single -dose drug trial); or (4) Sponsor’s product(s) is/are only used one time.)
Rechallenge Was the subject re- exposed to the Sponsor’s product in this study?
If yes, did the AE recur or worsen?
If yes, this is a positive rechallenge. If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability, or (2) the trial isa single -dose drug trial); or 
(3) Sponsor’ s product(s) is/are used only one time).
NOTE: IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE BEEN 
CAUSED BY THE SPONSOR'S PRODUCT, OR IF REEXPOSURE TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL 
SIGNIFICANT RISK TO THE SUBJECT, THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE SPONSOR 
CLINICAL DIRECTOR AS PER DOSE MODIFICATION GUIDELINES IN THE PROTOCOL.
Consistency 
with Trial 
Treatment 
ProfileIs the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Sponsor’s product or drug class pharmacology 
or toxicology?
The assessment of relationship will be reported on the case report forms /worksheets by an investigator who is a qualified ph ysician according to his/her best clinical judgment, including 
consideration of the above elements.
Record one of the following Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor’s product rel ationship).
Yes, there is a reasonable 
possibility of Sponsor's product 
relationship.There is evidence of exposure to the Sponsor's product.  The temporal sequence of the AE onset relative to the administration of the Sponsor's 
product is reasonable.  The AE is more likely exp lained by the Sponsor's product than by another cause.
No, there is not a reasonable 
possibility of Sponsor's product 
relationshipSubject did not receive the Sponsor's product OR temporal sequence of the AE onset relative to administration of the Sponsor 's product is not 
reasonable ORthe AE is more likely explained by another cause than the Sponsor’s product .  (Also entered for a subject with overdose without an 
associated AE.)
Product:   MK-3475 100
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Sponsor Responsibility for Reporting Adverse Events
AllAdverse Events will be reported to regulatory authorities, IRB/IECs and investigators in 
accordance with all applicable global laws and regulations , i.e., per ICH Topic E6 (R1) 
Guidelines for Good Clinical Practice .
TRIAL GOVERNANCE AND OVERSIGHT
Executive Oversight Committee
The Executive Oversight Committee (EOC) comprises members of Sponsor Senior 
Management.  The EOC will receive anddecide upon any recommendations made by the 
DMCregarding the trial.
Data Monitoring Committee
To supplement the routine trial monitoring outlined in this protocol, an external Data 
Monitoring Committee (DMC) will monitor the interim data from this trial.  The voting 
members of the committee are external to the Sponsor.  The members of the DMC must not 
be involved with the trial in any other way (e.g., they cannot be trial investigators) and must 
have no competing interests that could affect their roles with respect to the trial. 
The DMC will make recommendations to the EOC regarding steps to ensure both subject 
safet y and the continued ethical integrity  of the trial.  Also, the DMC will review interim trial 
results, consider the overall risk and benefit to trial participants (see Section 8.7-Interim 
Analy ses) and recommend to the EOC if the trial should continue in accordance with the 
protocol.
Specific details regarding composition, responsibilities ,and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the trial govern ance structure; and requirements for and proper documentation of 
DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by all the DMC members.
A DMC recommendation will be communicated to the Sponsor as agreed in the DMC 
Charter .  
8.0STATISTICAL ANALYSIS PLAN
This section outlines the statistical analy sis strategy  and procedures for the study .If, after the 
study  has begun, changes are made to primary and/or key secondary  hypotheses, or the 
statistical methods related to those hypotheses, then the protocol will be amended (consistent 
with ICH Guideline E9). Changes to exploratory or other non-confirmatory  analyses made 
after the protocol has been finalized, but prior to the conduct of any analysis, will be
documented in a supplemental statistical analysis plan (sSAP) and referenced in the Clinical 
Study  Report (CSR) for the study .The PRO anal ysis plan will also be included in the sSAP.
Product:   MK-3475 101
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Statistical Analysis Plan Summary
Key elements of the Statistical Analy sis Plan (SAP) are summarized below .The 
comprehensive plan is provided in Section 8.2through Section 8.12.
Analy sis Strategy  for Key  Efficacy  Endpoints
Study Design OverviewThis is a Phase 3, randomized, multi -site, double -blind study of 1L
pembrolizumab+EP versus saline placebo+EP in ES-SCLC (KEYNOTE -
604)
Treat mentAssignmentApproximately 430 subjects were planned to be randomized in a 1:1 ratio to
receive pembrolizumab+EP or saline placebo+EP. The stratification factors 
used for this study are a) cisplatin vs carboplatin, b) ECOG status (0vs 1), 
and, c) LDH at baseline ( ≤ vs > ULN). This is a double -blind study.
By the time of the current amendment, 453 subjects were randomized for 
the study.
Analysis PopulationsEfficacy: Intent ion-to-Treat (ITT)
Safety: AllSubjects asTreated (ASaT)
PrimaryEndpoints1)PFS as assessed by BICR RECIST 1.1 modified to follow a maximum 
of 10 target lesions and a maximum of 5 target lesions per organ
2)OS
Secondary Endpoints3)ORR as assessed by BICR perRECIST 1.1 modified to follow  a 
maximum of 10 target lesions and a maximum of 5 target lesions per 
organ
4)DOR as assessed by BICR perRECIST 1.1modified to follow  a 
maximum of 10 target lesions and a maximum of 5 target lesions per 
organ
5)AEs
Statistical Methods for
Key Efficacy AnalysesThe primary hypotheses will be evaluated by comparing 1L 
pembrolizumab+EP to 1L saline placebo+EP based on PFS as assessed by 
BICR RECIST 1.1 modified to follow  a maximum of10 target lesions and 
a maximum of 5target lesions per organ and OS in subjects with ES-SCLC 
using a stratified log-rank test. Hazard ratios (HRs) will be estimated using 
a stratified Cox regression model. Event rates over time will be estimated 
within e ach treatment group using the Kaplan -Meier method.
Statistical Methods for
Key Safety AnalysesThe analysis of safety results will follow a tiered approach. There are no 
Tier 1 safety parameters in this trial. All safety param eters are considered 
either Tier 2 or Tier 3.Tier 2 parameters will be assessed via point 
estimates with 95% CIs provided for betw een-group comparisons; only 
point estimates by treatment group are provided for Tier 3 safety 
parameters. The betw een-treatm ent difference will be analyz ed using the 
Miettinen and Nurminen method.
Product:   MK-3475 102
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialInterim and Final 
AnalysesTwointerim analy sesare planned inthisstudy. Results will be reviewed 
bytheexternal DMC .Details areprovided inSection 8.7 –Interim 
Analyses .
Interim analysis 1
oTiming: T
o be performed at approximately 18 months from 
study start , where study start is the date on which the first 
subject was randomized .ORR p-value from the first interim 
analysis (IA1)may be evaluated for statistical significance if PFS 
and OS null hypotheses are rejected at IA1 or at a later analysis 
time.
oPurpose :Interim PFS and OSanalys es to demonstrate superiority 
of pembrolizumab+EP over saline placebo+EP .
Interim analysis 2
oTiming: To be performed at approximately 22 months from study 
start.Purpose :Final PFS analysis and interim OS analy sis to 
demonstrate superiority of pembrolizumab+EP over saline 
placebo+EP .
Final analysis
oTiming: To be performed after a minimum of 294 deaths are 
observed or approximately 31 months after first subject enrolled, 
whichever occurs later .
oPurpose: Final analysis of OS to demonstrate superiority of 
pembrolizumab+EP over saline placebo+EP .
Multiplicity The family -wise type I error rate for this study is strongly controlled at 
2.5% (one-sided) for the hypothesis testing of PFS,OS,and ORR .The 
multiplicity strategy will follow  the graphical approach of Maurer and 
Bretz [114] as described in Section 8.8, with 0.6% and 1.9% alpha initially 
allocated to the PFS and OS hypotheses, respectively. Group sequential 
methods will be used to allocate alpha betw een the interim and final 
analyses for PFS and OS endpoints .Further details of the interim analysis 
strategy can be found in Section 8.7 and Section 8.8.
SampleSizeand Power The planned sample size is approximately 430 subjects. The actual sample 
size is 453 subjects. For PFS, based on 387 events, the study has 95.6% 
power to detect a HR of 0.65 (pembrolizumab+EP vs saline placebo+EP) at 
α=0.6% (one-sided). For OS, based on a minimum of 294events, the study 
has at least 94.4% power to detect a HRof 0.65 (pembrolizumab+EP vs
saline placebo+EP ) at α=1.9% (one -sided).
Responsibility for Analyses/In -house Blinding
The statistical analysis of the data obtained from this study  will be the responsibility  of the 
Clinical Biostatistics department of the Sponsor.
The Sponsor will generate the randomized allocation schedule for study  treatment 
assignment for this protocol and the randomization will be implemented in IVRS /IWRS.
Planned interim analyses are described in Section 8.7. Participant -level unblinding will be 
restricted to an external unblinded statistician and scientific programmer performing the 
interim analy sis, who will have no other responsibilities associated with the study .
Product:   MK-3475 103
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialAn external DMC will be convened to review accumulating safety  data to provide an 
opportunity  to terminate the study  early if there are concerns regarding safet y. 
Treatment -level results at the interim analy ses will be provided by the external unblinded 
statistician to the DMC. The DMC will also review the unblinded efficacy results at the 
planned interim analy ses.The DMC responsibilities and review schedules will be outlined in 
the DMC charter. The recommendation of the DMC will be communicated to the Sponsor
EOC and, in the event of a recommendation to halt the trial early  due to safet y concerns, to 
the appropriate regulatory agencies. If the DMC recommends modifications to the design of 
the protocol or discontinuation of the study , the EOC may be unblinded to results at the 
treatment level in order to act on these recommendations. Participant -level unblinding to 
support regulatory  filing, should one occur before the end of the study ,willbe restricted to a 
designate dSponsor/MSD team, who will have no other responsibilities associated with the 
study .
The extent to which individuals are unblinded with respect to the results will be documented.
Additional logistical details, revisions to the above plan,and data monitoring guidance will 
be provided in the DMC Charter.
Hypotheses/Estimation
Objectives and h ypotheses of the stud y are stated in Section 3.0.
Analysis Endpoints
Efficacy Endpoints
Primary
Progression- free S urvival –RECIST 1.1 assessed by BICR
Progression -free survival is defined as the time from randomization to the first documented 
disease progres sion as assessed by BICR per RECI ST 1.1 modified to follow a maximum of 
10 target lesions and a maximum of 5 target lesions per organ or death due to any cause, 
whichever occurs first. See Section 8.6.1 for definition of censoring.
Overall Survival
Overall survival is defined as the time from randomization to death due to any cause.
Subjec tswithout documented death atthetime ofanalysiswill becensored atthe date of 
last known contact.
Product:   MK-3475 104
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialSecondary
Objective Response Rate –RECIST 1.1 assessed by BICR
Objective response r ate is defined as the proportion of subjects who have a CR or a PR. 
Responses are based on confi rmed assessments by  BICRper RECI ST 1.1 modified to follow 
a maximum of 10 target lesions and a maximum of 5 target lesions per organ .
Duration of Response –RECIST 1.1 assessed by BICR
For subjects who demonstrate CR or PR, DOR is defined as the time from first documented 
evidence of CR or PR until disease progression or death due to any cause, whichever occurs 
first. DOR will be assessed by BICR per RECI ST 1.1 modified to follow a maximum of 10 
target lesions and a maximum of 5 target lesions per organ.
Safety Endpoints
Safety  measurements are described in Section 4.2.3. 3and Section 7.Safety and tolerabilit y 
will be assessed by clinical review of all relevant parameters including AEs, laboratory  tests, 
and vital signs. Safety  parameters to be analyzed include, but are not limited to, AEs, SAEs, 
fatal AEs, and laboratory changes. Furthermore, specific events will be collected and 
designated as ECIs as described in Section 7.2.3.
Analysis Populations
Efficacy Analysis Populations
The analy ses of primary  efficacy  endpoints are based on the intent ion-to-treat (ITT)
population (ie, subjects will be included in the treatment group to which they are 
randomized). Details on the approach to handling missing data are provided in Section 8.6.
Safety Analysis Populations
The All Subjects as Treated (ASaT) population will be used for the analy sis of safet y data in 
this study .The ASaT population consists of all randomized subjects who received at least 
1dose of study  treatment. Subjects will be included in the treatment group corresponding to 
the study  treatment they  actuall y received. For most subjects, this will be the treatment group 
to which they are randomized. Subjects who take incorrect study  treatment for the entire 
treatment period will be included in the treatment group corresponding to the study  treatment 
actuall y received. Any subject who receives the incorrect study  medication for 1cycle,but 
receives the correct treatment for all other cycles will be analyzed according to the correct 
treatment group and a narrative will be provided for any events that occur during the cycle 
for which the subject is incorrectly dosed.
At least 1 laboratory  or vital sign measurement obtained subsequent to at least 1 dose of 
study  treatment is required for inclusion in the analy sis of each specific parameter. To assess 
change from baseline, a baseline measurement is also required.
Product:   MK-3475 105
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Statistical Methods
Statistical Methods for Efficacy Analyses
This section describes the statistical methods that address the primary and secondary 
objectives. Methods related to exploratory  objectives will be descri bed in the sSAP.
Efficacy  results that will be deemed to be statistically  significant after consideration of the 
Type I error control strategy  are described in Section 8.8. Nominal p- values will be computed 
for other efficacy  analyses, but should be interp reted with caution due to potential issues of 
multiplicity .
Progression-f ree Survival
The non-parametric Kaplan -Meier method will be used to estimate the PFS curve in each 
treatment group. The treatment difference in PFS will be assessed by the stratified log-rank 
test (based on the stratification factors defined in Section 5.4). A stratified Cox proportional 
hazard model with Efron's method of tie handling will be used to assess the magnitu deof the 
treatment difference (ie, the hazard ratio [HR]) between the treatment arms. The HRand its 
95% CIfrom the stratified Cox model with Efron's method of tie handling and with a single 
treatment covariate will be reported. The stratification factor s used for randomization (See 
Section 5.4) will be applied to both the stratified log -rank test and the stratified Cox model.
Since disease progression is assessed periodicall y, PD can occur any  time in the time interval 
between the last assessment where PD was not documented and the assessment when PD is 
documented. For the primary  analysis, for the subjects who have PD, the true date of disease 
progression will be approximated by the date of the first assessment at which PD is 
objectively  documented as assessed by BICR per RECI ST 1.1 modified to follow a 
maximum of 10 target lesions and a maximum of 5 target lesions per organ , regardless of 
discontinuation of study  drug. Death is alway s considered as a confirmed PD event.
In order to evaluate the robustness of the PFS endpoint per modified RECI ST 1.1 by central 
imaging vendor , we will perform 2 sensitivity  analy ses with a different set of censoring rules. 
The first sensitivity  analysis is the same as the primary  analysis except that data for any 
subject who misses more than one disease assessment (with or without a subsequent death or 
progression) are censored at the last disease assessment prior to missing visits. The second 
sensitivity  analysis is the same as the primary  analysis except that it considers 
discontinuation of treatment or initiation of an anticancer treatment subsequent to 
discontinuation of study -specified treatments, whichever occurs later, to be a PD event for 
subjects without documented PD or death. If a subject meets multiple criteria forcensoring, 
the censoring criterion that occurs earliest will be applied. The censoring rules for primary  
and sensitivity  anal yses are summarized in Table 11.
Product:   MK-3475 106
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialTable 11 Censoring Rules for Primary  and Sensitivity  Analy ses of Progression- free 
Survival
Situation Prim ary AnalysisSensitivity
Analysis 1Sensitivity
Analysis 2
No PD and no death; 
new anticancer 
treatment is not 
initiatedCensored at last 
disease assessment Censored at last disease 
assessment Censored at last disease 
assessment if still on study 
therapy; progressed at 
treatment discontinuation 
otherwise
No PD and no death; 
new anticancer 
treatment is initiatedCensored at last 
disease assessment 
before new  anticancer 
treatmentCensored at last disease 
assessment before new 
anticancer treatmentProgressed at date of new  
anticancer treatment
No PD and no death; 
≥2 consecutive missed 
disease assessmentsCensored at last 
disease assessmentCensored at last disease 
assessment prior to ≥2 
consecutive missed 
visitsCensored at last disease 
assessment
PD or death 
documented after 
≤1missed disease 
assessmentProgressed at date of 
documented PD or 
deathProgressed at date of 
documented PD or 
deathProgressed at date of 
documented PD or death
PD or death 
documented at any 
time after ≥2 m issed 
disease assessmentsProgressed at date of 
documented PD or 
deathCensored at last disease 
assessment prior to the 
≥2 missed disease 
assessmentProgressed at date of 
documented PD or death
Overall Survival
The non-parametric Kaplan -Meier method will be used to estimate the survival curves. The 
treatment difference in survival will be assessed by the stratified log-rank test (based on the 
stratification factor defined in Section 5.4). A stratified Cox proportional hazard model with 
Efron's method of tie handling will be used to assess the magnitude of the treatment 
difference (ie, the HR).The HRand its 95% CIfrom the stratified Cox model with a single 
treatment covariate will be reported. The stratification factors used for randomization (See 
Section 5.4) will be applied to both the stratif ied log-rank test and the stratified Cox model. 
Restricted Mean Survival Time (RMST) method may  be conducted for OS to account for the 
possible non- proportional hazards effect.
Since subjects in the placebo+EP arm are expected to discontinue from the study earlier 
compared to subjects in the pembrolizumab arm because of earlier onset of PD and may 
switch to another anti PD-1 treatment following confirmation of PD , adjustment for the effect 
of crossover on OS may be performed based on recognized methods, (eg,the Rank 
Preserving Structural Failure Time (RPSFT) model proposed by Robins and Tsiatis [115] ), 
based on an examination of the appropriateness of the data to the assumptions required by  the 
method used.
Product:   MK-3475 107
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Objective Response Rate
The ORR is defined as the proportion of subjects who achieve a best objective response of 
PR or CR.
Stratified Miettinen and Nurminen’s method will be used for comparison of ORR between 
the treatment groups. The difference in ORR and its 95% CI from the stratified Miettinen and 
Nurminen method with strata weighting by sample size will be provided. The same 
stratification factors used for randomization (see Section 5.4) will be used as stratification 
factors in the anal ysis.
Duration of Response
For subjects who demonstrate CR or PR, DOR is defined as the time from first documented 
evidence of CR or PR until disease progression or death due to any cause, whichever occurs 
first. Censoring rules for DOR are summarized in Table 12.DOR will be assessed by BICR 
per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 
5target lesions per organ .
For each DOR analysis, a corresponding summary  of the reasons responding subjects are 
censored will also be provided. Subjects who are alive, have not progressed, have not 
initiated new anti-cancer treatment, have not been determined to be lost to follow -up, and 
have had adisease assessment within ~5 months of the data cutoff date are considered 
ongoing responders at the time of analy sis.If a subject meets multiple criteria for censoring, 
the censoring criterion that occurs earliest will be applied.
Table 12 Censoring Rules for Duration of Response
SituationDate of 
Progression or CensoringOutcome
No progression nor death, no new anti -
cancer therapy initiatedLast adequate disease 
assessmentCensor
(non-event)
No progression nor death, new anti -
cancer therapy initiatedLast adequate disease 
assessment before new anti -
cancer therapy initiatedCensor
(non-event)
Death or progression after 
≥2consecutive missed disease 
assessmentsLast adequate disease 
assessment prior to ≥2 missed 
adequate di sease assessmentsCensor
(non-event)
Death or progression after ≤1 missed 
adequate disease assessmentsProgressive disease or death End of response
(Event)
Note:  A missed disease assessment includes any assessment that is not obtained or is considered inadequate 
for evaluation of response.
A summary  of the primary  analy sis strategy  for the primary  and secondary efficacy  endpoints 
is provided in Table 13.
Product:   MK-3475 108
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialTable 13 Efficacy  Anal ysis Methods for Primary  and Secondary  Efficacy  Endpoints
Endpoint/Variable
(Description, Time Point)Statistical Method Analysis Population Missing Data Approach
Prim ary Analyses:
PFS (RECIST 1.1 *)by 
BICRTesting: Stratified Log -
rank test
Estimation: Stratified Cox 
model with Efron's tie 
handling method ITT Censored according to 
rules in Table 11
OS Testing: Stratified Log -
rank test
Estimation: Stratified Cox 
model with Efron's tie 
handling methodITT Censored at last known 
alive date
Secondary Analys es:
ORR (RECIST 1.1 *) by 
BICRTesting: Stratified 
Miettinen and Nurminen 
methodITT Subjects with missing 
data are considered non -
responders
DOR (RECIST 1.1 *) by 
BICRSummary statistics using 
Kaplan -Meier methodAll responders in ITT Non-responders are 
excluded in analysis
*As assessed by BICR per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum 
of 5 target lesions per organ
Statistical Methods for Safety Analyses
Safety  and tolerability  will be assessed by  clinical review of all relevant parameters including 
AEs and laboratory  tests .
The analysis of safet y results will follow a tiered approach (Table 14). The tiers differ with 
respect to the analyses that will be performed. Safet y parameters or AEs of special interest 
that are identified a priori constitute “Tier 1” safet y endpoints that will be subject to 
inferential testing for statistical significance with p-values and 95% CIs provided for 
between -group comparisons. Other safet y parameters will be considered Tier 2 or Tier 3.
Tier 2 parameters will be assessed via point estimates with 95% CIs provided for 
between -group comparisons; only point estimates by treatment group are provided for Tier 3 
safet y parameters.
Adverse events of special interest (AEOSIs) that are immune -mediated or potentially  
immune -mediated are well documented and will be evaluated separately ; however, these 
events have been characterized consistently throughout the pembrolizumab clinical 
development program and determination of statistical significance is not expected to add 
value to the safet y evaluation. Further, pemb rolizumab added to platinum doublets studied 
thus far have not been found to impact safety , and in an ongoing Phase 1clinical trial, the 
chemotherapeutic regimen used here with pembrolizumab has not led to increased toxicity  
Product:   MK-3475 109
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential([STUDY_ID_REMOVED]). Additionally , there are no known AEs associated with subjects with SCLC 
for which determination of a p-value is expected to impact the safety  assessment. For these 
reasons, there are no events of interest that warrant inferential testing. Therefore, there are no 
Tier I e vents in this study .
Adverse experiences (specific terms as well as system organ class terms ) that are not 
pre-specified as Tier -1 endpoints will be classified as belonging to "Tier 2" or "Tier 3", based 
on the number of events observed. Membership in Tier 2 requires that at least 10% of 
subjects in any treatment group exhibit the 
event; all other AEs and predefined limits of 
change will belong to Tier 3.
The threshold of at least 10% was chosen for membership in Tier 2 because subjects enrolled 
in this study  are in critical condition and usually  experience various AEs of similar types 
regardless of treatment, events reported less frequently  than in 10% of subjects would 
obscure the assessment of the overall safety  profile and add little to the interpretation of 
potentially  meaningful treatment differences. In addition, Grades 3 to 5 AEs (≥5% of 
subjects in one of the treatment arms) and SAEs (≥5% of subjects in one of the treatment 
arms) will be considered Tier 2 events .For Tier 2 events , 95% CIswill be provided for 
between -treatment differences in the percentage of subjects with events; these analyses will 
be performed using the Miettinen and Nurminen method [116] , an unconditional, asymptotic 
method. Because many  95% CIs may be provided without adjustment for multiplicity , the 
CIs should be regarded as a helpful descriptive measure to be used in safet y review, not a 
formal method for assessing the statistical significance of the between -treatment differences .
For laboratory  parameters, the number and percentage of subjects with increases from 
baseline in laboratory  test toxicity  grades based on the highest post-baseline toxicity  grade 
and shift of toxicity  grade from baseline to the wors t post-baseline toxicity  grade will be 
summarized by  treatment arm.
Table 14 Analy sis Strategy for Safety  Parameters
Safety Tier Safety Endpoint95% CI for 
Treatment 
ComparisonDescriptive 
Statistics
Tier 2 Any AE ( ≥10% of subjects in one of the 
treatment arms)X X
Any Grade s3 to 5 AE ( ≥5% of subjects in one 
of the treatment arms)X X
Any serious AE ( ≥5% of subjects in one of the 
treatment arms)X X
Tier 3 Any AE X
Any c hange from baseline r esults (laboratory 
tests)X
Abbreviations: AE=adverse event, CI=confidence interval
Product:   MK-3475 110
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Summaries of Baseline Characteristics and Demographics
The comparability  of the treatment groups for each relevant characteristic will be assessed by 
the use of tables and/or graphs. No statistical hypothesis tests will be performed on these 
characteristics. The number and percentage of subjects randomized, and the primary  reason 
for discontinuation will be display ed.Demographic variables (such as age) and baseline 
characteristics will be summarized by treatment either by descriptive statistics or categorical 
tables. The reasons for exclusion from the I TT population (if an y) will be summarized.
Interim Analyses
Two interim efficacy  analy ses are planned for this study .
The (IA1) will be performed approximately  18 months from study  start.PFS and 
OS will be evaluated at IA1.ORR p-value from IA1 may be evaluated for 
statistical significance if PFS and OS null hypotheses are rejected at IA1 or at a 
later anal ysis time.
The second interim analy sis(IA2) is the final formal analysis of PFS. It will be 
performed atapproximately  22 months after first subject enrolled. The second 
interim analy sis evaluation of OS will be performed at this time.
The final analysis will evaluate OS only.It is planned when a minimum of 294
deaths have been observed orapproximately 31 months after first subject
enrolled, whichever occurs later .
In addition to the formal efficacy  anal yses, the DMC will conduct regular safet y monitoring , 
the timing of whic h isspecified in the DMC charter. Decisions to stop the trial early will be 
based on DMC recommendations with review b y the EOC .
Type I error control for the efficacy  analyses as well as efficacy  bounds are described in the 
next section.
Multiplicity
The trial uses the graphical method of Maurer and Bretz [114] to control multiplicity  for 
multiple hypotheses as well as interim analy ses. Figure 3shows the initial one-sided α 
allocation for each hypothesis in the ellipse representing the hypothesis. The weights for 
reallocation from each hypothesis to the others are represented in the boxes on the lines 
connecting h ypotheses.
Product:   MK-3475 111
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialNote: If both PFS and OS null hypotheses are rejected, the reallocation strategy allows testing of ORR at 
alpha= 0.025.
Figure 3Multiplicity  Graph for Ty pe I Error Control
Progression -free Survival
If the null hypothesis for OS is rejected, Figure 3shows that its α=0.019 is essentially  fully 
reallocated to PFS hypothesis testing. Thus, the PFS null hypothesis may be tested at 
α=0.006 or at α=0.025. For PFS hypotheses, the targeted number of events at the final PFS 
analysis will be 387. A Lan-DeMets O'Brien -Fleming spending function will be used for 
information fraction -based alpha -spending to generate the group sequential design. The 
bounds provided in Table 15are based on the assumption that the number of events at IA1 
and IA2 are 332 and 387, respectivel y. The actual boundaries and the nominal alpha level 
will be determined based on the actual number of PFS events observed at the time of the 
analyses and from the overall alpha level after any potential alpha -shifting as the result of a 
successful OS analy sis.The final PFS analysis at IA2 will use the remaining Ty pe I error not 
spent at the IA1, regardless of the actual number of PFS events observed. The p -value bound 
at the 
final PFS analy sis will be calculated by considering the correlation between the test 
statistics as determined by  the actual number of PFS events at IA1 and the final PFS analysis
at IA2 . The bounds given in Table 15will be adjusted accordingl y.

Product:   MK-3475 112
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialTable 15 Efficacy  Boundaries and Properties for Progression -free Survival Anal yses
AnalysisTargeted Analysis 
TimeCumulative 
alpha spent1 Efficacy Bars1
IA1 (86%2)Approximately  
18months from study  
start30.003(One -sided) p -value <0.00 3
Observed HR < ~
0.74
IA2 (100%2)Approximately  
22months from study  
start30.006(One -sided) p -value <0.00 51
Observed HR < ~
0.77
1 Nom inal alpha, boundaries, and cumulative alpha are based on the assumption that 332 and 387 events are at 
IA1 and IA2, respectively. The p-value boundaries will be updated at the time of analyses based on actual 
number of PFS events.
2 Percentage of expected number of events at final analysis targeted at interim analysis.
3Study start is defined as the date w hen the first subject w as randomized.
Note that if the α-reallocation from OS hypothesis testin g occurs at the final analysis after 
hypothesis testing for PFS has been completed, the previousl y computed PFS test statistic for 
the PFS final anal ysis may  be re -evaluated based on the updated bounds .
Overall Survival
The OS hy pothesis may  be tested at α=0.01 9(initially  allocated α)or at α=0.025 (if PFS null 
hypothes is isrejected) following the multiplicity  strategy  as outlined in Figure 3. The bounds 
and boundary  properties for OS hypothesis testing at the initial alpha level are demonstrated 
inTable 16.The alpha spending at each interim analysis is determined using a Lan-DeMets 
O'Brien -Fleming spending function, and the information fraction (ratio of the actual number 
of events at the interim analysis relative to a targe ted 294 events at the final analy sis). The 
final analysis will use the remaining Type I error not spent at earlier analy ses, regardless of 
the number of events observed at the final analysis. The p-value bounds at second interim 
and final analy sis will be calculated by considering the correlation between the test statistics 
as determined by the actual number of OS events at the previous and current analy sis. The p -
value bounds at each analy sis time may also be updated after potential alpha -shifting as the 
result of a successful PFS analy sis.
Product:   MK-3475 113
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialTable 16 Efficacy  Boundaries and Properties for Overall Survival Anal yses
AnalysisTargeted Analysis 
TimeCumulative 
alpha spent1 Efficacy Bars1
IA1(60%2) Approximately 18 months 
from study start30.0024 (One -sided) p -value <0.0024
Observed HR < ~0.65
IA2(76%2) Approximately 22 months 
from study start30.0071 (One -sided) p -value <0.0064
Observed HR < ~0.72
FA(100%2)Aminimum of 294 deaths 
observed in 2 arms or
approximately 31 months 
from study  start , 
whichever occurs later30.019 (One -sided) p -value <0.0167
Observed HR < ~0.78
1 Nominal alpha , boundaries, and cumulative alpha are based on the number of deaths expected assuming the 
projected number of events using protocol assumptions, ie, 175, 224, and 294 at IA1, IA2 and final 
analysis, respectively. The p-value boundaries will be updated at the time of analyses based on actual 
number of deaths.
2 Percentage of expected number of events at final analysis targeted at interi m analysis.
3Study start is defined as the date w hen the first subject w as randomized.
The DMC has responsibility  for assessment of overall risk: benefit. When prompted by safet y 
concerns, the DMC can request corresponding efficacy  data. DMC review of efficacy data to 
assess the overall risk: benefit to study  participants will not require a multiplicity adjustment 
typicall y associated with a planned efficacy  IA. However, to account for anymultiplicity 
concerns raised by the DMC review of unplanned efficacy data when prompted by safety 
concerns, a sensitivity  analysis for OS adopting a conservative multiplicity adjustment will 
be pre -specified in the sSAP.
Objective Response Rate
The trial does not allocate initial alpha to ORR. ORR will be formall y tested only if the 
hypotheses for PFS and OS are significant. The testing of ORR will be based on the first 
352subjects enrolled in the trial. If the null hy potheses for OS and PFS are rejected at IA1or
at a time later than IA1, the p -value of ORR from the IA1 analysis willbe compared to an α-
level of 0.025. Power at the possible α-level as well as the approximate treatment difference 
required to reach the bound (ΔORR) are shown in Table 17, assuming underly ing 50% and 
70% response rates in the control and experimental groups, resp
ectivel y. 
Product:   MK-3475 114
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialTable 17 Possible Alpha -levels and Approximate ORR Difference Required to 
Demonstrate Efficacy for ORR
α ~ΔORR Power
0.025 0.1002 0.9719
Sample Size and Power Calculations
Four hundred and thirty  subjects were planned to be randomized in 1:1 ratio into 
pembrolizumab+EP and thesaline placebo+EP arms.By the time of the current amendment,
453 subjects were enrolled for this study .
The final PFS analysis for the study  will occur about 22 months from study  start. If 387 PFS 
events occur by the time of the final PFS analysis, the study  will have a power of 96% 
approxi mately  to demonstrate a HRof 0.65 on PFS at initially  allocated α=0.006. 
The final OS analy sis will occur when at least 294 events have occurred or approximately  31 
months from study  start, whichever occurs later. With a minimum of 294events at thetime 
of final analy sis, the study  hasat least 94% power to demonstrate a HRof 0.65 on OS at
initially  allocated α=0.019.
The above power calculations for OS and PFS are based on the following assumptions: 
1) 453 subjects were enrolled over 14.5 months following the actual enrollment pattern ; 
2)median PFS is 4.3months in the control armand HRis 0.65; 3) median OS is 10months 
in the control arm and HRis 0.65; 4) The exponential dropout rate sassumed for OSand PFS 
are1% per month.
The sample size and power calculations were performed in the software R (package 
“gsDesign”).
Subgroup Analyses and Effect of Baseline Factors
To determine whether the treatment effect is consistent across various subgroups, the 
between -group treatment effect for OS, PFS and ORR (with a nominal 95% CI) will be 
estimated and plotted within each category of the following classification variables:
Stratification factors
oPlatinum chemotherap y (cisplatin, c arboplatin)
oLDH ( ≤ULN, >ULN)
oECOG Performance Scale (0, 1)
Age category  (<65,65years)
Product:   MK-3475 115
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialSex (female, male)
Race (white, all others )
Smoking status (former ,current)
Brain /liver metastasis status at diagnosis (yes, no)
Region ( East Asia, non -East Asia)
Sites of metastas is at d iagnosis (<3, ≥3)
PD-L1 expression 
positive ( TPS<1% vs ≥1%, CPS <1 vs ≥1 )
Compliance (Medication Adherence)
Drug accountability  data for trial treatment will be collected during the study .Any deviation 
from protocol -directed administration will be reported .
Extent of Exposure
Extent of exposure for a subject is defined as number of cycles in which the subject receives 
the study  medication infusion. Summary  statistics will beprovided on extent of exposure for 
the ASaT population.
9.0LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES
Investigational Product
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate suppl y, storage, handling, distribution and usage of 
investigational product in accordance with the protocol and any applicable laws and 
regulations.
Clinical Supplies will be provided by the Sponsor as summarized in Table 18.All other 
supplies not indicated in Table 18will be provided centrally by the Spons or or locally  by the 
trial site, subsidiary  or designee, depending on local country  operational or regulatory  
requirements. For any commercially  available product that is provided by the trial site, 
subsidiary  or designee every  attempt will be made to source these supplies from a single 
lot/batch number.
Product:   MK-3475 116
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
ConfidentialTable 18 Product Descriptions
Product Name & 
PotencyDosage Form Source/Additional Information
Pembrolizumab 25 
mg/mL
(MK- 3475)Solution for I nfusion Provided centrall y by the Sponsor
Carboplatin Solution for I nfusion Provided centrall y by the Sponsor 
or locally  by the trial site, 
subsidiary , or designee . 
Product is not I MP
Cisplatin Solution for I nfusion Provided centrall y by the Sponsor 
or locally  by the trial site, 
subsidiary , or designee
Product is not I MP
Etoposide Solution for I nfusion Provided centrall y by the Sponsor 
or locally  by the trial site, 
subsidiary , or designee
Product is not I MP
Abbreviations:  IMP=investigational medicinal product
All supplies indicated in Table 18will be provided per the “Source/Additional Information” 
column depending on local country  operational requirements .
Any commercially  available product not included in Table 18will be provided by the trial 
site, subsidiary  or designee .Every  attempt should be made to source these supplies from a 
single lot/batch number. The trial site is responsible for recording the lot number, 
manufacturer, and expiry  date for any locally  purchased product as per local guidelines 
unless otherwise instructed by  the Sponsor.
Packagi ng and Labeling Information
Clinical supplies will be affixed with a clinical label in accordance with regulator y 
requirements.
Open -label pembrolizumab will be provided in 2 vial kits. Open -label carboplatin, cisplatin ,
and etoposide will be provided as single -vial kits.
Clinical Supplies Disclosure
The pembrolizumab treatment in the trial is blinded but supplies are provided open label; 
therefore, an unblinded pharmacist or qualified trial site personnel will be used toblind 
Product:   MK-3475 117
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialsupplies. Trial t reatment identity  (name, strength or potency ) is included in the label text; 
random code/ disclosure envelopes or lists are notprovided.
Storage and Handling Requirements
Clinical supplies must be stored in a secure, limited -access location under the storage 
conditions specified on the label.  
Receipt and dispensing of trial medication must be recorded by an authorized person at the 
trial site.
Clinical supplies may  not be used for an y purpose other than that stated in the protocol .
Discard/Destruction/ Returns and Reconciliation
The investigator is responsible for keeping accurate records of the clinical supplies received 
from the Sponsor or designee, the amount dispensed to and returned by the subjects and the 
amount remaining at the conclusion of the trial. For all trial sites, the local country  Sponsor 
personnel or designee will provide appropriate documentation that must be completed for 
drug accountability  and return, or local discard and destruction if appropriate.  Where local
discard and destruction is appropriate, the investigator is responsible for ensuring that a local 
discard/destruction procedure is documented .
Standard Policies
Trial site personnel will have access to a central electronic treatment 
allocation/ randomizati on system (IVRS/I WRS system) to allocate subjects, to assign trial 
treatment to subjects and to manage the distribution of clinical supplies. Each person 
accessing the IVRS system must be assigned an individual unique PIN.  They must use only 
their assigned PIN to access the system, and they must not share their assigned PIN with 
anyone.
10.0 ADMINISTRATIVE AND R EGULATORY DETAILS
Confidentiality
Confidentiality of Data
By signing this protocol, the investigator affirms to the Sponsor that information furnished t o 
the investigator by the Sponsor will be maintained in confidence, and such information will 
be divulged to the institutional review board, ethics review committee (IRB/ERC) or similar 
or expert committee; affiliated institution and employ ees, only under an appropriate 
understanding of confidentiality  with such board or committee, affiliated institution and 
employ ees.  Data generated by this trial will be considered confidential by the investigator, 
except to the extent that it is included in a publication as provided in the Publications section 
of this protocol.
Product:   MK-3475 118
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Confidentiality of Subject Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/ERC, or regulatory  authority  representatives may consult and/o r copy trial documents in 
order to verify  worksheet/case report form data.  By signing the consent form, the subject 
agrees to this process.  If trial documents will be photocopied during the process of verify ing 
worksheet/case report form information, thesubject will be identified by unique code only; 
full names/initials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all subject data used and disclosed in 
connection with this trial in accord ance with all applicable privacy laws, rules and 
regulations.
Confidentiality of Investigator Information
By signing this protocol, the investigator recognizes that certain personal identify ing 
information with respect to the investigator, and all subinvestigators and trial site personnel, 
may be used and disclosed for trial management purposes, as part of a regulatory  
submissions, and as required b y law.  This information may include:
1.name, address, telephone number and e -mail address;
2.hospit al or clinic address and telephone number;
3.curriculum vitae or other summary  of qualifications and credentials; and
4.other professional documentation.
Consistent with the purposes described above, this information may be transmitted to the 
Sponsor, and subsidiaries, affiliates and agents of the Sponsor, in your country  and other 
countries, including countries that do not have laws protecting such information.  
Additionally , the investigator’s name and business contact information may be included 
when reporting certain serious adverse events to regulatory  authorities or to other 
investigators.  By signing this protocol, the investigator expressly  consents to these uses and 
disclosures.
If this is a multicenter trial, in order to facilitate contact betwee n investigators, the Sponsor 
may share an investigator’s name and contact information with other participating 
investigators upon request.
Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this trial.  The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements by requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
Product:   MK-3475 119
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Compliance with Financial Disclosure Requirements
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54).  It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required.  It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.  
The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements.  
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by 
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States for these purposes.  This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Compliance with Law, Audit and Debarment
By signing this protocol, the investigator agrees to conduct the trial in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of Good 
Clinical Practice (e.g., International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice: 
Consolidated Guidel ine and other generally  accepted standards of good clinical practice); and 
all applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical trial.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by  Merck, is provided in Section 12.1 -
Merck Code of Conduct for Clinical Trials .
The investigator also agrees to allow monitoring, audits, IRB/IEC review and regulatory  
authority  inspection of trial- related documents and procedures and provide for direct access 
to all trial -related source data and documents.
The investigator agrees not to seek reimbursement from subjects, their insurance providers or 
from government programs for procedures included as part of the trial reimbursed to the 
investigator b y the Sponsor.
The investigator shall prepare and maintain complete and accurate trial documentation in 
compliance with Good Clinical Practice standards and applicable federal, state and local 
laws, rules and regulations; and, for each subject participating in the trial, provide all data, 
and, upon completion or termination of the clinical trial, submit any other reports to the 
Sponsor as required by  this protocol or as otherwise re quired pursuant to any  agreement with 
the Sponsor.
Product:   MK-3475 120
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialTrial documentation will be promptly  and fully disclosed to the Sponsor by the investigator 
upon request and also shall be made available at the trial site upon request for inspection, 
copy ing, review and audit at reasonable times by representatives of the Sponsor or any 
regulatory  authorities.  The investigator agrees to promptly  take any  reasonable steps that are 
requested b y the Sponsor as a result of an audit to cure deficiencies in the trial documentat ion 
and worksheets/case report forms.
The investigator must maintain copies of all documentation and records relating to the 
conduct of the trial in compliance with all applicable legal and regulatory  requirements.  This 
documentation includes, but is not limited to, the protocol, worksheets/case report forms, 
advertising for subject participation, adverse event reports, subject source data, 
correspondence with regulatory  authorities and IRBs/ERCs, consent forms, investigator’s 
curricula vitae, monitor visit logs, laboratory  reference ranges, laboratory  certification or 
quality  control procedures and laboratory  director curriculum vitae.  By  signing this protocol, 
the investigator agrees that documentation shall be retained until at least 2 years after the last 
approval of a marketing application in an ICH region or until there are no pending or 
contemplated marketing applications in an ICH region or until at least 2 years have elapsed 
since the formal discontinuation of clinical development of the investigat ional product.  
Because the clinical development and marketing application process is variable, it is 
anticipated that the retention period can be up to 15 years or longer after protocol database 
lock. The Sponsor will determine the minimum retention perio d and notify  the investigator 
when documents may be destro yed.  The Sponsor will determine the minimum retention 
period and upon request, will provide guidance to the investigator when documents no longer 
need to be retained.  The Sponsor also recognizes t hat documents may  need to be retained for 
a longer period if required by local regulatory  requirements. All trial documents shall be 
made available if required by relevant regulatory  authorities. The investigator must consult 
with and obtain written approv al by the Sponsor prior to destro ying trial and/or subject files.  
ICH Good Clinical Practice 
guidelines recommend that the investigator inform the subject’s 
primary  physician about the subject’s participation in the trial if the subject has a primary  
physician and if the subject agrees to the primary  physician being informed.
The investigator will promptly  inform the Sponsor of any regulatory  authority  inspection 
conducted for this trial.
Persons debarred from conducting or working on clinical trials by any court or regulatory 
authority  will not be allowed to conduct or work on this Sponsor’s trials.  The investigator 
will immediately  disclose in writing to the Sponsor if any person who is involved in 
conducting the trial is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
In the event the Sponsor prematurel y terminates a particular trial site, the Sponsor will 
promptly  notify  that trial site’s I RB/IEC.
According to European legislation, a Sponsor must designate an overall coordinating 
investigator for a multi- center trial (including multinational).  When more than one trial site 
Product:   MK-3475 121
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidentialis open in an EU country, Merck, as the Sponsor, will designate, per country , a national 
principal coordinator (Protocol CI), responsible for coordinating the work of the principal 
investigators at the different trial sites in that Member State, according to national 
regulations.  For a single -center trial, the Protocol CI is the principal investigator.  In 
addition, the Sponsor must designate a principal or coordinating investigator to review the 
trial report that summarizes the trial results and confirm that, to the best of his/her 
knowledge, the report accuratel y describes the conduct and results of the trial [Clini cal Study  
Report (CSR) CI].  The Sponsor may consider one or more factors in the selection of the 
individual to serve as the Protocol CI and or CSR CI (e.g., availabilit y of the Protocol/CSR 
CI during the anticipated review process, thorough understanding of clinical trial methods, 
appropriate enrollment of subject cohort, timely achievement of trial milestones).  The 
Protocol CI  must be a participating trial investigator.
Compliance with Trial Registration and Results Posting Requirements
Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007 
and the European Medicines Agency  (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the trial is solely  responsible for determining whether the trial and its results are subject to 
the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries.  Merck, as Sponsor of this trial, will 
review this protocol and submit the information necessary  to fulfill these requirements. 
Merck entries are not limited to FDAAA or the EMA clinical trial directive mandated trials.  
Information posted will allow subjects to identify  potentiall y appropriate trials for their 
disease conditions and pursue participation by calling a central contact numb er for further 
information on appropriate trial locations and trial site contact information.  
By signing this protocol, the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive or other locall y mandated registries are that of the 
Sponsor and agrees not to submit any information about this trial or its results to those 
registries.
Quality Management System
By signing this protocol, the Sponsor agrees to be responsible for implementing and 
maintaining a quality management system with written development procedures and 
functional area standard operating procedures (SOPs) to ensure that trials are conducted and 
data are generated, documented, and reported in compliance with the protocol, accepted 
standards of Good Clinical Practice, and all applicable federal, state, and local laws, rules and 
regulations relating to the conduct of the clinical trial.
Product:   MK-3475 122
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Data Management
The investigator or qualified designee is responsible for recording and verify ing the accuracy
of subject data.  By signing this protocol, the investigator acknowledges that his/her 
electronic signature is the legall y binding equivalent of a written signature.  By enterin g 
his/her electronic signature, the investigator confirms that all recorded data have been 
verified as accurate.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
Publications
This trial is intended for publication, even if terminated prematurel y. Publication may include 
any or all of the following: posting of a synopsis online, abstract and/or presentation at a 
scientific conference, or publication of a full manuscript.  The Sponsor will work with the 
authors to submit a manuscript describing trial results within 12 months after the last data 
become available, which may take up to several months after the last subject visit in some 
cases such as vaccine trials.  However, manuscript submission timelines may  be extended on 
OTC trials.  For trials intended for pediatric -related regu latory  filings, the investigator agrees 
to delay  publication of the trial results until the Sponsor notifies the investigator that all 
relevant regulatory  authority  decisions on the trial drug have been made with regard to 
pediatric -related regulatory  filings. Merck will post a synopsis of trial results for approved 
products on www.clinicaltrials.gov by 12 months after the last subject's last visit for the 
primary  outcome, 12 months after the decision to discontinue development, or product 
marketing (dispensed, administered, delivered or promoted), whichever is later.
These timelines may be extended for products that are not yet marketed, if additional time is 
needed for analysis, to protect intellectual property , or to compl y with confidentiality 
agreements with other parties.  Authors of the primary  results manuscript will be provided 
the complete results from the Clinical Study  Report, subject to the confidentiality  agreement. 
When a manuscript is submitted to a biomedical journal, the Sponsor's policy  is to also 
include the protocol and statistical analy sis plan to facilitate the peer and editorial review of 
the manuscript.  If the manuscript is subsequently accepted for publication, the Sponsor will 
allow the journal, if it so desires, to post on its webs ite the key sections of the protocol that 
are relevant to evaluating the trial, specifically  those sections describing the trial objectives 
and hypotheses, the subject inclusion and exclusion criteria, the trial design and procedures, 
the efficacy  and safe ty measures, the statistical analy sis plan, and any  amendments relating to 
those sections.  The Sponsor reserves the right to redact proprietary information.
For multicenter trials, subsequent to the multicenter publication (or after public disclosure of 
the results online at www.clinicaltrials.gov if a multicenter manuscript is not planned), an 
investigator and his/her colleagues may publish their data independentl y.  In most cases, 
publication of individual trial site data does not add value to complete multicenter results, 
due to statistical concerns.  In rare cases, publication of single trial site data prior to the main 
Product:   MK-3475 123
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidentialpaper may be of value.  Limitations of single trial site observations in a multicenter trial 
should alway s be described in such a manus cript.
Authorship credit should be based on 1) substantial contributions to conception and design, 
or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising 
it critically  for important intellectual content; and 3) final approval of the version to be 
published. Authors must meet conditions 1, 2 and 3.  Significant contributions to trial 
execution may also be taken into account to determine authorship, provided that 
contributions have also been made to all three of th e preceding authorship criteria.  Although 
publication planning may  begin before conducting the trial, final decisions on authorship and 
the order of authors’ names will be made based on participation and actual contributions to 
the trial and writing, as discussed above. The first author is responsible for defending the 
integrit y of the data, method(s) of data anal ysis and the scientific content of the manuscript.
The Sponsor must have the opportunity  to review all proposed abstracts, manuscripts or 
present ations regarding this trial 45days prior to submission for publication/presentation. 
Any information identified by the Sponsor as confidential must be deleted prior to 
submission; this confidentiality  does not include efficacy  and safety  results. Sponsor review 
can be expedited to meet publication timelines.
11.0 LIST OF REFERENCES
[1] Disis ML . Immune regulation of cancer. J Clin Oncol 2010;28(29):4531- 8.
[2] Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor -
associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune 
evasion. Nat Med 2002;8(8):793 -800.
[3] Sharpe AH, Freeman GJ. The B7-CD28 superfamil y. Nat Rev Immunol 
2002;2(2):116 -26.
[4] Brown JA, Dorfman DM, Ma F-R, Sullivan EL, Munoz O, Wood CR, et al. 
Blockade ofprogrammed death -1 ligands on dendritic cells enhances T cell 
activation and cy tokine production. J I mmunol 2003;170(3):1257-66.
[5] Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway  in tolerance and 
autoimmunity . Immunol Rev 2010;236:219 -42.
[6] Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. 
PD-1 is expressed by tumor -infiltrating immune cells and is associated with poor 
outcome for patients with renal cell carcinoma. Clin Cancer Res 2007;13(6):1757 -
61.
[7] Hino R, Kabashim a K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell 
expression of programmed cell death -1 ligand 1 is a prognostic factor for 
malignant melanoma. Cancer 2010;116:1757-66.
Product:   MK-3475 124
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential[8] Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical 
significance and therapeutic potential of the programmed death -1 
ligand/programmed death -1 pathway  in human pancreatic cancer. Clin Cancer Res 
2007;13(7):2151 -7.
[9] Gao Q, Wang X-Y, Qiu S- J, Yamato I, Sho M, Nakajima Y, et al. Overexpression 
of PD-L1 significantl y associates with tumor aggressiveness and postoperative 
recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009;15(3):971 -9.
[10] Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. 
Programmed cell death 1 ligand 1 and tumor -infiltrating CD8+ T lymphocy tes are 
prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 
2007;104(9):3360 -5.
[11] Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, et al. PD-1 is a 
regulator of NY-ESO -1-specific CD8+ T cell expansion in melanoma patients. J 
Immunol 2009;182:5240 -
9.
[12] Cai G, Karni A, Oliveira EML, Weiner HL, Hafler DA, Freeman GJ. PD-1 
ligands, negative regulators for activation of naïve, memory , and recentl y 
activated human CD4+ T cells. Cell I mmunol 2004;230(2):89-98.
[13] Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway  to T- cell 
exhaustion: an update on implications for chronic infections and tumor evasion. 
Cancer Immunol Immunother. 2007 May ;56(5):739 -45.
[14] Iwai Y, Ishida M,Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-
L1 on tumor cells in the escape from host immune system and tumor 
immunotherapy  by PD-L1 blockade. Proc Natl Acad Sci U S A 
2002;99(19):12293 -7.
[15] Tsushima F, Tanaka K, Otsuki N, Youngnak P, Iwai H, Omura K, et al. 
Predominant expression of B7-H1 and its immunoregulatory  roles in oral 
squamous cell carcinoma. Oral Oncol 2006;42:268-74.
[16] Korman A, Chen B, Wang C, Wu L, Cardarelli P, Selby  M. Activit y of anti-PD-1 
in murine tumor models: roleof "host" PD-L1 and synergistic effect of anti-PD-1 
and anti -CTLA -4 [Abstract]. J I mmunol 2007;178:48.37.
[17] Oble DA, Loewe R, Yu P, Mihm MC Jr. Focus on TILs: prognostic significance 
of tumor infiltrating lymphocy tes in human melanoma. Cancer Immun. 2009 Apr 
2;9:3.
[18] Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et 
al. Safety , activity , and immune correlates of Anti-PD-1 antibody  in cancer. N 
Engl J Med. "in press" 2012.
Product:   MK-3475 125
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential[19] Patnaik A, Kang SP, Tolcher AW, Rasco DW, Pap adopoulos KP, Beeram M, et al.  
2012 ASCO Annual Meeting:  Phase I study  of MK-3475 (anti-PD-1 monoclonal 
antibody ) in patients with advanced solid tumors.
[20] Hodi FS, O'Day  SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. 
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl 
J Med 2010;363(8):711 -23.
[21] Chapman PB, Hauschild A, Robert C, Hannen JB, Ascierto P, Larkin J, et al. 
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N 
Engl J Med 2011;3 64(26):2507-16.
[22] Robert C, Thomas L , Bondarenko I, O'Day  S, Weber J, Garbe C, et al. Ipilimumab 
plus dacarbazine for previously  untreated metastatic melanoma. N Engl J Med 
2011;364(26):2517 -26.
[23] Bellati F, Visconti V, Napoletano C, Antonilli M, F rati L, Benedetti Panici P, et al. 
Immunology  of gynecologic neoplasms: analysis of the prognostic significance of 
the immune status. Curr Cancer Drug Targets 2009;9(4):541-65.
[24] Ruffell B, DeNardo DG, Affara NI, Coussens LM. Lym phocy tes in cancer 
deve lopment: polarization towards pro-tumor immunity . Cytokine Growth Factor 
Rev 2010;21:3-10.
[25] Shirabe K, Motomura T, Muto J, Toshima T, Matono R, Mano Y, et al. Tumor -
infiltrating lymphocy tes and hepatocellular carcinoma: pathology  and clinical 
management. Int J Clin Oncol 2010;15:552-8.
[26] Al-Shibli K, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Busund L-T. The 
prognistic value of intraepithelial and stromal CD3-, CD117- and CD138- positive 
cells in non- small cell lung carcinoma. APMI S 2010;1 18:371 -82.
[27] Clark CE, Beatt y GL, Vonderheide RH. Immunosurveillance of pancreatic 
adenocarcinoma: insights from genetically  engineered mouse models of cancer. 
Cancer Lett 2009;279:1 -7.
[28] Diederichsen ACP, Hjelmborg JvB, Christensen PB, Zeuthen J, Fenger C. 
Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocy tes in 
colorectal cancer and HLA -DR expression on tumour cells. Cancer Immunol 
Immunother 2003;52:423-8.
[29] Gao Q, Qiu 
S-J, Fan J, Zhou J, Wang X-Y, Xiao Y-S, et al. Intrat umoral balance 
of regulatory  and cytotoxic T cells is associated with prognosis of hepatocellular 
carcinoma after resection. J Clin Oncol 2007;25(18):2586-93.
Product:   MK-3475 126
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential[30] Hillen F, Baeten CIM, van de Winkel A, Creytens D, van der Schaft DWJ, 
Winnepenninckx V, etal. Leukocy te infiltration and tumor cell plasticity  are 
parameters of aggressiveness in primary  cutaneous melanoma. Cancer Immunol 
Immunother 2008;57(1):97-106.
[31] Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, et al. CD3+ cells 
at the invasive margin of deepl y invading (pT3 -T4) colorectal cancer and risk of 
post-surgical metastatsis: a longitudinal study . Lancet Oncol 2009;10:877-84.
[32] Li JF, Chu YW, Wang GM, Zhu TY, Rong RM, Hou J, et al. The prognostic value 
of peritumoral regulatory  T cells and its correlation with 
intratumoral 
cyclooxy genase -2 expression in clear cell renal cell carcinoma. BJU Intern 
2008;103:399-405.
[33] Nemolato S, Fanni D, Naccarato AG, Ravarino A, Bevilacqua G, Faa G. 
Lym phoepithelioma -like hepatocel lular carcinoma: a case report and a review of 
the literature. World J Gastroenterol 2008;14(29):4694-6.
[34] Nobili C, Degrate L, Caprotti R, Franciosi C, L eone BE, Trezzi R, et al. Prolonged 
survival of a patient affected by pancreatic adenocarcinoma with massive 
lymphocy te and dendritic cell infiltration after interleukin -2 immunotherap y. 
Report of a case. Tumori 2008;94(3):426-30.
[35] Oshikiri T, Miyamoto M, Shichinohe T, Suzuoki M, Hiraoka K, Nakakubo Y, et 
al. Prognostic value of intratumoral CD8+ T lymphocy te in extrahepatic bile duct 
carcinoma as essential immune response. J Surg Oncol 2003;84:224 -8.
[36] Piersma SJ, Welters MJP, van der Burg SH. Tumor -specific regulatory  T cells in 
cancer patients. Human Immunol 2008;69:241 -9.
[37] Rao UNM, Lee SJ, Luo W, Mihm Jr. MC, Kirkwood JM. Presence of tumor -
infiltrating lymphocy tes and a dominant nodule within primary  melanoma are 
prognostic factors for relapse -free survival of patients with thick (T4) primary  
melanoma: pathologic analy sis of the E1690 and E1694 intergroup trials. Am J 
Clin Pathol 2010;133:646 -53.
[38] Sasaki A, Tanaka F, Mimori K, Inoue H, Kai S, Shibata K, et al. Prognostic value 
of tumor -infiltrating FOXP3+ regulatory  T cells in patients with hepatocellular 
carcinoma. EJSO 2008;34:173-9.
[39] Shen Z, Zhou S, Wang Y, Li R, Zhong C, Liang C, et al. Higher intratumoral 
infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with 
adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol 
2010;136:1585-95.
Product:   MK-3475 127
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential[40] Talmadge JE, Donkor M, Scholar E. Inflammatory  cell infiltration of tumors: 
Jekyll or Hy de. Cancer Metastasis Rev 2007;26(3 -4):373-400.
[41] Usubütün A, Ayhan A, Uygur MC, Özen H, Toklu C, Ruacan S. Prognostic 
factors in renal cell carcinoma. J Exp Clin C ancer Res 1998;17(1):77 -81.
[42] Leffers N, Gooden MJM, de Jong RA, Hoogeboom B-N, ten Hoor KA, Hollema 
H, et al. Prognostic significance of tumor -infiltrating T-lymphocy tes in primary  
and metastatic lesions of advanced stage ovarian cancer. Cancer Immuno l 
Immunother 2009;58(3):449-59.
[43] Nishimura H, Honjo T, Minato N. Facilitation of beta selection and modification 
of positive selection in the thymus of PD-1-deficient mice. J Exp Med. 2000 Mar 
6;191(5):891 -
8.
[44] Pölcher M, Braun M, Friedrichs N, Rudlowski C, Bercht E, Fimmers R, et al. 
Foxp3(+) cell infiltration and granzy me B(+)/Foxp3(+) cell ratio are associated 
with outcome in neoadjuvant chemotherap y-treated ovarian carcinoma. Cancer 
Immunol Immunother 2010;59(6):909-19.
[45] Suzuki H, Chikazaw a N, Tasaka T, Wada J, Yamasaki A, Kitaura Y, et al. 
Intratumoral CD8+ T/FOXP3+ cell ratio is a predictive marker for survival in 
patients with colorectal cancer. Cancer Immunol Immunother 2010;59:653-61.
[46]
Chew V, Tow C, Teo M, Wong HL , Chan J, Gehrin g A, et al. Inflammatory  tumor 
microenvironment is associated with superior survival in hepatocellular carcinoma 
patients. J Hepatol 2010;52:370-9.
[47] Liotta F, Gacci M, Frosali F, Querci V, Vittori G, Lapini A, et al. Frequency  of 
regulatory  T  c ells inperipheral blood and in tumour -infiltrating lymphocy tes 
correlates with poor prognosis in renal cell carcinoma. BJU Int 2011;107(9):1500 -
6.
[48] Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma V-M. Prognostic 
value of tumour -infiltrating lymphocy tes (TILs) in colorectal cancer. J Pathol 
1997;182(3):318 -24.
[49] Dudley  ME, Wunderlich JR, Yang JC, Sherry  RM, Topalian SL , Restifo NP, et al. 
Adoptive cell transfer therapy  following non-myeloablative but lymphodepleting 
chemotherap y for the treatment of patients with refractory  metastatic melanoma. J 
Clin Oncol 2005;23(10):2346
-57.
[50] Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly  JZ, Rodm yre R, et al. 
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-
ESO -1. N Engl J Med 200 8;358(25):2698 -703.
Product:   MK-3475 128
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential[51] Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor 
inhibits B cell receptor -mediated signaling by recruiting src homology  2-domain -
containing tyrosine phosphatase 2 to phosphoty rosine. Proc Natl Acad Sci U SA 
2001;98(24):13866 -71.
[52] Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family  revisited. Annu Rev 
Immunol 2005;23:515 -48.
[53] Sierocki JS, Hilaris BS, Hopfan S, Martini N, Barton D, Golbey  RB, et al. cis-
Dichlorodiammineplatinum(II) and VP-16-213: anactive induction regimen for 
small cell carcinoma of the lung. Cancer Treat Rep. 1979 Sep- Oct;63(9 -10):1593 -
7.
[54] Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, et al. 
Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus 
cisplatin and etoposide versus alternation of these regimens in small -cell lung 
cancer. J Natl Cancer Inst. 1991 Jun 19;83(12):855-61.
[55] Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. 
Randomized study  of cyclophosphami de, doxorubicin, and vincristine versus 
etoposide and cisplatin versus alternation of these two regimens in extensive 
small -cell lung cancer: a phase III trial of the Southeastern Cancer Study  Group. J 
Clin Oncol. 1992 Feb;10(2):282-91.
[56] Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al. 
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and 
vincristine regimen in small -cell lung cancer: results from a randomized phase III 
trial with 5 y ears' follow -up. J Clin Oncol. 2002 Dec 15;20(24):4665 -72.
[57] Chute JP, Venzon DJ, Hankins L, Okunieff P, Frame JN, Ihde DC, et al. Outcome 
of patients with small -cell lung cancer during 20 years of clinical research at the 
US National Cancer Institute. Mayo Clin Proc. 1 997 Oct;72(10):901 -12.
[58] Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, et al. A 
systematic review of the role of etoposide and cisplatin in the chemotherap y of 
small cell lung cancer with methodology  assessment and meta -analysis. Lung 
Cancer. 2000 Oct;30(1):23-36.
[59] Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of 
small -cell lung cancer? A meta -analysis of randomized trials of a cisplatin-
containing regimen versus a regimen without this alkylating agent. Br J Cancer. 
2000 Jul;83(1):8 -15.
Product:   MK-3475 129
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential[60] Hanna N, Bunn PA, Jr., Langer C, Einhorn L, Guthrie T, Jr., et al. Randomized 
phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients 
with previously  untreated extensive -stage disease small -cell lung cancer. J Clin 
Oncol 2006;24(13):2038 -43.
[61] Lara PN Jr, Natale R, Crowley  J, Lenz HJ, Redman MW, Carleton JE, et al. Phase 
III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive -
stage small -cell lung cancer: clinical and pharmacogenomic results from SWOG 
S0124. J Clin Oncol. 2009 May  20;27(15):2530 -5.
[62] Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. 
First-line atezolizumab plus chemotherap y in extensive -stage small -cell lung 
cancer. N Engl J Med. In press 2018.
[63] Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley  W, et al. Phase III 
Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo 
Plus Etoposide and Platinum in Extensive -Stage Small -Cell Lung Cancer. J Clin 
Oncol. 2016 Nov 25;34:3740-8.
[64] Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, et 
al. Randomized comparison of etoposide -cisplatin vs. etoposide -carboplatin and 
irradiation in small -cell lung cancer. A Hellenic Co-operative Oncology Group 
study . Ann Oncol. 1994 Sep;5(7):601-7.
[65] Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. 
Carboplatin -or cisplatin -based chemotherap y in first-line treatment of small -cell 
lung cancer: the COCI Smeta -analysis of individual patient data. J Clin Oncol. 
2012 May  10;30(14):1692 -8.
[66] Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al. 
Duration of chemotherapy  in small cell lung cancer: a Cancer Research Campaign 
trial. Br J Cancer. 1989 Apr;59(4):578-83.
[67] Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JT, et 
al. Maintenance chemotherap y in small -cell lung cancer: long-term results of a 
randomized trial. J Clin Oncol. 1993 Jul;11(7):1230 -40.
[68] Hanna NH, Sandier AB, Loehrer PJ Sr, Ansari R, Jung SH, Lane K, et al. 
Maintenance daily oral etoposide versus no further therapy  following induction 
chemotherap y with etoposide plus ifosfamide plus cisplatin in extensive small- cell 
lung cancer: a Hoosier Oncology Group randomized study . Ann Oncol. 2002 
Jan;13(1):95-102.
Product:   MK-3475 130
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential[69] Ready  NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, et al. 
Chemotherap y With or Without Maintenance Sunitinib for Untreated Extensive -
Stage Small -Cell Lung Cancer: A Randomized, Double -Blind, Placebo -Controlled 
Phase II Study -CALGB 30504 (Alliance). J Clin Oncol. 2015 May 
20;33(15):1660 -5.
[70] Beith JM, Clarke SJ, Woods RL, Bell DR, Levi JA. Long-term follow -up of a 
randomised trial of combined chemoradiotherapy  induction treatm ent, with and 
without maintenance chemotherap y in patients with small cell carcinoma of the 
lung. Eur J Cancer. 1996 Mar;32A(3):438 -43.
[71] Schiller JH, Adak S, Cella D, DeVore III RF, Johnson DH. Topotecan versus 
observation after cisplatin plus etoposide in extensive -stage small -cell lung cancer: 
E7593 -A phase III trial of the Eastern Cooperative Oncology  Group. J Clin 
Oncol 2001;19(8):2114 -22.
[72] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in 
Oncology -Non-Small Cell Lung Cancer: version 2.2017 [Internet]. Fort 
Washington, PA: National Comprehensive Cancer Network (NCCN); 2016. 
Available from:  
https://www.nccn.org/professionals/phy sician_gls/f_guidelines.asp
[73] Fruh M, De Ruysscher D, Popat S, Crino L, Peters S, Felip E, et al. Small -cell 
lung cancer (SCL C): ESMO Clinical Practice Guidelines for diagnosis, treatment 
and follow -up. Ann Oncol. 2013 Oct;24 Suppl 6:vi99 -105.
[74] Rudin CM, Ismaila N, Hann CL, Malhotra N, Movsas B, Norris K, et al. 
Treatment of Small -Cell Lung Cancer: American Society  of Clinical Oncology  
Endorsement of the American College of Chest Physicians Guideline. J Clin 
Oncol. 2015 Dec 1;33(34):4106 -11.
[75] Seute T, Leffers P, ten Velde GP, Twijnstra A. Neurologic disorders in 432 
consecutive patients with small cell lung carcinoma. Cancer. 2004 Feb 
15;100(4):801 -6.
[76] Komaki R, Cox JD, Whitson W. Risk of brain metastasis from small cell 
carcinoma of the lung related to length of survival and proph ylactic irradiation. 
Cancer Treat Rep. 1981 Sep-Oct;65(9 -10):811 -4.
[77] Nugent JL , Bunn PA Jr, Matthews MJ, I hde DC, Cohen MH, Gazdar A, et al. CNS 
metastases in small cell bronchogenic carcinoma: increasing frequency  and 
changing pattern with lengthening survival. Cancer. 1979 Nov;44(5):1885 -93.
[78] Hirsch FR, Paulson OB, Hansen HH, Vraa -Jensen J. Intracranial metastases in 
small cell carcinoma of the lung: correlation of clinical and autops y findings. 
Cancer. 1982 Dec 1;50(11):2433 -7.
Product:   MK-3475 131
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential[79] Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Grego r A, Stephens RJ, et al. 
Prophy lactic cranial irradiation for patients with small -cell lung cancer in 
complete remission. Prophy lactic Cranial Irradiation Overview Collaborative 
Group. N Engl J Med. 1999 Aug 12;341(7):476- 84.
[80] Slotman B, Faivre -Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. 
Prophy lactic cranial irradiation in extensive small -cell lung cancer. N Engl J Med. 
2007 Aug 16;357(7):664-72.
[81] Le Pechoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre -Finn C, et al. 
Standard- dose versus higher -dose prophy lactic cranial irradiation (PCI) in patients 
with limited -stage small -cell lung cancer in complete remission after 
chemotherap y and thoracic radiotherap y (PCI 99-01, EORTC 22003-08004, 
RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009 
May;10(5):467 -
74.
[82] Johnson BE, Becker B, Goff WB 2nd, Petronas N, Krehbiel MA, Makuch RW, et 
al. Neurologic, neuropsy chologic, and computed cranial tomography  scan 
abnormalities in 2-to 10-year survivors of small -cell lung cancer. J Clin Oncol. 
1985 Dec;3(12):1659 -
67.
[83] Fleck JF, Einhorn LH, Lauer RC, Schultz SM, Miller ME. Is prophylactic cranial 
irradiation indicated in small -cell lung cancer? J Clin Oncol. 1990 Feb;8(2):209-
14.
[84] Varghese AM, Zakowski MF, Yu HA, Won HH, Riely  GJ, Krug LM, et al. Small -
cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol. 2014 
Jun;9(6):892-6.
[85] Ou SH, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small 
cell lung cancer (ED-SCLC): theimportance of smoking history , socioeconomic 
and marital statuses, and ethnicity. J Thorac Oncol. 2009 Jan;4(1):37 -43.
[86] American Cancer Society . Cancer facts and figures 2014 [Internet]. Atlanta: 
American Cancer Society ; 2014. Available from: 
http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acsp
c-042151.pdf.
[87] Gaspar LE, McNamara EJ, Gay EG, Putnam JB, Crawford J, Herbst RS, et al. 
Small -cell lung cancer: prognostic factors and changing treatment over 15 years. 
Clin L ung Can cer. 2012 Mar;13(2):115-22.
[88] Pietanza MC, Krug LM, Wu AJ, Kris MG, et al. Small Cell and Neuroendocrine 
Tumors of the Lung. In Devita, Hellman & Rosenberg, ed. Cancer: Principles and 
practice of Oncology . 10th ed. Philadelphia (PA): Lippincott, Willia ms & Wilkins; 
2015. p. 536-559.
Product:   MK-3475 132
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential[89] Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence -
based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3 
Suppl):324S -339S.
[90] von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chry sson NG, et 
al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the 
treatment of recurrent small -cell lung cancer. J Clin Oncol. 1999 Feb;17(2):658 -
67.
[91] O'Brien ME, Ciuleanu TE, Tsekov H, Shpary k Y, Cucevia B, Juhasz G, et al. 
Phase III trial comparing supportive care alone with supportive care with oral 
topotecan in patients with relapsed small -cell lung cancer. J Clin Oncol. 2006 Dec 
1;24(34):5441 -7.
[92] Eckardt JR, von Pawel J, Pujol JL , Papai Z, Quoix E, Ardizzoni A, et al. Phase III 
study  of oral compared with intravenous topotecan as second -line therapy  in 
small -cell lung cancer. J Clin Oncol. 2007 May 20;25(15):2086 -92. Erratum in: J 
Clin Oncol. 2007 Aug 1;25(22):3387.
[93] Graus F, Dalmou J, Rene R, Tora M, Malats N, Verschuuren JJ, et al. Anti- Hu 
antibodies in patients with small -cell lung cancer: association with complete 
response to therapy  and improved survival. J Clin Oncol. 1997 Aug;15(8):2866-
72.
[94] Tanio Y, Watanabe M, Osaki T, Tachibana I, Kawase I, Kuritani T, et al. High 
sensitivity  to peripheral blood lymphocy tes and low HLA -class I antigen 
expression of small cell lung cancer cell lines with diverse chemo -radiosensitivity . 
Jpn J Cancer Res. 1992 Jul;83(7):736-45.
[95] Yazawa T, Kamma H, Fujiwara M, Matsui M, Horiguchi H, Satoh H, et al. Lack 
of class II transactivator causes severe deficiency  of HLA -DR expression in small 
cell lung cancer. J Pathol. 1999 Jan;187(2):191 -9.
[96] Koyama K, Kagamu H, Miura S, Hiura T, Mi yabayashi T, Itoh R, et al. Reciprocal 
CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ 
regulatory  T cells in small cell lung cancer reflects disease stage. Clin Cancer Res. 
2008 Nov 1;14(21):6770-9.
[97] Schultheis AM, Scheel AH, Ozretic L, George J, Thomas RK, Hagemann T, et al. 
PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer. 2015 
Feb;51(3):421 -
6.
[98] Komiy a T, Madan R. PD-L1 expression in small cell lung cancer. Eur J Cancer. 
2015 Sep;51(13):1853-5.
Product:   MK-3475 133
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential[99] Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T, et al. 
Significance of programmed cell death -ligand 1 expression and its association 
with survival in patients with small cell lung cancer. J Thorac Oncol. 2015 
Mar;10(3):426-30.
[100] Miao L, Lu Y, Xu Y, Zhang G, Huang Z, Gong L, et al. PD-L1 and c-MET 
expression and survival in patients with small cell lung cancer. Oncotarget. 
Forthcoming 2016.
[101] Berghoff AS, Ricken G, Wilhelm D, Rajky  O, Widhalm G, Dieckmann K, et al. 
Tumor infiltrating ly mphocy tes and PD -L1 expression in brain metastases of small 
cell lung cancer (SCL C). J Neurooncol. 2016 Oct;130(1):19 -29.
[102] Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. 
Cancer immunology . Mutational landscape determines sensitivity  to PD-1
blockade in non -small cell lung cancer. Science. 2015 Apr 3;348(6230):124 -8.
[103] Ott PA, Felip E, Hiret S, Kim DW, Morosky  A, Saraf S, et al. Pembrolizumab in 
Patients With Extensive -Stage Small Cell Lung Cancer: Updated Survival Results 
From KEYNOTE-028. Poster session presented at: IASLC 17th World 
Conference on Lung Cancer; 2016 Dec 4 -
7; Vienna, AUT.
[104] Ardizzoni A, Hansen H, Dombernowsk y P, Gamucci T, Kaplan S, Postmus P, et 
al. Topotecan, a new active drug in the second -line treatment of small -cell lung 
cancer: a phase II study  in patients with refractory  and sensitive disease. The 
European Organization for Research and Treatment of Cancer Early Clinical 
Studies Group and New Drug Development Office, and the Lung Cancer 
Cooperative Group. J Clin Oncol. 1997 May ;15(5):2090-6.
[105] Depierre A, von Pawel J, Hans K, Moro D, Clark P, Gatzemeier U, et al. 
Evaluation of topotecan (Hycamtin) in relapsed small cell lung cancer (SCL C). A 
multicenter phase II study  [abstract]. Lung Cancer. 1997; 18(1 Suppl):35. Abstract 
no. 126.
[106] Eckardt J, Gralla R, Palmer MC, Gandara D, Laplante J, Sandier A, et al. 
Topotecan (T) as Second -Line Therap y In Patients (Pts) with Small Cell Lung 
Cancer (SCL C): A Phase II Study  [abstract]. Ann Oncol. 1996;7 Suppl 5:107. 
Abstract no. 513P.
[107] Eckardt J, Depierre A, Ardizzoni A, Von Pawel J, Fields S. Pooled analysis of 
topotecan (T) in the second -line treatment of patients (pts) with sensitive small cell 
lung cancer (SCL C). Proc Am Soc Clin Oncol. 1997;16. Abstract no. 1624.
Product:   MK-3475 134
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential[108] Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, 
Powell SF, et al. Carboplatin and pemetrexed with or without pembrolizumab for 
advanced, non-squamous non-small -cell lung cancer: a randomised, phase 2 
cohort of the open -label KEYNOTE - 021 study . Lancet Oncol. 2016 Oct 9. [Epub 
ahead of print].
[109] Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, et al. 
Multitrial evaluation of progression- free survival as a surrogate end point for 
overall survival infirst-line extensive stage small -cell lung cancer. J Thorac 
Oncol. 2015 Jul;10(7):1099 -106.
[110] Nishino M, Giobbie -Hurder A, Gargano M, Suda M, Ramaiy a NH, Hodi FS. 
Developing a common language for tumor response to immunotherapy : immune -
related respon se criteria using unidimensional measurements. Clin Cancer Res. 
2013 Jul 15;19(14):3936-43.
[111] Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. 
Pembrolizumab for the Treatment of Non -Small -Cell L ung Cancer. N Engl J Med. 
2015 Apr 19.
[112] Smith TJ, Bohlke K, Lym an GH, Carson KR, Crawford J, Cross SJ, et al. 
Recommendations for the Use of WBC Growth Factors: American Society  of 
Clinical Oncology  Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 
1;33(28):3199 -212.
[113] Gralla RJ, Roila F, Tonato M, Herrstedt J.  MASCC/ESMO Antiemetic Guideline 
2013: Multinational association of supportive care in cancer.
[114] Maurer W, Bretz F. Multiple testing in group sequential trials using graphical 
approaches. Stat Biopharm Res 20 13;5(4):311-20.
[115] Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using  
rank preserving structural failure time models. Commun Stat-Theor M 
1991;20(8):2609 -
31.
[116] Miettinen O, Nurminen M. Comparative analy sis of two rates. Stat Med 
1985;4:213-26.
Product:   MK-3475 135
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential12.0 APPENDICES
Merck Code of Conduct for Clinical Trials
Merck *
Code of Conduct for Clinical Trials
I. Introduction
A. Purpose
Merck, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in 
compliance with the highest ethical and scientific standards. Protection of subject safety is the overriding concern in 
the design of clinical trials. In all cases, Merck clinical trials will be conducted in compliance with local and/or 
national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. 
B. Scope
Such standards shall be endorsed for all clinical interventional investigations sponsored by Merck irrespective of the 
party (parties) employed for their execution (e. g., contract research organizations, collaborative research efforts). This 
Code is not intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code 
does not apply to investigator -initiated trials which are n ot under the control of Merck.
II.Scientific Issues
A. Trial Conduct
1.Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of Merck or comparator products.  Alternatively, Merck may 
conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine 
subject preferences, etc.  
The design (i.e., subject population, duration, statistical power) must be adequate to address the specific purpose 
of the trial.  Research subjects must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
Merck selects investigative sites based on medical expertise, access to appropriate subjects, adequacy of facilities 
and staff, previous performance in Merck trials, as well as budgetary considerations.  Prior to trial initiation, sites 
are evaluated by Merck personnel to assess the ability to successfully conduct the trial.
3.Site Monit oring/Scientific Integrity
Trial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical 
Practice.  Merck reviews clinical data for accuracy, completeness and c onsistency. Data are verified versus source 
documentation according to standard operating procedures.  Per Merck policies and procedures, if fraud, 
misconduct or serious GCP -non-Compliance are suspected, the issues are promptly investigated. When necessary, 
the clinical site will be closed, the respons ible regulatory authorities and ethics review committees notified and 
data disclosed accordingly. 
B. Publication and Authorship
To the extent scientifically appropriate, Merck seeks to publish the results of trials it conducts.  Some early phase or 
pilot trials are intended to be hypothesis -generating rather than hypothesis testing.  In such cases, publication of 
results may not be appropriate since the trial may be underpowered and the analyses complicated by statistical issues 
of multiplicity.
Merck’s policy on authorship is consistent with the requirements outlined in the ICH-Good Clinical Practice 
guidelines. In summary, authorship should reflect significant contribution to the design and conduct of the trial, 
performance or interpretation of the analysis, and/or writing of the manuscript.  All named authors must be able to 
defend the trial results and conclusions.  Merck funding of a trial will be acknowledged in publications. 
Product:   MK-3475 136
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialIII. Subject Protection
A.IRB/ERC review
All clinical trials will be reviewed and approved by an independent IRB/ERC before being initiated at each site.  
Significant changes or revisions to the protocol will be approved by the IRB/ERC prior to implementation, except that 
changes required urgentl y to protect subject safety and well-being may be enacted in anticipation of IRB/ERC 
approval. For each site, the IRB/ERC and Merck will approve the subject informed consent form. 
B.Safety
The guiding principle in decision -making in clinical trials is that subject welfare is of primary importance.  Potential 
subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial 
designs will take into account the local standard of care.  Subjects are ne ver denied access to appropriate medical care 
based on participation in a Merck clinical trial. 
All participation in Merck clinical trials is voluntary.  Subjects are enrolled only after providing informed consent for 
participation.  Subjects may withdraw from a Merck trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C.Confidentiality
Merck is committed to safeguarding subject confidentiality, to the greatest extent possible. Unless required by law, 
only the investigator, Sponsor (or representative) and/or regulatory authorities will have access to confidential medical 
records that might identify the research subject by name.  
D.Genomic Research
Genomic Research will only beconducted in accordance with informed consent and/or as specifically authorized by 
an Ethics Committee.
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time- and labor-intensive.  It is Merck’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performe d in support of Merck trials.  Merck does not pay incentives to 
enroll subjects in its trials.  However, when enrollment is particularly challenging, additional payments ma y be made 
to compensate for the time spent in extra recruiting efforts.
Merck does not pay for subject referrals.  However, Merck may compensate referring physicians for time spent on 
chart review to identify potentially eligible subjects.
B.Clinical Rese arch Funding 
Informed consent forms will disclose that the trial is sponsored by Merck, and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial.  However, the local IRB/ERC may wish to alter 
the wordi ng of the disclosure statement to be consistent with financial practices at that institution.  As noted above, 
publications resulting from Merck trials will indicate Merck as a source of funding.
C.Funding for Travel and Other Requests
Funding of travel by investigators and support staff (e.g.,to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices including, in the U.S., those established by the American Medical 
Association (AMA). 
V. Investigator Commi tment
Investigators will be expected to review Merck’s Code of Conduct as an appendix to the trial protocol, and in signing 
the protocol, agree to support these ethical and scientific standards.
* In this document, "Merck" refers to Merck Sharp & Dohme Corp. and Schering Corporation, each of which is a 
subsidiary of Merck & Co., Inc.  Merck is known as MSD outside of the United States and Canada.  As warranted by 
context, Merck also includes affiliates and subsidiaries of Merck & Co., Inc."
Product:   MK-3475 137
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Collection and Management of Specimens for Future Biomedical Research
1.Definitions
a.Biomarker:  A biological molecule found in blood, other body  fluids, or tissues that is 
a sign of a normal or abnormal process or of a condition or disease.  A biomarker may 
be used to see how well the body  responds to a treatment for a disease or condition.1
b.Pharmacogenomics:  The investigation of variations of DNA and RNA characteristics 
as related to drug response.2
c.Pharmacogenetics:  A  s ubset of pharmacogenomics, pharmacogenetics is the 
influence of variations in DNA sequence on drug response.2
d.DNA:  Deox yribonucleic acid.
e.RNA:  Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this trial as outlined in Section 7.1.3.4 will 
be used in various experiments to understand:
The biology of how drugs work
Biomarkers responsible for how a drug enters and is removed b y the bod y
Other pathway s drugs may  interact with
The biology  of disease
The specimen(s) may be used for future assay  developm ent and/or drug/vaccine 
development.
It is now well recognized that information obtained from study ing and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs /vaccines, enhance our underst anding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need.  All specimens will be used by the Sponsor or those working for 
or with the Sponsor .
3. Summary of Procedur es for Future Biomedical Research
a.Subjects for Enrollment
All subjects enrolled in the clinical trial will be considered for enrollment in the 
Future Biomedical Research sub -trial.
b.Informed Consent
Informed consent for specimens (i.e., DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all subjects or legal guardians, at a trial 
visit by the investigator or his or her designate.  Informed consent for Future 
Biomedical Research should be presented to the subjects on the visit designated in the 
Product:   MK-3475 138
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidentialtrial flow chart .  If delayed, present consent at next possible Subject Visit.   Consent 
forms signed by the subject will be kept at the clinical trial site under secure storag e 
for regulatory  reasons.  
A template of each trial site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository .
c.eCRF Documentation for Future Biomedical Research Specimens
Documentation of subject consent for Future Biomedical Research will be captured in 
the electronic Case Report Forms (eCRFs). Any specimens for which such an 
informed consent cannot be verified will be destroy ed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for Future Biomedical Research will be performed as 
outlined in the trial flow chart. In general, if additional blood specimens are being 
collected for Future Biomedical Research, these will usually  be obtained at a time 
when the subject is having blood drawn for other trial purposes.
4. C onfidential Subject Information for Future Biomedical Research 
In order to optimize the research that can be conducted with Future Biomedical Research 
specimens, it is critical to link subject' clinical information with fu ture test results. In fact 
little or no research can be conducted without connecting the clinical trial data to the 
specimen. The clinical data allow specific analy ses to be conducted. Knowing subject 
characteristics like gender, age, medical history  and treatment outcomes are critical to 
understanding clinical context of analy tical results.
To maintain privacy  of information collected from specimens obtained for Future 
Biomedical Research, the Sponsor has developed secure policies and procedures. All 
speci mens will be single -coded per ICH E15 guidelines as described below . 
At the clinical trial site, unique codes will be placed on the Future Biomedical Research 
specimens.  This code is a random number which does not contain any personall y 
identify ing infor mation embedded within it. The link (or key) between subject identifiers 
and this unique code will be held at the trial site.  No personal identifiers will appear on 
the specimen tube.  
5.Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for analyses using good scientific 
practices.  Anal yses utilizing the Future Biomedical Research specimens may be 
performed by the Sponsor , or an additional third party (e.g., a university  investigator) 
designated by the Sponsor . The investigato r conducting the analy sis will follow the 
Sponsor’s privacy  and confidentiality  requirements. Any contracted third party  analyses 
will conform to the specific scope of anal ysis outlined in this sub- trial. Future Biomedical 
Research specimens remaining with the third party  after specific analy sis is performed 
will be reported to the Sponsor .
Product:   MK-3475 139
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential6. Withdrawal From Future Biomedical Research 
Subjects may withdraw their consent for Future Biomedical Research and ask that their 
biospecimens not be used for Futur e Biomedical Research.  Subjects may withdraw 
consent at any time by contacting the principal investigator for the main trial. If medical 
records for the main trial are still available, the investigator will contact the Sponsor 
using the designated mailbox (clinical.specimen.management@merck.com). 
Subsequently , the subject's specimens will be flagged in the biorepository and restricted 
to main study  use only. If specimens were collected from study  participants specificall y 
for Future Biomedical Research, th ese specimens will be removed from the biorepository  
and destro yed. Documentation will be sent to the investigator confirming withdrawal 
and/or destruction, if applicable. It is the responsibility  of the investigator to inform the 
subject of completion of the withdrawal and/or destruction, if applicable.  Any analyses 
in progress at the time of request for withdrawal/destruction or already  performed prior to 
the request being received by the Sponsor will continue to be used as part of the overall 
research trial data and results. No new analy ses would be generated after the request is 
received.
In the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by regulatory  authorities to retain the main trial 
records) or the specimens have been completel y anony mized, there will no longer be a 
link between the subject’s personal information and their specimens. In this situation, the 
request for withdrawal of consent and/or destruction cannot be pr ocessed.
7. Retention of Specimens 
Future Biomedical Research specimens will be stored in the biorepository  for potential 
analysis for up to 20 years from the end of the main study . Specimens may be stored for 
longer if a regulatory  or governmental authority  has active questions that are being  
answered. In this special circumstance, specimens will be stored until these questions 
have been adequatel y addressed.
Specimens from the trial site will be shipped to a central laboratory  and then shipped to 
the Sponsor -designated biorepository . If a central laboratory  is not utilized in a particular 
trial, the trial site will ship directly  to the Sponsor -designated biorepository . The 
specimens will be stored under strict supervision in a limited access facilit y which 
operates to assure the integrity  of the specimens.  Specimens will be destroy ed according 
to Sponsor policies and procedures and this destruction will be documented in the 
biorepository  database.
8.Data Security
Databases containing specimen information and test results are accessible only to the 
authorized Sponsor representatives and the designated trial administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
Product:   MK-3475 140
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
Confidential9. Reporting of Future Biomedical Research Data to Subjects
No information obtained from exploratory  laboratory  studies will be reported to the 
subject, family , or physicians. Principle reasons not to inform or return results to the 
subject include: Lack of relevance to subject health, limitations of predictive capability , 
and concerns regarding misinterpretation.
If important research findings are discove red, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapidly  report this information to doctors and subjects.  Subjects will not be identified by 
name in any published repor ts about this study  or in any other scientific publication or 
presentation.
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all subjects diagnosed and treated on Sponsor clinical 
trials for Future Biomedical Research .
11.Risks Versus Benefits of Future Biomedical Research 
For future biomedical research, risks to the subject have 
been minimized. Risks include 
those associated with venipuncture to obtain the whole blood specimen. This specimen 
will be obtained at the time of routine blood specimens drawn in the main trial.
The Sponsor has developed strict security, policies and procedures to address subject data 
privacy  concerns.  Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality .  In this highly unlikely  situation there is risk that the 
information, like all medical information, may  be misused.
12.Questions
Any questions related to the future biomedical research should be e
-mailed directly  to 
clinical.specimen.management@merck.com.
13.References
1.
National Cancer Institute: http://www.cancer.gov/dictionary /?searchTxt=biomarker
2.International Conference on Harmonization: Definitions f or Genomic Biomarkers, 
Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding 
Categories -E15; http://www.ich.org/LOB/media/MEDIA3383.pdf
3.Industry  Pharmacogenomics Working Group. Understanding the Intent, Scope and 
Public Health Benefits of Exploratory  Biomarker Research: A Guide for IRBs/IECs 
andInvestigational Site Staff. Available at http://i- pwg.org/
4.Industry  Pharmacogenomics Working Group. Pharmacogenomics Informational 
Brochure for IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/
Product:   MK-3475 141
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
ECOG Performance Status 
Grade Description
0Normal activity .Fully active, able to carry on all pre-disease 
performance without restriction.
1Symptoms, but ambulatory . Restricted in physicall y strenuous 
activity , but ambulatory and able to carry  out work of a light or 
sedentary  nature (e.g., light housework, office work).
2In bed <50% of the time. Ambulatory  and capable of all self-care, 
but unable to carry  out any work activities. Up and about more than 
50% of waking hours.
3In bed >50% of the time. Capable of only  limited self-care, confined 
to bed or chair more than 50% of waking hours.
4100% bedridden. Completely  disabled. Cannot carry on any self-
care. Totally  confined to bed or chair.
5 Dead.
* As published in Am. J. Clin. Oncol.: Oken MM, Creech RH, Torm ey DC, Horton J, Davis TE, 
McFadden ET, Carbone PP: Toxicity And Response Criteria Of The Eastern Cooperative Oncology 
Group. Am J Clin Oncol. 1982;5:649 -655. The Eastern Cooperative Oncology Group, Robert Com is 
M.D., Group Chair.
Product:   MK-3475 142
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Common Terminology Criteria for Adverse Events V ersion 4.0
The descriptions and grading scales found in the revised NCI CTCAE 4.0 will be utilized for 
AEreporting ( http://ctep.cancer.gov/reporting/ctc.html ).
Product:   MK-3475 143
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 Criteria for 
Evaluating Response in Solid Tumors
A modification to RECIST Version 1.1* will be used in this study  for subject management.
While either CT or MRI may be used utilized, as per RECI ST 1.1, CT is the preferred 
imaging technique in this study . Details are pr ovided in the I mage Acquisition Guidelines.
* As published in the European Journal of Cancer:
New response evaluation criteria in solid tumours: revised RECIST guideline (Version 1.1). 
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey  J, Arbuck 
S, Gwyther S, Mooney  M, Rubinstein L , Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij 
J. New response evaluation criteria in solid tumors: Revised RECI ST guideline (Version 
1.1). Eur J Cancer. 2009 Jan;45(2):228 -247. 
Product:   MK-3475 144
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential
List of Abbreviations
Abbreviation/Term Definition
1L first-line
2L second -line
ADA anti-drug antibodies
AE adverse event
AEOSI adverse event of special interest
ALT alanine aminotransferase
ANC Absolute neutrophil count
ASaT All Subjects as Treated
AST aspartate aminotransferase
AUC area under the plasma drug concentration time curve
β-HCG beta-human chorionic gonadotropin
BCG Bacillus Calmette– Guérin
BICR blinded independent central review
BSA body surface area
CBC complete blood count
CI confidence interval
Cmax maximum concentration
CR complete response
CrCl creatinine clearance
CSF colony -stimulating factors
CSR clinical study report
CT computed tomography
CTCAE Common Terminology Criteria for Adverse Events
CTLA -4 cytotoxic T-lymphocyte -associated protein 4
DL dose level
DMC Data Monitoring Committee 
DNA deoxyribonucleic acid
DOR duration of response
ECG electrocardiogram
ECIs events of clinical interest
Product:   MK-3475 145
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialAbbreviation/Term Definition
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
EDC electronic data capture
EMA European Medicines Agency
EOC Executive Oversight Committee
EORTC European Organization for Research and Treatment of Cancer
EP etoposide/platinum
EQ-5D-5L European Quality of Life Five -dimension Five -level Scale Questionnaire
ERC Ethics Review Committee
ES-SCLC extensive stage small cell lung cancer
FDA Food and Drug Administration
FDAAA Food and Drug Administration Amendments Act
FSH follicle -stimulating hormone
FT4 free thyroxine
GCP Good Clinical Practice
GFR glomerular filtration rate
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HIV human immunodeficiency virus
HR hazard ratio
IA1 first interim analysis
IA2 second interim analysis
IB Investigator’s Brochure
ICH International Council for Harmoni zation of Technical Requirements for 
Pharmaceuticals for Human Use (formerly International Conference on 
Harmonisation)
IEC Independent Ethics Committee
Ig immunoglobulin
IgC immunoglobulin constant
IgG immunoglobulin G
IgV immunoglobulin variable
IHC immunohistochemistry
Product:   MK-3475 146
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialAbbreviation/Term Definition
INR international normalized ratio
irAE immune -related adverse event
IRB Institutional Review Board
irRECIST Immune -related Response Evaluation Criteria in Solid Tumors
IRT interactive response technology
ITT intention -to-treat
IV intravenous
IVRS/IWRS interactive voice response system/integrated web response system
LDH lactate dehydrogenase
LS-SCLC limited -stage small cell lung cancer
MRI magnetic resonance imaging
MSD Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
N/A not applicable
NCI National Cancer Institute
NSCLC non-small cell lung cancer
ORR objective response rate
OS overall survival
OTC over-the-counter
PBPK physiologically based pharmacokinetics
PCI prophylactic cranial irradiation
PD progressive disease
PD-1 programmed cell death protein -1
PD-L1 programmed cell death -ligand 1
PD-L2 programmed cell death -ligand 2
PFS progression- free survival
PK pharmacokinetic
PR partial response
PRO patient -reported outcome 
PT prothrombin time
Q2W every 2 weeks
Q3W every 3 weeks
QLQ -C30 Quality of Life Questionnaire Core 30
Product:   MK-3475 147
Protocol/Amendment No.:   604-09 
MK-3475-604-09 Final Protocol 23-Apr- 2019
ConfidentialAbbreviation/Term Definition
QLQ -LC13 Quality of Life Questionnaire and Lung Cancer Module 13
RBC red blood cell
RECIST 1.1 Response Evaluation Criteria in Solid Tumors version 1.1
RNA ribonucleic acid
SAE serious adverse events
SAP Statistical Analysis Plan
SCLC small cell lung cancer
SD stable disease
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SOC standard of care
sSAP supplemental statistical analysis plan
T1DM Type 1 diabetes mellitus
T3 triiodothyronine
TB Bacillum Tuberculosis
TIL tumor -infiltrating lymphocyte
TSH thyroid- stimulating hormone
ULN upper limit of normal
WBRT whole brain radiation therapy
Product:   MK-3475 148
Protocol/Amendment No.:   604- 09 
MK-3475- 604-09Final Protocol 23-Apr-2019
Confidential13.0 SIGNATURES
Sponsor's Representative
TYPED NAME
TITLE
SIGNATURE
DATE SIGNED
Investigator
I agree to conduct this clinical trial in accordance with the design outlined in this protocol 
and to abide by all provisions of this protocol (including other manuals and documents 
referenced from this protocol).  I  agree to conduct the trial in accordance with generally 
accepted standards of Good Clinical Practice.  I also agree to report all information or data in 
accordance with the protocol and, in particular, I agree to report any serious adverse events 
as defined in Section 7.0–TRIAL PROCEDURES (Assessing and Recording Adverse 
Events ).  I also agree to handle all clinical supplies provided by the Sponsor and collect and 
handle all clinical specimens in accordance with the protocol.  I understand that information 
that identifies me will be used and disclosed as described in the protocol, and that such 
information may be transferred to countries that do not have laws protecting such
information.  Since the information in this protocol and the referenced Investigator’s 
Brochure is confidential, I understand that its disclosure to any third parties, other than those 
involved in approval, supervision, or conduct of the trial is prohibit ed.  I will ensure that the 
necessary  precautions are taken to protect such information from loss, inadvertent disclosure 
or access b y third parties.
TYPED NAME
TITLE
SIGNATURE
DATE SIGNED
MK-3475 PAGE 1 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
Supplemental Statistical Analysis Plan (sSAP)
0575BN
082JZZ
MK-3475 PAGE 2 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
TABLE OF CONTENTS
1.INTRODUCTION ................................................................ ......................................... 5
2.SUMMARY OF CHANGES ......................................................................................... 5
3.STATI STICAL ANALYSI S PL AN SUMMARY ........................................................ 5
3.1RESPONSIBILITY FOR A NALYSES/IN- HOUSE BLI NDING................. 6
3.2HYPOTHESES/ESTI MATIO N.....................................................................7
3.3ANALYSIS ENDPOINTS ............................................................................. 7
3.3.1 Efficacy  Endpoints .............................................................................. 7
3.3.2 Safety  Endpoints ................................................................................. 8
3.3.3 Patient Reported Outcome (PRO) Endpoints .....................................8
3.4ANALYSIS POPULATIONS ........................................................................9
3.4.1 Efficacy  Anal ysis Populations ............................................................ 9
3.4.2 Safety Anal ysis Populations ............................................................... 9
3.4.3 PRO Analy sis Population ...................................................................9
3.5STATI STICAL METHODS ........................................................................... 9
3.5.1 Statistical Methods for Efficacy  Anal yses........................................10
3.5.1.1 Progression -Free Survival (PFS) .......................................... 10
3.5.1.2 Overall Survival (OS) ........................................................... 11
3.5.1.3 Objective Response Rate (ORR) .......................................... 12
3.5.1.4 Duration of Response (DOR) ............................................... 12
3.5.2 Statistical Methods for Safety Anal yses........................................... 13
3.5.3 Summaries of Baseline Characteristics and Demographics ............. 15
3.5.4 Patient Reported Outcomes (PRO) Anal ysis....................................15
3.6INTERIM ANALYSES ................................................................................ 19
3.7MUL TIPLIC ITY .......................................................................................... 19
3.8SAMPLE SIZE AND POWE R CAL CULATIONS .....................................23
3.9SUBGROUP ANALYSES AND EFFECT OF BASELINE
FACTORS ....................................................................................................23
3.10 COMPLIANCE (MEDICATI ON ADHERENCE) ................................ 24
3.11 EXTENT OF EXPOSURE .....................................................................24
4.REFERENCES ............................................................................................................ 24
0575BN
082JZZ
MK-3475 PAGE 3 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
List of Tables
Table 1 Censoring rules for Primary  and Sensitivity  Anal yses of PFS ....................................... 11
Table 2  Censoring Rules for DOR ................................
............................................................... 12
Table 3 Efficacy  Anal ysis Methods for Primary  and Secondary  Efficac y Endpoints .................. 13
Table 4 Anal ysis Strategy  for Safet y Parameters ......................................................................... 14
Table 5 Mapping Relative Day to Analy sisVisit ......................................................................... 16
Table 6 Censoring Rules for Time -to-Deterioration ..................................................................... 18
Table 7   Efficacy  Boundaries and Properties for Progression -free Survival Analy ses............... 21
Table 8    Efficacy  Boundaries and Properties for Overall Survival Anal yses............................. 22
Table 9  Possible Alpha -levels and Approximate ORR Difference Required to Demonstrate 
Efficacy  for ORR .................................................................................................................. 23
0575BN
082JZZ
MK-3475 PAGE 4 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
List of Figures
Figure 1 Multiplicity  Graph for Ty pe I Error Control .................................................................. 20
0575BN
082JZZ
MK-3475 PAGE 5 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
1.INTRODUCTION
This supplemental SAP (sSAP) is a companion document to the protocol. In addition to the 
information presented in the protocol SAP which provides the principal features of confirmatory  
analyses for this trial, this supplemental SAP provide sadditional statistical analysisdetails/data 
derivations and documents modifications or additions to the analysis plan that are not “princip al” 
in nature andresult from information that was not available at the time of protocol finalization.  
2.SUMMARY OF CHANGES
This sSAP was amended to update the timing of the final analysis to match the SAP of protocol 
amendment 09.
3.STATISTICAL ANALYSIS PLAN SUMMARY
Key elements ofthe statistical analy sis plan are summarized below; the comprehensive plan is 
provided in Section s3.2 through 3.11.  
Study Design OverviewThis is a Phase 3, randomized, multi -site, double -blind study of 1L 
pembrolizumab+ Etoposide/Platinum (EP)versus saline placebo+EP in 
Extensive Stage Small Cell Lung Cancer ES-SCLC 
Treat mentAssignmentApproximately 430 subjects will be randomized in a 1:1 ratio toreceive 
pembrolizumab+EP or saline placebo+EP. The stratification factors used for 
this study are a) cisplatin vs carboplatin, b) ECOG status (0vs 1), and, c) 
LDH at baseline ( ≤ vs > ULN).  This is a double -blind study.
Analysis PopulationsEfficacy: Intention -to-Treat (ITT)
Safety: AllSubjects asTreated (ASaT)
PrimaryEndpoints1)PFS per RECIST 1.1 assessed by BICR
2)Overall survival (OS)
Secondary Endpoints3)ORR per RECIST 1.1 assessed by BICR
4)DOR per RECIST 1.1 assessed by BICR
5)AEs
Statistical Methods for
Key Efficacy AnalysesThe primary hypotheses will be evaluated by comparing 1L 
pembrolizum ab+EP to 1L saline placebo+EP based on PFS per RECIST 1.1 
(BICR) and OS in subjects with ES-SCLC using a stratified log-rank test. 
Hazard ratios (HRs) will be estimated using a stratified Cox regression 
model.  Event rates over time will be estimated within each treatment group 
using the Kaplan -Meier method.
Statistical Methods for
Key Safety AnalysesThe analysis of safety results will follow a tiered approach.  There are no 
Tier 1 safety parameters in this trial.  All safety param eters are considered 
either Tier 2 or Tier 3.  Tier 2parameters will be assessed via point estimates 
with 95% CIs provided for between -group comparisons; only point estimates 
by treatment group are provided for Tier 3 safety parameters.  The betw een-
treatment difference will be analyzed using the Miettinen and Nurm inen 
method.
Interim AnalysesTwointerim analy sesare planned in thisstudy.  Results willbe reviewed by
theexternal DMC .  Details areprovided inSection 3.6 – Interim Analyses .
Interim analysis 1
0575BN
082JZZ
MK-3475 PAGE 6 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
oTiming: To be performed approximately 18 months from study 
start, where study start is the date on which the first subject 
was randomized.
oPurpose :Interim PFS and OS analys es to demonstrate superiority of 
pembrolizumab+EP over saline placebo+EP .
Interim analysis 2
oTiming: To be performed approximately 22 months from study 
start. 
oPurpose :Final PFS analysis and interim OS analysis to demonstrate 
superiority of pembrolizumab+EP over saline placebo+EP
Final analysis
oTiming: To be performed after a minimum of 294 deaths are 
observed or approximately 31 months after first subject enrolled, 
whichever occurs later.
oPurpose: Primary analysis of OS to demonstrate superiority of 
pembrolizumab+EP over saline placebo+EP .
Multiplicity The family -wise type I error rate for this study is strongly controlled at 2.5% 
(one-sided) for the hypothesis testing of ORR, PFS and OS. The multiplicity 
strategy will follow the graphical approach of Maurer and Bretz as described 
in Section 3 .7 –Multiplicity, with 0.6% and 1.9% alpha initially allocated to 
the PFS and OS hypotheses, respectively . Group sequential methods will be 
used to allocate alpha betw een the interim and final analyses for PFS and OS 
endpoints .Further details of the interim analysis strategy can be found in 
Section 3.6 – Interim Analyses.
SampleSizeand Power The planned sample size is approximately 430 subjects. The actual sample 
size is 453 subjects. For PFS, based on 387 events, the study has 95.6% 
power to detect a HR of 0.65 (pembrolizumab+EP vs saline placebo+EP) at 
α=0.6% (one-sided). For OS, based on a minimum of 294 events, the study 
has at least 94.4% power to detect a HR of 0.65 (pembrolizumab+EP vs 
saline placebo+EP) at α=1.9% (one -sided).  
3.1 RESPONSIBILITY FOR A NALYSES/IN -HOUSE BLI NDING
The statistical analysis of the data obtained from this study  will be the responsibility  of the Clinical 
Biostatistic s department of the Sponsor.
The Sponsor will generate the randomized allocation schedule for study  treatment assignment for 
this protocol and the randomization will be implemented in IVRS /IWRS.
Planned interim analyses are described in Section 3.6. Partic ipant -level unblinding will be 
restricted to an external unblinded statistician and scientific programmer performing the interim 
analysis, who will have no other responsibilities associated with the study .
An external DMC will be convened to review accumulating safet y data to provide an opportunit y 
to terminate the study  early if there are concerns regarding safety . Treatment-level results at the 
interim analy ses will be provided by the external unblinded statistician to the DMC. The DMC 
will also review the unblinded efficacy  results at the planned interim analyses. The DMC 
responsibilities and review schedules will be outlined in the DMC charter. The recommendation 
of the DMC will be communicated to the Sponsor EOC and, in the event of a recommendation to 
0575BN
082JZZ
MK-3475 PAGE 7 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
halt the trial early due to safet y concerns, to the appropriate regulatory  agencies. If the DMC 
recommends modifications to the design of the protocol or discontinuation of the study , the EOC
may be unblinded to results at the treatment level in order to act on these recommendations.
Participant -level unblinding to support regulatory filing , should one occur before the end of the 
study ,willbe restricted to a designate dSponsor/MSD team, who will have no other responsibilities 
associated with the stud y.
The extent to which individuals are unblinded with respect to the results will be documented. 
Additional logistical details, revisions to the above plan,and data monitoring guidance will be 
provided in the DMC Charter.
3.2 HYPOTHESES/ESTIMATIO N
Objectives and hypotheses of the study  are stated in Protocol Section Section 3.0–Objective (s) 
and hy pothesi s(es).
3.3 ANALYSIS ENDPOINTS
Efficacy  and safet y endpoints that will be evaluated are listed below.
3.3.1 Efficacy Endpoints
Primary
Progression- free Survival –RECIST 1.1 assessed by BICR
Progression -free-survival is defined as the time from randomization to the first documented 
disease progres sion per RECI ST 1.1 based on BICR or death due to any cau se, whichever occurs 
first. See Section 3.5 .1–Statistical Methods for Efficacy  Anal ysesfor definition of censoring.
Overall Survival
Overall Survival is defined as the time from randomization to death due to any cause.  Subjec ts
without documented death atthetime ofanalysiswill becensored atthe date of last known 
contact.
Secondary
Objective Response Rate –RECIST 1.1 assessed by BICR
Objective Response Rate is defined as the proportion of subjects who have a CR or a PR. 
Responses are based on confi rmed assessments b y BICR per RECIST 1.1.
Duration of Response –RECIST 1.1 assessed by BICR
For subjects who demonstrate CR or PR, DOR is defined as the time from first documented 
evidence of CR or PR until disease progression or death due to an y cause, whichever occurs first.
Exploratory 
0575BN
082JZZ
MK-3475 PAGE 8 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
Exploratory  endpoints of this study include:
1.ORR, DOR and PFS perimmune -related RECI ST (irRECI ST) as assessed by the 
investigator.
2.ORR and PFS per RECIST 1.1 by  BICR, and OS by  PD-L1 expression (TPS <1% versus 
≥1%, CPS < 1 versus ≥1).
3.3.2 Safety Endpoints
Safety  measurements are described in the protocol in Section 4.2.3. 3 –Safet y Endpoints and 
Section 7 – Trial Procedures. Safet y and tolerability  will be assessed by clinical review of all 
relevant parameters including AEs, laboratory  tests, and vital signs. Safet y parameters to be 
analyzed include, but are not limited to, AEs, SAEs, fatal AEs, and laboratory changes.
Furthermore, specific events will be collected and designated as ECIs as described in Section 7.2.3
–Immediate Reporting of Adverse Events in the protocol .
3.3.3 Patient Reported Outcome (PRO) Endpoints
Secondary
Mean change in Score
Mean chang e from baseline at Week 18 in the European Organization for Research and Treatment 
of Cancer (EORTC) Quality  of Life Questionnaire Core 30 (QLQ-C30) global health status/quality  
of life scores (Items 29-30). If the overall PRO completion or compliance rates at Week 18 are less 
than 60% or 80%, respectively , then the primary analysis time point will be moved to the next 
earliest time point in which the rates are at least 60% for completion and at least 80% for 
compliance.
Time -to-deterioration (TTD)
For the EORTC QLQ -C30 and QLQ -LC13, a 10 points or greater worsening from baseline for 
each scale represent sa clinicall y relevant deterior ation based on prior literature. Time -to-
deterioration is defined as the time to first onset of 10 or more (out of 100) deterioration from 
baseline in a given scale/sub -scale/item and confirmed by a  s econd adjacent 10 or more 
deterioration from baseline under a right -censoring rule. The endpoint of interest is the composite 
endpoint of cough (QLQ -LC-13 Item 1) , chest pain (QLQ- LC-13 Item 10), or dy spnea (QLQ -C30 
Item 8).
Exploratory 
ThePRO endpoints which will be used for exploratory anal yses are :
mean change in score from baseline at weeks 18of Physical functioning scale (QLQ -C30 Items 
1-5)and EQ -5D-5L Health State Score using visual analogue scale (VAS)
time-to deterioration forGlobal Health Status/QoL scale (QLQ -C30 Items 29-30)and Physical 
functioning scale (QLQ -C30 I tems 1 -5)
0575BN
082JZZ
MK-3475 PAGE 9 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
Proportion improved/stable in Global Health Status/QoL  scale (QLQ -C30 Items 29-30) and
Physical functioning scale (QLQ -C30 Items 1-5). Improved/Stable is defined as an 
improvement or less than 10 points worsening in score from baseline at any time during the 
trial and confirmed by improvement or less than 10 points worsening at thenext consecutive 
visit.
3.4 ANALYSIS POPULATIONS
3.4.1 Efficacy Analysis Populations
The analyses of primary  efficacy  endpoints are based on the intention -to-treat (ITT) population, 
i.e., subjects will be included in the treatment group to which they  are randomized .Details on the 
approach to handling missing data are provided in Section 3.5Statistical Methods.
3.4.2 Safety Analysis Populations
The All Subjects as Treated (ASaT) population will be used for the analy sis of safety  data in this 
study .  The ASaT population consists of all randomized subjects who received at least 1dose of 
study  treatment.  Subjects will be included in the treatment group corresponding to the study 
treatment they actually received.  For most subjects, this will be the treatment group to which the y 
are randomized.  Subjects who take incorrect study  treatment for the entire treatment period will 
be included in the treatment group corresponding to the study  treatment actually  received.  Any 
subject who receives the incorrect study  medication for 1 cycle but receives the correct treatment 
for all other cycles will be analy zed according to the correct treatment group and a narrative will 
be provided for an y events that occur during the cycle for which the subject is incorrectl y dosed.
At least 1 laboratory or vital sign measurement obtained subsequent to at least 1 dose of study  
treatment is required for inclusion in the analysis of each specific parameter.  To assess change 
from baseline, a baseline measurement is also required.
3.4.3 PRO Analysis Population
The primary  anal ysis approach for the pre -specified PRO endpoints will be based on
a quality  of life related full analy sis set (FAS) population following the intention -to-treat (ITT)
principle and ICH E9 guidelines. This population consists of all randomized patients who have
received at least one dose of study  medication and have completed at least one PRO assessment.
3.5 STATISTICAL METHODS
This section describes the statistical methods that address the primary , secondary  and exploratory
objectives as stated in the protocol.
Statistical methods for efficacy  analyses are described in Section 3.5.1. Statistical testing and 
inference for safet y analy ses are described in Section 3.5.2
. Efficacy  results that will be deemed 
to be statistically  significant after consideration of the Ty pe I error control strategy  are described 
in Section 3.7, Multiplicity . Nominal p
-values may becomputed for other efficacy  analysesas a 
measure of strength of association between the endpoint and the treatment effect rather than formal 
tests of hy pothese s.  
0575BN
082JZZ
MK-3475 PAGE 10 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
3.5.1 Statistical Methods for Efficacy Analyses
3.5.1.1 Progression-Free Survival (PFS)
The non-parametric Kaplan -Meier method will be used to estimate the PFS curve in each treatment 
group. The treatment difference in PFS will be assessed by the stratified log-rank test.A stratified 
Cox proportional hazard model with Efron's method of tie handling will be used to assess the 
magnitude of the treatment difference (ie, the HR) between the treatment arms. The HRand its 
95% CIfrom the stratified Cox model with Efron's method of tie handling and with a single 
treatment covariate will be reported. The stratification factors used for randomization will be 
applied to both the stratified log -rank test and the stratified Cox model. In case there is a stratum
which has =<10 subjects , the stratumwill be combined with the stratumwith the next smallest
number of subjects till the number of subject in the smallest stratumis >10.The same strategy  will 
be used for determining the strata for the stratified anal yses of OS,ORR and PROs.
Since disease progression is assessed periodically , PD can occur any time in the time interval 
between the last assessment where PD was not documented and the assessment when PD is 
documented. For the primary  analysis, for the subjects who have PD, the true date of disease 
progression will be approximated by the date of the first assessment at which PD is objectively  
documented per RECIST 1.1 (BICR) , regardless of discontinuation of study  drug. Death is alway s 
considered as a confirmed PD event. Sensitivity  analyses will be performed for comparison of PFS 
based on investigator's assessment.
In order to evaluate the robustness of the PFS endpoint per RECI ST 1.1 by central imaging vendor , 
we will perform 2 sensitivity  analyses with a different set of censoring rules. The first sensitivity 
analysis is the same as the primary  analysis except that it censors at the last disease assessment 
without PD when PD or death is documented after more than one m issed disease assessment. The 
second sensitivity  analysis is the same as the primary  analysis except that it considers 
discontinuation of treatment or initiation of an anticancer treatment subsequent to discontinuation 
of study -specified treatments, whiche ver occurs later, to be a PD event for subjects without 
documented PD or death. The censoring rules for primary  and sensitivity  analyses are summarized 
inTable 1 .  
0575BN
082JZZ
MK-3475 PAGE 11 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
Table 1 Censoring rules for Primary  and Sensitivity  Anal yses of PFS
Situation Primary AnalysisSensitivity
Analysis 1Sensitivity
Analysis 2
No PD and no death; 
new anticancer 
treatment is not 
initiatedCensored at last disease 
assessment Censored at last disease 
assessment Censored at last disease 
assessment if still on study 
therapy; progressed at 
treatment discontinuation 
otherwise
No PD and no death; 
new anticancer 
treatment is initiatedCensored at last disease 
assessment before new 
anticancer treatmentCensored at last disease 
assessment before new 
anticancer treatmentProgressed at date of new 
anticancer treatment
No PD and no death; ≥ 
2 consecutive missed 
disease assessmentsCensored at last disease 
assessmentCensored at last disease 
assessment prior to ≥2 
consecutive missed 
visitsCensored at last disease 
assessment
PD or death 
documented after ≤ 1 
missed disease 
assessmentProgressed at date of 
documented PD or 
deathProgressed at date of 
documented PD or deathProgressed at date of 
documented PD or death
PD or death 
documented at any time 
after ≥ 2 missed disease 
assessmentsProgressed at date of 
documented PD or 
deathCensored at last disease 
assessment prior to the ≥ 
2 missed disease 
assessmentProgressed at date of 
documented PD or death
Restricted Mean Survival Time (RMST) method (Uno et al. [5]) may be conducted for PFS to 
account for the possible non- proportional hazards effect.
3.5.1.2 Overall Survival (OS)
The non-parametric Kaplan -Meier method will be used to estimate the survival curves. The 
treatment difference in survival will be assessed by the stratified log-rank test (based on the 
stratification factor defined in Section 5.4of the Protocol –Stratifi cation ). A stratified Cox 
proportional hazard model with Efron's method of tie handling will be used to assess the magnitude 
of the treatment difference (ie, the HR). The HRand its 95% CIfrom the stratified Cox model 
with a single treatment covariate w ill be reported. The same stratification factors as used for PFS 
analysis in the overall population will be applied to both the stratified log-rank test and the 
stratified Cox model. Restricted Mean Survival Time (RMST) method may be conducted for OS 
to account for the possible non -proportional hazards effect.
Since subjects in the Placebo+EP arm are expected to discontinue from the study  earlier compared 
to subjects in the pembrolizumab arm because of earlier onset of PD and may switch to another 
anti PD-1 treatment following confirmation of PD, adjustment for the effect of crossover on OS 
may be performed based on recognized methods, (eg,the Rank Preserving Structural Failure Time 
(RPSFT) model proposed by Robins and Tsiatis ), based on an examination of the appropriateness 
of the data to the assumptions required b y the method used.  
0575BN
082JZZ
MK-3475 PAGE 12 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
3.5.1.3 Objective Response Rate (ORR)
Stratified Miettinen and Nurminen’s method will be used for comparison of ORR between the 
treatment groups.  The difference in ORR and its 95% CI from the stratified Miettinen and 
Nurminen method with strata weighting by  sample size will be provided.  The same stratification 
factors as used for PFS and OS analy ses will be used as stratification f actors in the anal ysis.
3.5.1.4 Duration of Response (DOR)
For subjects who demonstrate CR or PR, DOR is defined as the time from first documented 
evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.  
Censoring rules fo r DOR  are summarized in Table 2.  DOR will be assessed using RECIST 1.1 b y 
BICR .
For each DOR anal ysis, a corresponding summary of the reasons responding subjects are 
censored will also be provided.  Subjects who are alive, have not progressed, have not initiated 
new anti -cancer treatment, have not been determined to be lost to follow -up
, and have had a 
disease assessment within ~5 months of the data cutoff date are considered ongoing responders 
at the time of anal ysis.  If a subject meets multiple criteria for censoring, the censoring criterion 
that occurs earliest will be applied.
Table 2 Censoring Rules for DOR
SituationDate of 
Progression or Censoring Outcome
No progression nor death, no new anti-
cancer therapy initiatedLast adequate disease 
assessmentCensor
(non-event)
No progression nor death, new anti-
cancer therapy initiatedLast adequate disease 
assessment before new anti-
cancer therapy initiatedCensor
(non-event)
Death or progression after ≥2 
consecutive missed disease assessmentsLast adequate disease 
assessment prior to ≥2 missed 
adequate disease assessmentsCensor
(non-event)
Death or progression after ≤1 missed 
adequate disease assessmentsProgressive disease or death End of response
(Event)
A missed disease assessment includes any assessment that is not obtained or is considered inadequate for 
evaluation of response.
Table 3 summarizes the key  efficacy  anal yses.
0575BN
082JZZ
MK-3475 PAGE 13 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
Table 3 Efficacy  Anal ysis Methods for Primary  and Secondary  Efficacy  Endpoints
Endpoint/Variable
(Description, Time Point) Statistical Method Analysis Population Missing Data Approach
Prim ary Analyses:
PFS (RECIST 1.1) by 
BICRTesting: Stratified Log-
rank test
Estimation: Stratified Cox 
model with Efron's tie 
handling method ITT Censored according to 
rules in Table 1
OS Testing: Stratified Log-
rank test
Estimation: Stratified Cox 
model with Efron's tie 
handling methodITT Censored at last known 
alive date
Secondary Analyses:
ORR (RECIST 1.1) by 
BICRStratified Miettinen and 
Nurminen methodITT Subjects with missing 
data are considered non-
responders
DOR (RECIST 1.1) by 
BICRSummary statistics using 
Kaplan -Meier methodAll responders in ITT Non-responders are 
excluded in analysis
The strategy  to address multiplicity  issues with regard to multiple treatment comparisons, multiple 
endpoints, multiple populations, and interim analy ses is described in Section 3.6, Interim Anal yses 
and in Section 3.7, Multiplicity .
3.5.2 Statistical Methods for Safety Analyses
Safety  and tolerability  will be assessed by clinical review of all relevant parameters including AEs
and laboratory  tests .
The anal ysis of safet y results will follow a tiered approach ( Table 4).  The tiers differ with respect 
to the analyses that will be performed. Safet y parameters or AEs of special interest that are 
identified a priori constitute “Tier 1” safet y endpoints that will be subject to inferential testing for 
statistical significance with p-values and 95% CIs provided for between -group comparisons.  Other 
safet y parameters will be considered Tier 2 or Tier 3.  Tier 2 parameters will be assessed via point 
estimates with 95% CIs provided for between -group comparisons; only point estimates by 
treatment group are provided for Tier 3 safety parameters.
Adverse events of special interest (AEOSIs) that are immune -mediated or potentially  immune -
mediated are well documented and will be evaluated separately ; however, these events have been 
characterized consistently  throughout the pembrolizumab clinical development program and 
determination of statistical significance is not expected to add value to the safet y evaluation.  
Further, pembrolizumab added to platinum doublets studied thus far have not been found to impact 
safet y, and in an ongoing Phase 1clinical trial, the chemotherapeutic regimen used here with 
pembrolizumab has not led to increased toxicity  ([STUDY_ID_REMOVED]).  Additionally , there are no 
known AEs associated with subjects with SCL C for which determination of a p -value is expected 
0575BN
082JZZ
MK-3475 PAGE 14 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
to impact the safety  assessment.  For these reasons, there are no events of interest that warrant 
inferential testing.  Therefore, there are no Tier I events in this study .
Adverse experiences (specific terms as well as system organ class terms) that are not pre-specified 
as Tier -1endpoints will be classified as belonging to "Tier 2" or "Tier 3", based on the number of 
events observed.  Membership in Tier 2 requires that at least 4subjects in any treatment group 
exhibit the event; all other AEs and predefined limits of change will belong to Tier 3.
The threshold of at least 10% was chosen for membership in Tier 2 because subjects enrolled in 
this study  are in critical condition and usually  experience various AEs of similar ty pes regardless 
of treatment, events reported less frequen tly than in 10% of subjects would obscure the assessment 
of the overall safety  profile and add little to the interpretation of potentially  meaningful treatment 
differences. In addition, Grades 3 to 5 AEs (≥5% of subjects in one of the treatment arms) and 
SAEs (≥5% of subjects in one of the treatment arms) will be considered Tier 2 events .For Tier 2 
events, 95% CIswill be provided for between -treatment differences in the percentage of subjects 
with events; these analyses will be performed using the Miettin en and Nurminen method , an 
unconditional, asymptotic method. Because many 95% CIs may be provided without adjustment 
for multiplicity , the CIs should be regarded as a helpful descriptive measure to be used in safet y 
review, not a formal method for assessing the statistical significance of the between -treatment
differences . 
For laboratory  parameters, the number and percentage of subjects with increases from baseline in 
laboratory  test toxicity  grades based onthe highest post-baseline toxicity  grade and shift of toxicity  
grade from baseline to the worst post-baseline toxicity  grade will be summarized by treatment arm.
Table 4 Anal ysis Strategy  for Safet y Parameters
Safety Tier Safety Endpoint 95% CI for 
Treatment 
ComparisonDescriptive 
Statistics
Tier 2 Any AE (≥10% of subjects in one of the 
treatment arm s)X X
Any Grade s3 to 5 AE (≥5% of subjects in one of 
the treatment arms)X X
Any serious AE (≥5% of subjects in one of the 
treatment arm s)X X
Tier 3 Any AE X
Any change from baseline results (laboratory 
tests)X
Abbreviations: AE=adverse event, CI=confidence interval
0575BN
082JZZ
MK-3475 PAGE 15 PROTOCOL NO. 604-09                                 
Supplemental SAP                                                                                                                       21 APRIL 2019 - AMENDMENT 04     
Exposure-Adjusted Approach
To properly account for the potential difference in follow-up time between the study arms, which 
is expected to be longer in the pembrolizumab arm, summary of AE incidence adjusted for treatment exposure analyses may be provided as appropriate.  
3.5.3 Summaries of Baseline Characteristics and Demographics
The comparability of the treatment groups for each relevant characteristic will be assessed by the 
use of tables and/or graphs.  No statistical hypothesis tests will be performed on these characteristics.  The number and percentage of subjects randomized, and the primary reason for discontinuation will be displayed.  Demographic variables (such as age) and baseline characteristics will be summarized by treatment either by descriptive statistics or categorical tables.  The reasons for exclusion from the ITT population (if any) will be summarized.
3.5.4 Patient Reported Outcomes (PRO) Analysis 
This section describes the planned analyses fo r the key PRO endpoints. As there is no formal 
hypothesis testing for PRO endpoints, nominal p-values will be provided for treatment 
comparisons of pembrolizumab combination therapy vs. standard of care. No multiplicity adjustment will be performed. 
PRO compliance summary
Completion and compliance of QLQ-C30, LC13 and EQ-5D-5L by visit and by treatment will be 
described within the PRO FAS population. Numbers and percentages of complete and missing data at each visit will be summarized for each of the treatment groups. 
Completion Rate is defined as the percentag e of observed visit over number of randomized 
subjects at each time points.
݊݋݅ݐ݈݁݌݉݋ܥ  ݁ݐܴܽ ൌ  ݎܾ݁݉ݑܰ  ݂݋ ݏݐ݆ܾܿ݁ݑܵ  ݋݄ݓ  ݁ݐ݈݁݌݉݋ܥ  ݐܽ ݐݏ݈ܽ݁  ݁݊݋ ݉݁ݐܫ
ݎܾ݁݉ݑܰ  ݂݋ ݀݁ݖ݅݉݋ܴ݀݊ܽ  ݏݐ݆ܾܿ݁ݑܵ
The completion rate is expected to shrink in the later visit during study period due to the subjects 
who discontinued early. Therefore, another measurement, Compliance Rate, defined as the percentage of observed visit over number of eligib le subjects who are expected to complete the 
PRO assessment (not including the subjects missing by design (such as death, discontinuation, translation not available) will be employed as the support for completion rate).
݈݁ܿ݊ܽ݅݌݉݋ܥ  ݁ݐܴܽ ൌ  ݎܾ݁݉ݑܰ  ݂݋ ݏݐ݆ܾܿ݁ݑܵ  ݋݄ݓ  ݁ݐ݈݁݌݉݋ܥ  ݐܽ ݐݏ݈ܽ݁  ݁݊݋ ݉݁ݐܫ
ݎܾ݁݉ݑܰ  ݂݋ ݈ܾ݈݁݅݃݅ܧ  ݏݐ݆ܾܿ݁ݑܵ  ݋݄ݓ  ݁ݎܽ ݀݁ݐܿ݁݌ݔܧ  ݋ݐ ݁ݐ݈݁݌݉݋ܥ
The reasons of non-completion and non-compliance will be provided in supplementary table:
–Completed as scheduled
–Not completed as scheduled
–Off-study: not scheduled to be completed.
%1-==
MK-3475 PAGE 16 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
In addition, reasons for non-completion as scheduled of these measures will be collected using 
“miss_mode” forms filled by site personnel andwill be summarized in table format. An instrument 
is considered complete as at least one valid score available according to the missing item rules 
outlined in the EORTC Manual.
The schedule for PRO data collection:
PROs were scheduled to be completed every  cycle for Cy cles 1 to 9 while the subject was
receiving study  treatment, then every  other cy cle up to Cy cle 17 (ie, Cy cles 11, 13, 15, and 17).  
PROs were alsoscheduled to be obtained at the Treatment Discontinuation visit and 30 -day 
Safet y Follow- up visit. For analysis purposes, relative visit day s were mapped into anal ysis 
visits. The general rule of mapping relative day to analy sisvisit is provided in Table 5.Due to 
space restrictions visit windows until week 30 are provided
.
Table 5 Mapping Relative Day to Analy sisVisit
Analysis of Mean Score Change
To assess the treatment effects on the PRO, for each continuous endpoint defined, a constrained 
longitudinal data analysis (cLDA) method proposed by Liang and Zeger [1] will be used. This 
model assumes a common mean across treatment groups at baseline and a different mean for each 
treatment at each of the post-baseline time points. In this model, the response vector consists of 
baseline and the values observed at each p ost-baseline time point. Time is treated as a categorical 
variable so that no restriction is imposed on the trajectory  of the means over time. The analysis 
model will include the PRO score as the response variable, with covariates including treatment b y 
study visit interaction, and the same stratification factors as used in the stratified analyses of 
efficacy  endpoints . The treatment difference in terms of mean PRO score change from baseline at 
week 18(time defined by time windows instead of study  visit) will be estimated and tested from 
this model. If the overall PRO completion or compliance rates at Week 18 are less than 60% or 
80%, respectivel y, then the primary  analysis time point will be moved to the next earliest time 
point in which the rates are at least 60% for completion and at least 80% for compliance.
An unstructured covariance matrix will be used to model the correlation among repeated 
measurements. The cLDA model is specified as follows:
k t j X t I Y Ei jt ijt ,..2 , 1 , 0     2 , 1     , ) 0 ( ) (0         Treatment
WeekWeek
Baseline 3 6 9 12 15 18 21 24 30
Day 1 21 42 63 84 105 136 147 168 210
Range [-7,7] [8,31] [32,52] [53,73] [74,94] [95,115] [116,136] [137,157] [158,188 ][189,230]
0575BN
082JZZ
MK-3475 PAGE 17 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
where Yijtis the PRO score for s ubject i, with treatment assignment j, at visit t, 0is the baseline 
mean for all treatment groups,jtis the mean change from baseline for treatment group j at time 
t, iXis the stratification factor (binary ) vector for this patient, and is the coefficient vector for 
stratification factors.
Based on the cLDA model, g roup-wise comparisons will be performed and the differences in the 
lsmean change fro m baseline will be reported, together with 95% C.I . and nominal p -value at the 
primary  analysis time points. In addition, model -based lsmean score with 95% C.I. will be 
provided b y treatment group and study visit.
The analysis of mean change will be based primarily  under the assumption of missing -at-random 
(MAR) mechanism. The cLDA model implicitly  treats missing data as missing at random (MAR). 
Analy ses of change from baseline to Week 18 will be display ed in tables for the following scales 
as listed in section 3.2.3:  EORTC QLQ-C30 GHS/QoL  (QLQ -C30 Items 29-30), Physical 
functioning scale (QLQ -C30 I tems 1 -5), and EQ -5D-5L VAS .
The empirical mean change (with 95% CIs) from baseline across time will be display ed graphicall y 
for the following scales:   EORTC QLQ -C30 GHS/QoL  (QLQ -C30 Items 29-30), P hysical 
functioning scale (QLQ -C30 I tems 1 -5), and EQ -5D-5L VAS .
Analy ses of LS mean change (95% CI) from baseline to Week 18 will be display ed in bar plot 
format for the following questionnaires in 3 separate figures: 1) EORTC QLQ -C30 global health 
status and functional status scales, 2) EORTC QLQ -C30 sy mptom scales, 3) EORTC QLQ -LC13 
scales .
0575BN
082JZZ
MK-3475 PAGE 18 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
Time -to-Deterioration (TTD) Analysis
The TTD is defined as the time to first onset of 10 or more points deterioration from baseline with 
confirmation under right -censoring rule. The non-parametric Kaplan -Meier method will be used 
to estimate the deterioration curve in each treatment group. The estimate of median time to 
deterioration and its 95% confidence interval will be obtained from the Kaplan -Meier survival 
estimates. The treatment difference in TTD will be assessed by the stratified log-rank test. A 
stratified Cox proportional hazard model with Efron's method of tie handling and with a single 
treatment covariate will be used to assess the magnitude of the treatment difference (hazard ratio) . 
The same stratification factors as used for effica cy endpoints will be used as stratification factors 
for both Cox model and log -rank test.
The primary  approach for the time-to-deterioration analysis will be based on the assumption of 
non-informative censoring. The patients who do not have deterioration on the last date of 
evaluation will be censored. 
Table 6 provides censoring rule for TTD anal ysis.
Table 6 Censoring Rules for Time -to-Deterioration 
Scenario Outcome
No baseline assessments Right censored at treatment start date
Deterioration documented Event observed at time of assessment (first 
deterioration)
Ongoing or discontinued from study without 
deteriorationRight censored at time of last assessment
Analysis of Overall Improvement /Stability
Overall Improved/Stable rate will be calculated as the percentage of subjects who have 
improvement or less than 10 points worsening in score from baseline at any time during the trial 
and confirmed b y animprovement or a less than 10 points worsening at the next consecutive visit. 
The stratif ied Miettinen and Nurminen method will be used for comparison of the overall 
improvement /stability rate between the treatment groups. The difference in overall 
improvement /stability rate and its 95% CI from the stratified Miettinen and Nurminen method with 
strata weighting by sample size will be provided. The same stratification factors as used for 
efficacy  endpoints will be used for anal ysis.
0575BN
082JZZ
MK-3475 PAGE 19 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
3.6 INTERIM ANALYSES
Two interim efficacy analy ses are planned for this study .
The first interim analysis (IA1) will be performed approximately 18 months from study  
start, 3.5 months after the last patient was enr olled.  PFS and OS will be evaluated at IA1.  
ORR p-value from IA1 may be evaluated for statistical significance if PFS and OS null 
hypotheses are rejected at IA1 or at a later analy sis time.
The second interim anal ysis (I A2) will be performed approximately 22 months from study  
start, 7.5 months after the last patient was enrolled .The second interim analysis evaluation 
of OS and the final evaluation of PFS will be performed at this time.    
The final analysis will evaluate OS only. It is planned when a minimum of 294 deaths have 
been observed or approximately  31 months after first subjec t enrolled, whichever occurs 
later. 
In addition to the formal efficacy  anal yses, the DMC will conduct regular safet y monitoring , the 
timing of which is specified in the DMC charter. Decisions to stop the trial earl y will be based 
on DMC recommendations with review b y the EOC.
Type I error control for the efficacy  analyses as well as efficacy  bounds are described in the next 
section.
3.7 MULTIPLICITY
The trial uses the graphical method of Maurer and Bretz to control multiplicity  for multiple 
hypotheses as well as interim analyses. Figure 1shows the initial one-sided α allocation for each 
hypothesis in the ellipse represe nting the hypothesis.  The weights for reallocation from each 
hypothesis to the others are represented in the boxes on the lines connecting h ypotheses.
0575BN
082JZZ
MK-3475 PAGE 20 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
Note: If both PFS and OS null hypotheses are rejected, the reallocation strategy allows testing of ORR at 
alpha=0.025.
Figure 1Multiplicity  Graph for Ty pe I E rror Control
Progression- free Survival
If the null hypothesis for OSis rejected, shows that its α=0.0 19is essentially  fully reallocated to 
PFS hypothesis testing.  Thus, the PFS null hypothesis Figure 1may be tested at α=0.00 6 orat
α=0.025 .For PFS h ypotheses, the targeted number of ev ents at the final PFS analysis will be 387. 
A Lan-DeMets O'Brien -Fleming spending function
will be used for information fraction -based 
alpha -spending to generate the group sequential design. The bounds provided in Table 7are based 
on the assumption that the number of events at IA1 and IA2 are 332 and 387 respectivel y. The 
actual boundaries and the nominal alpha level will be determined based on the actual number of 
PFS events observed at the time of the analyses and from the overall alpha level after an y potential 
alpha -shifting as the result of a successful OS analysis. The final PFS anal ysis at IA2 will use the 
remaining Ty pe I error not spent at IA1, regardless of the ac tual number of PFS events observed.  
The p-value bound at the final PFS analysis will be calculated by considering the correlation 
between the test statistics as determined by the actual number of PFS events at IA1 and the final 
PFS analy sis at IA2. The bounds given in Table 7will be adjusted accordingly.
0575BN
082JZZ
MK-3475 PAGE 21 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
Table 7    Efficacy  Boundaries and Properties for Progression -free Survival Analy ses
Analy sis Targeted Analy sis 
TimeCumulative alpha 
spent3Efficacy  Bars3
IA1 (86%2) Around 18 months 
from study  start10.003 (One -sided) p-
value <0.00
3
Observed HR < ~0.74
IA2 (100%2) Around 22 months 
from study  start10.006 (One -sided) p-
value <0.00
51
Observed HR < ~0.77
1Study  start is defined as the date when the first subject was randomized.
2Percentage of expected number of events at final anal ysis target ed at interim analy sis
3Nominal alpha ,boundaries and cumulative alpha are based on the assumpti on that 332 and 
387 events areat IA1 and IA2 respectivel y. The p-value boundaries will be updated at the time 
of anal yses based on actual number of PFS events.
Note that if the α-reallocation from OS hypothesis testing occurs at the final analysis after 
hypothesis testing for PFS has been completed, the previously  computed PFS test statistic for the 
PFS final anal ysis may  be re -evaluated based on the updated bounds . 
Overall Survival
The OS hy pothesis may  be tested at α=0.019 (initially  allocated α) or at α=0.025 (if PFS null 
hypothesis is rejected) following the multiplicity  strategy  as outlined in Figure 1bounds and 
boundary  properties for OS hy pothesis testing at the i nitial alpha level are demonstrated in Table 8  
The alpha spending at each interim anal ysis is determined using a Lan -DeMets O'Brien -Fleming 
spending function, and the information fraction (ratio of the actual number of events at the 
interim analy sis relative to a targeted 294 events at the final anal ysis). The final anal ysis will use 
the remaining Ty pe I error not spent at earlier analy ses, regardless of the number of eve nts 
observed at the final analysis. The p -value bounds at second interim and final anal ysis will be 
calculated b y considering the correlation between the test statistics as determined by the actual 
number of OS events at the previous and current analy sis. The p -value bounds at each anal ysis 
time may  also be updated after potential alpha -shifting as the result of a successful PFS anal ysis.
0575BN
082JZZ
MK-3475 PAGE 22 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
Table 8     Efficacy  Boundaries and Properties for Overall Survival Anal yses
Analy sis Targeted Analy sis 
TimeCumulative 
alpha spent3Efficacy  Bars3
IA1 (60%2) Approximately 18 
months from study 
start10.0024 (One -sided) p-value 
<0.0024
Observed HR <~0.65 
IA2 (76%2) Approximately  2 2 
months from study 
start10.0071 (One -sided) p-value 
<0.0064
Obser ved HR <~0.72 
FA (100%2) Approxima tely 294 
deaths observed in 
two arms; 
approximately 31 
months from study 
start0.019 (One -sided) p-value 
<0.0167
Observed HR <~0.78 
1Study  start is defined as the date when the first subject was randomized.
2Percentage of expected number of events at final anal ysis targeted at interim analy sis
3Nominal alpha, boundaries and cumulative alpha are based on the number of deaths expected 
assuming the projected number of events using protocol assumptions, i.e., 175, 224 and 294 at 
IA1, IA2 and final anal ysis respectivel y. The p-value boundaries will be updated at the time of 
analyses based on actual number of deaths.
The DMC has responsibility  for assessment of overall risk: benefit. When prompted by
safet y concerns, the DM C can request corresponding efficacy data. DMC review of efficacy
data to assess the overall risk: benefit to study  participants will not require a multiplicity
adjustment typicall y associated with a planned efficacy  IA. However, if the DMC confirms that 
efficacy  data were considered in the overall risk: benefit assessment during periodic safet y 
reviews, a sensitivity analysis for OS taking a nominal alpha penalt y of 0.000001 for each of such 
incidence will be conducted.
Objective Response Rate
The trial does not allocate initial alpha to ORR. ORR will be formally tested only if the 
hypotheses for PFS and OS are significant. The testing of ORR will be based on the first 
352subjects enrolled in the trial. If the null h ypotheses for OS and PFS are rejected at IA1 or at a 
time later than IA1, the p -value of ORR from the IA1 anal ysis will be compared to an α -level of 
0.025. Power at the possible α -level as well as the approximate treatment difference required to 
0575BN
082JZZ
MK-3475 PAGE 23 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
reach the bound (ΔORR) are shown in Table 9assuming underl ying 50% and 70% response rates 
in the control and experimental groups, respectively. 
Table 9   Possible Alpha -levels and App roximate ORR Difference Required to Demonstrate 
Efficacy  for ORR
α ~ΔORR Power
0.025 0.1002 0.9719
3.8 SAMPLE SIZE AND POWE R CALCULATIONS
Four hundred and thirty  subjects were planned to be randomized in 1:1 ratio into 
pembrolizumab+EP and thesaline placebo+EP arms. By  the time of the current amendment, 453 
subjects were enrolled for this study .
The final PFS analysis for the study  will occur about 22 months from study  start. If 387 PFS events 
occur by  the time of the final PFS analy sis, the study  will have a power of 96% approximately to 
demonstrate a hazard ratio of 0.65 on PFS at initially  allocated α=0.0 06.
The final OS analysis will occur when at least 294 events have occurred or approximately  31 
months from study  start, whichever occurs later. With a minimum of 294 events at the time of final 
analysis, the stud y has at least 94% power to demonstrate a HR of 0.65 on OS at initially  allocated 
α=0.019 . The above power calculations for OS and PFS are based on the following assumptions: 
1) 453 subjects were enrolled over 14.5 months following the actual enrollment pattern; 2)median 
PFS is 4.3 months in the control armand hazard ratio is 0.65; 3) median OS is 10months in the 
control armand hazard ratio is 0.65; 4) The exponential dropout ratesassumed for OSand PFS 
are1% per month.
The sample size and power calculations were performed in the software EAST 6.2 and R (package 
“gsDesign”).
3.9 SUBGROUP ANALYSES AND EFFECT OF BASELINE FACTORS
To determine whether the treatment effect is consisten t across various subgroups, the between -
group treatment effect for OS, PFS and ORR (with a nominal 95% CI) will be estimated and plotted 
within each category  of the following classification variables:
Stratification factors
oPlatinum chemotherap y (cisplatin , carboplatin)
oLDH ( ≤ULN, >ULN)
oECOG Performance Scale (0, 1)
Age category  (≤65, >65 y ears)
Sex (female, male)
0575BN
082JZZ
MK-3475 PAGE 24 PROTOCOL NO. 604-09                                                                                                                           
Supplemental SAP                                                                                                                        21 APRIL 2019 - AMENDMENT 04     
Race (white, non -white)
Smoking status (former, current)
Brain/liver metastasis status at diagnosis (yes, no)
Region ( East Asia, non -East Asia)
Sites of metastasis at diagnosis (<3, ≥3)
PD-L1 expression positive (TPS<1% vs ≥1%, CPS <1 vs ≥1)
For PFS and OS, the unstratified Cox model will be used for computing the hazard ratio and its 
95% CI in the subgroups. For ORR, the unstratified Miettinen and Nurminen meth od will be 
used. The consistency  of the treatment effect will be assessed descriptively  via summary 
statistics by category  for the classification variables listed above. If any level of a subgroup 
variable has fewer than 10% of the ITT population, above analysis will not be performed for 
this level of the subgroup variable. If a subgroup variable has two levels and one level of the 
subgroup variable has fewer than 10% of the ITT population, then thissubgroup will not be 
display ed in the forest plot. The subgroup factor platinum chemotherap y will be determined 
based on the platinum which was administered to a subject at the first dose. If a subject didnot 
receive an y platinum ,they will be excluded from subgroup analysis.In general, a subj ect with
a missing subgroup factor will be excluded from analy sis of that subgroup. 
3.10 COMPLIANCE (MEDICATI ON ADHERENCE)
Drug accountability  data for trial treatment will be collected during the study .  Any deviation from 
protocol -directed administration will be reported.
3.11 EXTENT OF EXPOSURE
Extent of exposure for a subject is defined as number of cycles in which the subject receives the 
study  medication infusion. Summary  statistics will beprovided on extent of exposure for the ASaT 
population.
4.REFERENCES
1.Liang K, Zeger, S (2000). L ongitudinal data anal ysis of continuous and discrete 
responses for pre -post designs. Sankhy ā: The Indian Journal of Statistics, 62 (Series B), 
134-148. 
2.Maurer W, Bretz F. Multiple Testing in Group Sequential Trials using Graphi cal 
Approaches. Statistics in Biopharmaceutical Research 2013; 5(4): 311 -320.
3.Miettinen O, Nurminen M. Comparative anal ysis of two rates. Statistics in Medicine 
1985; 4:213- 226.
4.Robins, J.M., Tsiatis, A.A. Correcting for non -compliance in randomized trials using 
rank preserving structural failure time models. Communications in Statistics -Theory  and 
Methods, 1991; 20 (8): 2609 -2631
5.Uno, H., et al. Moving Beyond the Hazard Ratio in Quantify ing the Between -Group 
Difference in Survival Analysis. J Clin Oncol. 2 014; 32 (22): 2380- 2385. 
0575BN
082JZZ